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Overview {#bph14753-sec-0003}
--------

The majority of biological solutes are charged organic or inorganic molecules. Cellular membranes are hydrophobic and, therefore, effective barriers to separate them allowing the formation of gradients, which can be exploited, for example, in the generation of energy. Membrane transporters carry solutes across cell membranes, which would otherwise be impermeable to them. The energy required for active transport processes is obtained from ATP turnover or by exploiting ion gradients.

ATP‐driven transporters can be divided into three major classes: P‐type ATPases; F‐type or V‐type ATPases and ATP‐binding cassette transporters. The first of these, P‐type ATPases, are multimeric proteins, which transport (primarily) inorganic cations. The second, F‐type or V‐type ATPases, are proton‐coupled motors, which can function either as transporters or as motors. Last, are ATP‐binding cassette transporters, heavily involved in drug disposition as well as transporting endogenous solutes.

The second largest family of membrane proteins in the human genome, after the G protein‐coupled receptors, are the SLC solute carrier family. Within the solute carrier family, there are a great variety of solutes transported, from simple inorganic ions to amino acids and sugars to relatively complex organic molecules like haem. The solute carrier family includes 65 families of almost 400 members. Many of these overlap in terms of the solutes that they carry. For example, amino acids accumulation is mediated by members of the SLC1, SLC3/7, SLC6, SLC15, SLC16, SLC17, SLC32, SLC36, SLC38 and SLC43 families. Further members of the SLC superfamily regulate ion fluxes at the plasma membrane, or solute transport into and out of cellular organelles. Some SLC family members remain orphan transporters, in as much as a physiological function has yet to be dtermined. Within the SLC super‐family, there is an abundance in diversity of structure. Two families (SLC3 and SLC7) only generate functional transporters as heteromeric partners, where one partner is a single TM domain protein. Membrane topology predictions for other families suggest 3,4,6,7,8,9,10,11,12,13 or 14 TM domains. The SLC transporters include members which function as antiports, where solute movement in one direction is balanced by a solute moving in the reverse direction. Symports allow concentration gradients of one solute to allow co‐transport of a second solute across a membrane. A third, relatively small group are equilibrative transporters, which allow solutes to travel across membranes down their concentration gradients. A more complex family of transporters, the SLC27 fatty acid transporters also express enzymatic function. Many of the transporters also express electrogenic properties of ion channels.

Family structure {#bph14753-sec-0004}
----------------
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===========================================================================

Overview {#bph14753-sec-0006}
--------

ATP‐binding cassette transporters are ubiquitous membrane proteins characterized by active ATP‐dependent movement of a range of substrates, including ions, lipids, peptides, steroids. Individual subunits are typically made up of two groups of 6TM‐spanning domains, with two nucleotide‐binding domains (NBD). The majority of eukaryotic ABC transporters are 'full' transporters incorporating both TM and NBD entities. Some ABCs, notably the ABCD and ABCG families are half‐transporters with only a single membrane spanning domain and one NBD, and are only functional as homo‐ or heterodimers. Eukaryotic ABC transporters convey substrates from the cytoplasm, either out of the cell or into intracellular organelles. Their role in the efflux of exogenous compounds, notably chemotherapeutic agents, has led to considerable interest.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=151> {#bph14753-sec-0007}
===========================================================================

Overview {#bph14753-sec-0008}
--------

To date, 12 members of the human ABCA subfamily are identified. They share a high degree of sequence conservation and have been mostly related with lipid trafficking in a wide range of body locations. Mutations in some of these genes have been described to cause severe hereditary diseases related with lipid transport, such as fatal surfactant deficiency or harlequin ichthyosis. In addition, most of them are hypothesized to participate in the subcellular sequestration of drugs, thereby being responsible for the resistance of several carcinoma cell lines against drug treatment \[<http://www.ncbi.nlm.nih.gov/pubmed/16586097?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=756><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=758><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=759>Common abbreviationABC1, CERPABC3, ABCCABCRHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29), <http://www.uniprot.org/uniprot/O95477>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:33](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:33), <http://www.uniprot.org/uniprot/Q99758>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:34](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:34), <http://www.uniprot.org/uniprot/P78363>Selective ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9183> (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/18805791?dopt=AbstractPlus>\]----Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7277> \[<http://www.ncbi.nlm.nih.gov/pubmed/15514211?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15140889?dopt=AbstractPlus>\]----Comments--Loss‐of‐function mutations are associated with pulmonary surfactant deficiencyRetinal‐specific transporter of N‐retinylPE; loss‐of‐function mutations are associated with childhood‐onset Stargardt disease, a juvenile onset macular degenerative disease. The earlier onset disease is often associated with the more severe and deleterious *ABCA4* variants \[<http://www.ncbi.nlm.nih.gov/pubmed/25312043?dopt=AbstractPlus>\]. ABCA4 facilitates the clearance of all‐*trans*‐retinal from photoreceptor disc membranes following photoexcitation. ABCA4 can also transport N‐11‐*cis*‐retinylidene‐phosphatidylethanolamine, the Schiff‐base adduct of 11‐*cis*‐retinal; loss of function mutation cause a buildup of lipofuscin, atrophy of the central retina, and severe progressive loss in vision \[<http://www.ncbi.nlm.nih.gov/pubmed/24707049?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=760><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=761><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=762><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=766>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:35](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:35), <http://www.uniprot.org/uniprot/Q8WWZ7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:36](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:36), <http://www.uniprot.org/uniprot/Q8N139>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:37](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:37), <http://www.uniprot.org/uniprot/Q8IZY2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14637](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14637), <http://www.uniprot.org/uniprot/Q86UK0>CommentsABCA5 is a lysosomal protein whose loss of function compromises integrity of lysosomes and leads to intra‐endolysosomal accumulation of cholesterol. It has recently been associated with Congenital Generalized Hypertrichosis Terminalis (CGHT), a hair overgrowth syndrome, in a patient with a mutation in *ABCA5* that significantly decreased its expression \[<http://www.ncbi.nlm.nih.gov/pubmed/24831815?dopt=AbstractPlus>\].A recent genome wide association study identified an *ABCA6* variant associated with cholesterol levels \[<http://www.ncbi.nlm.nih.gov/pubmed/25751400?dopt=AbstractPlus>\].Genome wide association studies identify *ABCA7* variants as associated with Alzheimer\'s Disease \[<http://www.ncbi.nlm.nih.gov/pubmed/21460840?dopt=AbstractPlus>\].Reported to play a role in skin ceramide formation \[<http://www.ncbi.nlm.nih.gov/pubmed/18957418?dopt=AbstractPlus>\]. A recent study shows that *ABCA12* expression also impacts cholesterol efflux from macrophages. ABCA12 is postulated to associate with ABCA1 and LXR beta, and stabilize expression of *ABCA1*. ABCA12 deficiency causes decreased expression of *Abca1*, *Abcg1* and *Nr1h2* \[<http://www.ncbi.nlm.nih.gov/pubmed/23931754?dopt=AbstractPlus>\].

Comments {#bph14753-sec-0009}
--------

A number of structural analogues are not found in man: Abca14 ([http://www.ensembl.org/Mus_musculus/Gene/Summary?g=ENSMUSG00000062017;r=7:127347475‐127468866](http://www.ensembl.org/Mus_musculus/Gene/Summary?g=ENSMUSG00000062017;r=7:127347475‐127468866)); Abca15 ([http://www.ensembl.org/Mus_musculus/Gene/Summary?g=ENSMUSG00000054746;r=7:127472198‐127551201](http://www.ensembl.org/Mus_musculus/Gene/Summary?g=ENSMUSG00000054746;r=7:127472198‐127551201)); Abca16 ([http://www.ensembl.org/Mus_musculus/Gene/Summary?g=ENSMUSG00000051900;r=7:127553161‐127688327](http://www.ensembl.org/Mus_musculus/Gene/Summary?g=ENSMUSG00000051900;r=7:127553161‐127688327)) and Abca17 ([http://www.ensembl.org/Mus_musculus/Gene/Summary?g=ENSMUSG00000035435;r=17:24401204‐24487974](http://www.ensembl.org/Mus_musculus/Gene/Summary?g=ENSMUSG00000035435;r=17:24401204‐24487974)).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=152> {#bph14753-sec-0010}
===========================================================================

Overview {#bph14753-sec-0011}
--------

The ABCB subfamily is composed of four full transporters and two half transporters. This is the only human subfamily to have both half and full types of transporters. ABCB1 was discovered as a protein overexpressed in certain drug resistant tumor cells. It is expressed primarily in the blood brain barrier and liver and is thought to be involved in protecting cells from toxins. Cells that overexpress this protein exhibit multi‐drug resistance \[<http://www.ncbi.nlm.nih.gov/pubmed/11441126?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=768><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=769><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=770>Common abbreviationMDR1, PGP1TAP1TAP2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:40](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:40), <http://www.uniprot.org/uniprot/P08183>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:43](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:43), <http://www.uniprot.org/uniprot/Q03518>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:44](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:44), <http://www.uniprot.org/uniprot/Q03519>CommentsResponsible for the cellular export of many therapeutic drugs. The mouse and rat have two Abcb1 genes (gene names; *Abcb1a* and *Abcb1b*) while the human has only the one gene, *ABCB1*.Endoplasmic reticulum peptide transporter is a hetero‐dimer composed of the two half‐transporters, TAP1 (ABCB2) and TAP2 (ABCB3). The transporter shuttles peptides into the endoplasmic reticulum where they are loaded onto major histocompatibility complex class I (MHCI) molecules via the macromoldecular peptide‐loading complex and are eventually presented at the cell surface, attributing to TAP an important role in the adaptive immune response \[<http://www.ncbi.nlm.nih.gov/pubmed/24923865?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=771><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=772><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=773>Common abbreviationPGY3--MTABC3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:45](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:45), <http://www.uniprot.org/uniprot/P21439>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:46](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:46), <http://www.uniprot.org/uniprot/Q2M3G0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:47](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:47), <http://www.uniprot.org/uniprot/Q9NP58>CommentsTransports phosphatidylcholinefrom intracellular to extracellular face of the hepatocyte canalicular membrane \[<http://www.ncbi.nlm.nih.gov/pubmed/16622704?dopt=AbstractPlus>\]. Heterozygous *ABCB4* variants contribute to mild cholestatic phenotypes, while homozygous deficiency leads to Progressive Intrahepatic Familial Cholestasis (PFIC) Type 3, and increased risk of cholesterol gallstones \[<http://www.ncbi.nlm.nih.gov/pubmed/23583734?dopt=AbstractPlus>\].A drug efflux transporter that has been shown to identify cancer stem‐like cells in diverse human malignancies, and is also identified as a limbal stem cell that is required for corneal development and repair \[<http://www.ncbi.nlm.nih.gov/pubmed/25030174?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24934811?dopt=AbstractPlus>\].Putative mitochondrial porphyrin transporter \[<http://www.ncbi.nlm.nih.gov/pubmed/17006453?dopt=AbstractPlus>\]; other subcellular localizations are possible, such as the plasma membrane, as a specific determinant of the Langereis blood group system \[<http://www.ncbi.nlm.nih.gov/pubmed/22246506?dopt=AbstractPlus>\]. Loss of *Abcb6* expression in mice leads to decreased expression and activity of CYP450 \[<http://www.ncbi.nlm.nih.gov/pubmed/25623066?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=774><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=775><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=776>Common abbreviationABC7MABC1TAPLHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:48](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:48), <http://www.uniprot.org/uniprot/O75027>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:49](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:49), <http://www.uniprot.org/uniprot/Q9NUT2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:50](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:50), <http://www.uniprot.org/uniprot/Q9NP78>CommentsMitochondrial; reportedly essential for haematopoiesis \[<http://www.ncbi.nlm.nih.gov/pubmed/17192398?dopt=AbstractPlus>\]. Deletion studies in mice demonstrate that *Abcb7* is essential in mammals and substantiate a role for mitochondria in cytosolic Fe‐S cluster assembly \[<http://www.ncbi.nlm.nih.gov/pubmed/16467350?dopt=AbstractPlus>\].Mitochondrial; suggested to play a role in chemoresistance of melanoma \[<http://www.ncbi.nlm.nih.gov/pubmed/19147539?dopt=AbstractPlus>\]. Cardiac specific deletion of *Abcb8* leads to cardiomyopathy and accumulation of mitochondrial iron, and is thus thought to modulate mitochondrial iron export \[<http://www.ncbi.nlm.nih.gov/pubmed/22375032?dopt=AbstractPlus>\].A homodimeric transport complex that translocates cytosolic peptides into the lumen of lysosome for degradation \[<http://www.ncbi.nlm.nih.gov/pubmed/22641697?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=777><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=778>Common abbreviationMTABC2ABC16HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:41](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:41), <http://www.uniprot.org/uniprot/Q9NRK6>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:42](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:42), <http://www.uniprot.org/uniprot/O95342>Ligands--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4545> (Binding) (p*K* ~i~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/12404239?dopt=AbstractPlus>\]CommentsMitochondrial location; the first human ABC transporter to have a crystal structure reported \[<http://www.ncbi.nlm.nih.gov/pubmed/23716676?dopt=AbstractPlus>\]. ABCB10 is important in early steps of heme synthesis in the heart and is required for normal red blood cell development \[<http://www.ncbi.nlm.nih.gov/pubmed/23720443?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22085049?dopt=AbstractPlus>\].Loss‐of‐function mutations are associated with progressive familial intrahepatic cholestasis type 2 \[<http://www.ncbi.nlm.nih.gov/pubmed/19684528?dopt=AbstractPlus>\]. ATP‐dependent transport of bile acids into the confines of the canalicular space by ABCB11 (BSEP) generates an osmotic gradient and thereby, bile flow. Mutations in BSEP that decrease its function or expression cause Progressive Familial Cholestasis Type 2 (PFIC2), which in severe cases, can be fatal in the absence of a liver transplant. Drugs that inhibit BSEP function with IC50 values less than 25 *μ*M \[<http://www.ncbi.nlm.nih.gov/pubmed/20829430?dopt=AbstractPlus>\] or decrease its expression \[<http://www.ncbi.nlm.nih.gov/pubmed/24335466?dopt=AbstractPlus>\] can cause Drug‐Induced Liver Injury (DILI) in the form of cholestatic liver injury.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=153> {#bph14753-sec-0012}
===========================================================================

Overview {#bph14753-sec-0013}
--------

Subfamily ABCC contains thirteen members and nine of these transporters are referred to as Multidrug Resistance Proteins (MRPs). MRP proteins are found throughout nature and mediate many important functions. They are known to be involved in ion transport, toxin secretion, and signal transduction \[<http://www.ncbi.nlm.nih.gov/pubmed/11441126?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=779><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=780><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=781>Common abbreviationMRP1MRP2, cMOATMRP3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:51](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:51), <http://www.uniprot.org/uniprot/P33527>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:53](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:53), <http://www.uniprot.org/uniprot/Q92887>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:54](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:54), <http://www.uniprot.org/uniprot/O15438>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8762> (p*K* ~i~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/9647783?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8776> (p*K* ~i~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/10570049?dopt=AbstractPlus>\]--CommentsExhibits a broad substrate specificity \[<http://www.ncbi.nlm.nih.gov/pubmed/17187268?dopt=AbstractPlus>\], including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354> (K~m~ 97 nM \[<http://www.ncbi.nlm.nih.gov/pubmed/7961706?dopt=AbstractPlus>\]) and estradiol‐17β‐glucuronide \[<http://www.ncbi.nlm.nih.gov/pubmed/9875554?dopt=AbstractPlus>\].Loss‐of‐function mutations are associated with Dubin‐Johnson syndrome, in which plasma levels of conjugated bilirubin are elevated (<http://omim.org/entry/237500>).Transports conjugates of glutathione, sulfate or glucuronide \[<http://www.ncbi.nlm.nih.gov/pubmed/16586096?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=782><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=783><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=784>Common abbreviationMRP4MRP5MRP6HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:55](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:55), <http://www.uniprot.org/uniprot/O15439>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:56](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:56), <http://www.uniprot.org/uniprot/O15440>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:57](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:57), <http://www.uniprot.org/uniprot/O95255>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8802> (pIC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/12523936?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8829> (p*K* ~i~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/22380603?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743> (p*K* ~i~ 5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/22380603?dopt=AbstractPlus>\]--CommentsAlthough reported to facilitate cellular cyclic nucleotide export, this role has been questioned \[<http://www.ncbi.nlm.nih.gov/pubmed/16586096?dopt=AbstractPlus>\]; reported to export prostaglandins in a manner sensitive to NSAIDS \[<http://www.ncbi.nlm.nih.gov/pubmed/12835412?dopt=AbstractPlus>\]Although reported to facilitate cellular cyclic nucleotide export, this role has been questioned \[<http://www.ncbi.nlm.nih.gov/pubmed/16586096?dopt=AbstractPlus>\]Loss‐of‐function mutations in ABCC6 are associated with pseudoxanthoma elasticum (<http://omim.org/entry/264800>).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2594><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2746><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=786>Systematic nomenclatureABCC8----Common abbreviationSUR1SUR2MRP8HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:59](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:59), <http://www.uniprot.org/uniprot/Q09428>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:60](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:60), <http://www.uniprot.org/uniprot/O60706>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14639](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14639), <http://www.uniprot.org/uniprot/Q96J66>Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6841> (pIC~50~ 7) \[<http://www.ncbi.nlm.nih.gov/pubmed/15380228?dopt=AbstractPlus>\]----CommentsThe sulfonyurea drugs (acetohexamide, tolbutamide and glibenclamide) appear to bind sulfonylurea receptors and it has been shown experimentally that tritiated glibenclamide can be used to pull out a 140 kDa protein identified as SUR1 (now known as ABCC8) \[<http://www.ncbi.nlm.nih.gov/pubmed/22260657?dopt=AbstractPlus>\]. SUR2 (ABCC9) has also been identified \[<http://www.ncbi.nlm.nih.gov/pubmed/7502040?dopt=AbstractPlus>\]. However, this is not the full mechanism of action and the functional channel has been characterised as a hetero‐octamer formed by four SUR and four K~ir~6.2 subunits, with the K~ir~6.2 subunits forming the core ion pore and the SUR subunits providing the regulatory properties \[<http://www.ncbi.nlm.nih.gov/pubmed/10194514?dopt=AbstractPlus>\]. Co‐expression of K~ir~6.2 with SUR1, reconstitutes the ATP‐dependent K^+^ conductivity inhibited by the sulfonyureas \[<http://www.ncbi.nlm.nih.gov/pubmed/7502040?dopt=AbstractPlus>\].Associated with familial atrial fibrillation, Cantu syndrome and familial isolated dilated cardiomyopathy.Single nucleotide polymorphisms distinguish wet vs. dry earwax (<http://omim.org/entry/117800>); an association between earwax allele and breast cancer risk is reported in Japanese but not European populations.

Comments {#bph14753-sec-0014}
--------

ABCC7 (also known as <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707>, a 12TM ABC transporter‐type protein, is a cAMP‐regulated epithelial cell membrane Cl^‐^ channel involved in normal fluid transport across various epithelia and can be viewed in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=120> section of the Guide. ABCC8 ([http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006071;r=11:17414432‐17498449](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006071;r=11:17414432‐17498449), also known as SUR1, sulfonylurea receptor 1) and ABCC9 ([http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000069431;r=12:21950335‐22094336](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000069431;r=12:21950335‐22094336), also known as SUR2, sulfonylurea receptor 2) are unusual in that they lack transport capacity but regulate the activity of particular K^+^ channels (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=74>), conferring nucleotide sensitivity to these channels to generate the canonical K~ATP~ channels. ABCC13 ([http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000243064;r=21:15646120‐15735075](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000243064;r=21:15646120‐15735075)) is a possible pseudogene.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=154> {#bph14753-sec-0015}
===========================================================================

Overview {#bph14753-sec-0016}
--------

Peroxisomes are indispensable organelles in higher eukaryotes. They are essential for the oxidation of a wide variety of metabolites, which include: saturated, monounsaturated and polyunsaturated fatty acids, branched‐chain fatty acids, bile acids and dicarboxylic acids \[<http://www.ncbi.nlm.nih.gov/pubmed/21488864?dopt=AbstractPlus>\]. However, the peroxisomal membrane forms an impermeable barrier to these metabolites. The mammalian peroxisomal membrane harbours three ATP‐binding cassette (ABC) half‐transporters, which act as homo‐ and/or heterodimers to transport these metabolites across the peroxisomal membrane.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=788><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=789><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=790>Common abbreviationALDPALDRPMP70HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:61](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:61), <http://www.uniprot.org/uniprot/P33897>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:66](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:66), <http://www.uniprot.org/uniprot/Q9UBJ2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:67](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:67), <http://www.uniprot.org/uniprot/P28288>CommentsTransports coenzyme A esters of very long chain fatty acids \[<http://www.ncbi.nlm.nih.gov/pubmed/18757502?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21145416?dopt=AbstractPlus>\]. Loss‐of‐function mutations in *ABCD1* (mutation registry held by the Adrenoleukodystrophy database; <https://adrenoleukodystrophy.info/>) result in adrenoleukodystrophy (<http://omim.org/entry/300100>) \[<http://www.ncbi.nlm.nih.gov/pubmed/27312864?dopt=AbstractPlus>\].*In vitro* experiments indicate that ABCD2 has overlapping substrate specificity with ABCD1 towards saturated and monounsaturated very long‐chain fatty acids, albeit at much lower specificity. ABCD2 has affinity for the polyunsaturated fatty acids C22:6‐CoA and C24:6‐CoA. However, *in vivo* proof for its true function is still lacking. No disease has yet been linked to a deficiency of ABCD2.Transports long‐chain dicarboxylic acids, branched‐chain fatty acids and C27 bile acids DHC‐CoA and THC‐CoA \[<http://www.ncbi.nlm.nih.gov/pubmed/25168382?dopt=AbstractPlus>\]. In mitochondrial fatty acid deficient cells and mice, ABCD3 accepts medium and long‐chain fatty acids

Comments {#bph14753-sec-0017}
--------

ABCD4 ([http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119688;r=14:74752126‐74769759](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119688;r=14:74752126‐74769759), also known as PMP69, PXMP1‐L or P70R) is located at the lysosome and is involved in the transport of vitamin B12 (cobalamin) from lysosomes into the cytosol \[<http://www.ncbi.nlm.nih.gov/pubmed/22922874?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=155> {#bph14753-sec-0018}
===========================================================================

Overview {#bph14753-sec-0019}
--------

This family of 'half‐transporters' act as homo‐ or heterodimers; particularly ABCG5 and ABCG8 are thought to be obligate heterodimers. The ABCG5/ABCG heterodimer sterol transporter structure has been determined \[<http://www.ncbi.nlm.nih.gov/pubmed/27144356?dopt=AbstractPlus>\], suggesting an extensive intracellular nucleotide binding domain linked to the transmembrane domains by a fold in the primary sequence. The functional ABCG2 transporter appears to be a homodimer with structural similarities to the ABCG5/ABCG8 heterodimer \[<http://www.ncbi.nlm.nih.gov/pubmed/28554189?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=791><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=792><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=793><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=794><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=795>Common abbreviationABC8ABCP------HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:73](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:73), <http://www.uniprot.org/uniprot/P45844>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:74](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:74), <http://www.uniprot.org/uniprot/Q9UNQ0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13884](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13884), <http://www.uniprot.org/uniprot/Q9H172>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13886](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13886), <http://www.uniprot.org/uniprot/Q9H222>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13887](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13887), <http://www.uniprot.org/uniprot/Q9H221>Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1024> (p*K* ~i~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/11437380?dopt=AbstractPlus>\]------CommentsTransports sterols and choline phospholipids \[<http://www.ncbi.nlm.nih.gov/pubmed/21175590?dopt=AbstractPlus>\]Exhibits a broad substrate specificity, including urate and haem, as well as multiple synthetic compounds \[<http://www.ncbi.nlm.nih.gov/pubmed/21175590?dopt=AbstractPlus>\].Putative functional dependence on ABCG1The ABCG5/ABCG8 heterodimer transports phytosterols and cholesterol \[<http://www.ncbi.nlm.nih.gov/pubmed/27144356?dopt=AbstractPlus>\]. Loss‐of‐function mutations in ABCG5 or ABCG8 are associated with sitosterolemia (<http://omim.org/entry/210250>).The ABCG5/ABCG8 heterodimer transports phytosterols and cholesterol \[<http://www.ncbi.nlm.nih.gov/pubmed/27144356?dopt=AbstractPlus>\]. Loss‐of‐function mutations in ABCG5 or ABCG8 are associated with sitosterolemia (<http://omim.org/entry/210250>).

Comments on ATP‐binding cassette transporter family {#bph14753-sec-0020}
---------------------------------------------------

A further group of ABC transporter‐like proteins have been identified to lack membrane spanning regions and are not believed to be functional transporters, but appear to have a role in protein translation \[<http://www.ncbi.nlm.nih.gov/pubmed/16421098?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19570978?dopt=AbstractPlus>\]: [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:69](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:69) (<http://www.uniprot.org/uniprot/P61221>, also known as OABP or 2′‐5′ oligoadenylate‐binding protein); [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:70](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:70) (<http://www.uniprot.org/uniprot/Q8NE71>, also known as ABC50 or TNF‐a‐stimulated ABC protein); [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:71](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:71) (<http://www.uniprot.org/uniprot/Q9UG63>, also known as iron‐inhibited ABC transporter 2) and [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:72](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:72) (<http://www.uniprot.org/uniprot/Q9NUQ8>).

Further reading on ATP‐binding cassette transporter family {#bph14753-sec-0021}
----------------------------------------------------------
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=137> {#bph14753-sec-0022}
===========================================================================

Overview {#bph14753-sec-0023}
--------

The F‐type (ATP synthase) and the V‐type (vacuolar or vesicular proton pump) ATPases, although having distinct sub‐cellular locations and roles, exhibit marked similarities in subunit structure and mechanism. They are both composed of a 'soluble' complex (termed F~1~ or V~1~) and a membrane complex (F~o~ or V~o~). Within each ATPase complex, the two individual sectors appear to function as connected opposing rotary motors, coupling catalysis of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> synthesis or hydrolysis to proton transport. Both the F‐type and V‐type ATPases have been assigned enzyme commission number [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.6.3.14](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.6.3.14)

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=156> {#bph14753-sec-0024}
===========================================================================

Overview {#bph14753-sec-0025}
--------

The F‐type ATPase, also known as ATP synthase or ATP phosphohydrolase (H^+^‐transporting), is a mitochondrial membrane‐associated multimeric complex consisting of two domains, an F~0~ channel domain in the membrane and an F~1~ domain extending into the lumen. Proton transport across the inner mitochondrial membrane is used to drive the synthesis of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713>, although it is also possible for the enzyme to function as an AT‐Pase. The ATP5O subunit (oligomycin sensitivity‐conferring protein, [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:850](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:850), (<http://www.uniprot.org/uniprot/P48047>)), acts as a connector between F~1~ and F~0~ motors.

The **F~1~ motor**, responsible for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> turnover, has the subunit composition α3β3γδε.

The **F~0~ motor**, responsible for ion translocation, is complex in mammals, with probably nine subunits centring on A, B, and C subunits in the membrane, together with D, E, F2, F6, G2 and 8 subunits. Multiple pseudogenes for the F~0~ motor proteins have been defined in the human genome.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=156>.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=157> {#bph14753-sec-0026}
===========================================================================

Overview {#bph14753-sec-0027}
--------

The V‐type ATPase is most prominently associated with lysosomes in mammals, but also appears to be expressed on the plasma membrane and neuronal synaptic vesicles.

The **V~1~ motor**, for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> turnover, has subunits with a of A‐H.

The**V~0~ motor**, responsible for ion translocation, has six subunits (a‐e).

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=157>.

Further reading on F‐type and V‐type ATPases {#bph14753-sec-0028}
--------------------------------------------

Brandt K *et al*. (2015) Hybrid rotors in F1F(o) ATP synthases: subunit composition, distribution, and physiological significance. *Biol. Chem*. **396**: 1031--42 <https://www.ncbi.nlm.nih.gov/pubmed/25838297?dopt=AbstractPlus>

Krah A. (2015) Linking structural features from mitochondrial and bacterial F‐type ATP synthases to their distinct mechanisms of ATPase inhibition. *Prog. Biophys. Mol. Biol*. **119**: 94--102 <https://www.ncbi.nlm.nih.gov/pubmed/26140992?dopt=AbstractPlus>

Marshansky V *et al*. (2014) Eukaryotic V‐ATPase: novel structural findings and functional insights. *Biochim. Biophys. Acta* **1837**: 857--79 <https://www.ncbi.nlm.nih.gov/pubmed/24508215?dopt=AbstractPlus>

Noji H *et al*. (2017) Catalytic robustness and torque generation of the F_1‐ATPase. *Biophys Rev* **9**: 103--118 <https://www.ncbi.nlm.nih.gov/pubmed/28424741?dopt=AbstractPlus>

Okuno D *et al*. (2013) Single‐molecule analysis of the rotation of F_1‐ATPase under high hydrostatic pressure. *Biophys. J*. **105**: 1635--42 <https://www.ncbi.nlm.nih.gov/pubmed/24094404?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=138> {#bph14753-sec-0029}
===========================================================================

Overview {#bph14753-sec-0030}
--------

Phosphorylation‐type ATPases (EC 3.6.3.‐) are associated with membranes and the transport of ions or phospholipids. Characteristics of the family are the transient phosphorylation of the transporters at an aspartate residue and the interconversion between E1 and E2 conformations in the activity cycle of the transporters, taken to represent 'half‐channels' facing the cytoplasm and extracellular/luminal side of the membrane, respectively.

Sequence analysis across multiple species allows the definition of five subfamilies, P1‐P5. The P1 subfamily includes heavy metal pumps, such as the copper ATPases. The P2 subfamily includes calcium, sodium/potassium and proton/potassium pumps. The P4 and P5 subfamilies include putative phospholipid flippases.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=158> {#bph14753-sec-0031}
===========================================================================

Overview {#bph14753-sec-0032}
--------

The cell‐surface Na^+^/K^+^‐ATPase is an integral membrane protein which regulates the membrane potential of the cell by maintaining gradients of Na^+^ and K^+^ ions across the plasma membrane, also making a small, direct contribution to membrane potential, particularly in cardiac cells. For every molecule of ATP hydrolysed, the Na^+^/K^+^‐ATPase extrudes three Na^+^ ions and imports two K^+^ ions. The active transporter is a heteromultimer with incompletely defined stoichiometry, possibly as tetramers of heterodimers, each consisting of one of four large, ten TM domain catalytic α subunits and one of three smaller, single TM domain glycoprotein β‐subunits. Additional protein partners known as FXYD proteins (*e.g*. [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4026](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4026), <http://www.uniprot.org/uniprot/P54710>) appear to associate with and regulate the activity of the pump.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=158>.

Comments {#bph14753-sec-0033}
--------

Na^+^/K^+^‐ATPases are inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4826> and cardiac glycosides, such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4726>, as well as potentially endogenous cardiotonic steroids \[<http://www.ncbi.nlm.nih.gov/pubmed/19325075?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=159> {#bph14753-sec-0034}
===========================================================================

Overview {#bph14753-sec-0035}
--------

The sarcoplasmic/endoplasmic reticulum Ca^2^+‐ATPase (SERCA) is an intracellular membrane‐associated pump for sequestering calcium from the cytosol into intracellular organelles, usually associated with the recovery phase following excitation of muscle and nerves.

The plasma membrane Ca^2+^‐ATPase (PMCA) is a cell‐surface pump for extruding calcium from the cytosol, usually associated with the recovery phase following excitation of cells. The active pump is a homodimer, each subunit of which is made up of ten TM segments, with cytosolic C‐ and N‐termini and two large intracellular loops.

Secretory pathway Ca^2+^‐ATPases (SPCA) allow accumulation of calcium and manganese in the Golgi apparatus.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=159>.

Comments {#bph14753-sec-0036}
--------

The fungal toxin <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4672> has been described to activate SERCA in kidney microsomes \[<http://www.ncbi.nlm.nih.gov/pubmed/1417961?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5350> \[<http://www.ncbi.nlm.nih.gov/pubmed/2530215?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5351> \[<http://www.ncbi.nlm.nih.gov/pubmed/1832668?dopt=AbstractPlus>\] and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5486>are widely employed to block SERCA. Thapsigargin has also been described to block the TRPV1 vanilloid receptor \[<http://www.ncbi.nlm.nih.gov/pubmed/12054538?dopt=AbstractPlus>\].

The stoichiometry of flux through the PMCA differs from SERCA, with the PMCA transporting 1 Ca^2+^ while SERCA transports 2 Ca^2+^.

Loss‐of‐function mutations in SPCA1 appear to underlie Hailey‐Hailey disease \[<http://www.ncbi.nlm.nih.gov/pubmed/10615129?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=160> {#bph14753-sec-0037}
===========================================================================

Overview {#bph14753-sec-0038}
--------

The H^+^/K^+^ ATPase is a heterodimeric protein, made up of α and β subunits. The α subunit has 10 TM domains and exhibits catalytic and pore functions, while the β subunit has a single TM domain, which appears to be required for intracellular trafficking and stabilising the α subunit. The ATP4A and ATP4B subunits are expressed together, while the ATP12A subunit is suggested to be expressed with the β1 (ATP1B1) subunit of the Na^+^/K^+^‐ATPase \[<http://www.ncbi.nlm.nih.gov/pubmed/16525125?dopt=AbstractPlus>\].

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=160>.

Comments {#bph14753-sec-0039}
--------

The gastric H^+^/K^+^‐ATPase is inhibited by proton pump inhibitors used for treating excessive gastric acid secretion, including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5487> and a metabolite of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5488>.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=161> {#bph14753-sec-0040}
===========================================================================

Overview {#bph14753-sec-0041}
--------

Copper‐transporting ATPases convey copper ions across cell‐surface and intracellular membranes. They consist of eight TM domains and associate with multiple copper chaperone proteins (*e.g*. [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:798](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:798), <http://www.uniprot.org/uniprot/O00244>).

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=161>.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=162> {#bph14753-sec-0042}
===========================================================================

Overview {#bph14753-sec-0043}
--------

These transporters are thought to translocate the aminophospholipids phosphatidylserine and phosphatidylethanolamine from one side of the phospholipid bilayer to the other to generate asymmetric membranes. They are also proposed to be involved in the generation of vesicles from intracellular and cell‐surface membranes.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=162>.

Comments {#bph14753-sec-0044}
--------

Loss‐of‐functionmutations in ATP8B1 are associated with type I familial intrahepatic cholestasis.

A further series of structurally‐related proteins have been identified in the human genome, with as yet undefined function, including [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24215](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24215) (<http://www.uniprot.org/uniprot/Q9HD20>), [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30213](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30213) (<http://www.uniprot.org/uniprot/Q9NQ11>), [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24113](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24113) (<http://www.uniprot.org/uniprot/Q9H7F0>), [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:25422](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:25422) (<http://www.uniprot.org/uniprot/Q4VNC1>) and [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:31789](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:31789) (<http://www.uniprot.org/uniprot/Q4VNC0>).

Further reading on P‐type ATPases {#bph14753-sec-0045}
---------------------------------

Aperia A *et al*. (2016) Na+‐K+‐ATPase, a new class of plasma membrane receptors. *Am. J. Physiol*., Cell Physiol. **310**: C491--5 <https://www.ncbi.nlm.nih.gov/pubmed/26791490?dopt=AbstractPlus>

Brini M *et al*. (2017) The plasma membrane calcium pumps: focus on the role in (neuro)pathology. *Biochem. Biophys. Res. Commun*. **483**: 1116--1124 <https://www.ncbi.nlm.nih.gov/pubmed/27480928?dopt=AbstractPlus>

Bruce JIE. (2018) Metabolic regulation of the PMCA: Role in cell death and survival. *Cell Calcium* **69**: 28--36 <https://www.ncbi.nlm.nih.gov/pubmed/27553475?dopt=AbstractPlus>

Diederich M *et al*. (2017) Cardiac glycosides: From molecular targets to immunogenic cell death. *Biochem. Pharmacol*. **125**: 1--11 <https://www.ncbi.nlm.nih.gov/pubmed/27553475?dopt=AbstractPlus>

Dubois C *et al*. (2016) The calcium‐signaling toolkit: Updates needed. *Biochim. Biophys. Acta* **1863**: 1337--43 <https://www.ncbi.nlm.nih.gov/pubmed/26658643?dopt=AbstractPlus>

Krebs J. (2015) The plethora of PMCA isoforms: Alternative splicing and differential expression. *Biochim. Biophys. Acta* **1853**: 2018--24 <https://www.ncbi.nlm.nih.gov/pubmed/25535949?dopt=AbstractPlus>

Little R *et al*. (2016) Plasma membrane calcium ATPases (PMCAs) as potential targets for the treatment of essential hypertension. *Pharmacol. Ther*. **159**: 23--34 <https://www.ncbi.nlm.nih.gov/pubmed/26820758?dopt=AbstractPlus>

López‐Marqués RL *et al*. (2015) Structure and mechanism of ATP‐dependent phospholipid transporters. *Biochim. Biophys. Acta* **1850**: 461--475 <https://www.ncbi.nlm.nih.gov/pubmed/24746984?dopt=AbstractPlus>

Migocka M. (2015) Copper‐transporting ATPases: The evolutionarily conserved machineries for balancing copper in living systems. *IUBMB Life* **67**: 737--45 <https://www.ncbi.nlm.nih.gov/pubmed/26422816?dopt=AbstractPlus>

Padányi R *et al*. (2016) Multifaceted plasmamembrane Ca(2+) pumps: From structure to intracellular Ca(2+) handling and cancer. *Biochim. Biophys. Acta* **1863**: 1351--63 <https://www.ncbi.nlm.nih.gov/pubmed/26707182?dopt=AbstractPlus>

Pomorski TG *et al*. (2016) Lipid somersaults: Uncovering the mechanisms of protein‐mediated lipid flipping. *Prog. Lipid Res*. **64**: 69--84 <https://www.ncbi.nlm.nih.gov/pubmed/27528189?dopt=AbstractPlus>

Retamales‐Ortega R *et al*. (2016) P2C‐Type ATPases and Their Regulation. *Mol. Neurobiol*. **53**: 1343--54 <https://www.ncbi.nlm.nih.gov/pubmed/25631710?dopt=AbstractPlus>

Tadini‐Buoninsegni F *et al*. (2017) Mechanisms of charge transfer in human copper ATPases ATP7A and ATP7B. *IUBMB Life* **69**: 218--225 <https://www.ncbi.nlm.nih.gov/pubmed/28164426?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=863> {#bph14753-sec-0046}
===========================================================================

Overview {#bph14753-sec-0047}
--------

The SLC superfamily of solute carriers is the second largest family of membrane proteins after G protein‐coupled receptors, but with a great deal fewer therapeutic drugs that exploit them. As with the ABC transporters, however, they play a major role in drug disposition and so can be hugely influential in determining the clinical efficacy of particular drugs.

48 families are identified on the basis of sequence similarities, but many of them overlap in terms of the solutes that they carry. For example, amino acid accumulation is mediated by members of the SLC1, SLC3/7, SLC6, SLC15, SLC16, SLC17, SLC32, SLC36, SLC38 and SLC43. Further members of the SLC superfamily regulate ion fluxes at the plasma membrane, or solute transport into and out of cellular organelles.

Within the SLC superfamily, there is an abundance in diversity of structure. Two families (SLC3 and SLC7) only generate functional transporters as heteromeric partners, where one partner is a single TMdomain protein. Membrane topology predictions for other families suggest 3, 4 6, 7, 8, 9, 10, 11, 12, 13, or 14 TM domains.

Functionally, members may be divided into those dependent on gradients of ions (particularly sodium, chloride or protons), exchange of solutes or simple equilibrative gating. For many members, the stoichiometry of transport is not yet established. Furthermore, one family of transporters also possess enzymatic activity (SLC27), while many members function as ion channels (e.g. SLC1A7/EAAT5), which increases the complexity of function of the SLC superfamily.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=139> {#bph14753-sec-0048}
===========================================================================

Overview {#bph14753-sec-0049}
--------

The SLC1 family of sodium dependent transporters includes the plasma membrane located glutamate transporters and the neutral amino acid transporters ASCT1 and ASCT2 \[<http://www.ncbi.nlm.nih.gov/pubmed/8103691?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17088867?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14530974?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14612154?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9790568?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=163> {#bph14753-sec-0050}
===========================================================================

Overview {#bph14753-sec-0051}
--------

Glutamate transporters present the unusual structural motif of 8TM segments and 2 re‐entrant loops \[<http://www.ncbi.nlm.nih.gov/pubmed/10734120?dopt=AbstractPlus>\]. The crystal structure of a glutamate transporter homologue (GltPh) from *Pyrococcus horikoshii* supports this topology and indicates that the transporter assembles as a trimer, where each monomer is a functional unit capable of substrate permeation \[<http://www.ncbi.nlm.nih.gov/pubmed/17230192?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19924125?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15483603?dopt=AbstractPlus>\] reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/20708631?dopt=AbstractPlus>\]). This structural data is in agreementwith the proposed quaternary structure for EAAT2 \[<http://www.ncbi.nlm.nih.gov/pubmed/15265858?dopt=AbstractPlus>\] and several functional studies that propose the monomer is the functional unit \[<http://www.ncbi.nlm.nih.gov/pubmed/16128593?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17360917?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17360916?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14982939?dopt=AbstractPlus>\]. Recent evidence suggests that EAAT3 and EAAT4 may assemble as heterotrimers \[<http://www.ncbi.nlm.nih.gov/pubmed/21127051?dopt=AbstractPlus>\]. The activity of glutamate transporters located upon both neurones (predominantly EAAT3, 4 and 5) and glia (predominantly EAAT 1 and 2) serves, dependent upon their location, to regulate excitatory neurotransmission, maintain low ambient extracellular concentrations of glutamate (protecting against excitotoxicity) and provide glutamate for metabolism including the glutamate‐glutamine cycle. The <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=138> that maintains the ion gradients that drive transport has been demonstrated to co‐assemble with EAAT1 and EAAT2 \[<http://www.ncbi.nlm.nih.gov/pubmed/19553454?dopt=AbstractPlus>\]. Recent evidence supports altered glutamate transport and novel roles in brain for splice variants of EAAT1 and EAAT2 \[<http://www.ncbi.nlm.nih.gov/pubmed/20688910?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20883814?dopt=AbstractPlus>\]. Three patients with dicarboxylic aminoaciduria (DA) were recently found to have loss‐of‐function mutations in EAAT3 \[<http://www.ncbi.nlm.nih.gov/pubmed/21123949?dopt=AbstractPlus>\]. DA is characterized by excessive excretion of the acidic amino acids glutamate and aspartate and EAAT3 is the predominant glutamate/aspartate transporter in the kidney. Enhanced expression of EAAT2 resulting fromadministration of ß‐lactam antibiotics (e.g. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5326>) is neuroprotective and occurs through NF‐?B‐mediated EAAT2 promoter activation \[<http://www.ncbi.nlm.nih.gov/pubmed/16274998?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18326497?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15635412?dopt=AbstractPlus>\] reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/21792905?dopt=AbstractPlus>\]). <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=86> activation (*e.g*. by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1056>) also leads to enhanced expression of EAAT though promoter activation \[<http://www.ncbi.nlm.nih.gov/pubmed/17213861?dopt=AbstractPlus>\]. In addition, several translational activators of EAAT2 have recently been described \[<http://www.ncbi.nlm.nih.gov/pubmed/20508255?dopt=AbstractPlus>\] along with treatments that increase the surface expression of EAAT2 (*e.g*. \[<http://www.ncbi.nlm.nih.gov/pubmed/21309758?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21426345?dopt=AbstractPlus>\]), or prevent its down‐regulation (*e.g*. \[<http://www.ncbi.nlm.nih.gov/pubmed/21730107?dopt=AbstractPlus>\]). A thermodynamically uncoupled Cl‐ flux, activated by Na^+^ and glutamate \[<http://www.ncbi.nlm.nih.gov/pubmed/15834685?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14612154?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21572047?dopt=AbstractPlus>\] (Na+ and aspartate in the case of GltPh \[<http://www.ncbi.nlm.nih.gov/pubmed/21730107?dopt=AbstractPlus>\]), is sufficiently large, in the instances of EAAT4 and EAAT5, to influence neuronal excitability \[<http://www.ncbi.nlm.nih.gov/pubmed/17908688?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17041592?dopt=AbstractPlus>\]. Indeed, it has recently been suggested that the primary function of EAAT5 is as a slow anion channel gated by glutamate, rather than a glutamate transporter \[<http://www.ncbi.nlm.nih.gov/pubmed/21641307?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=868><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=869><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=870><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=871><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=872>Systematic nomenclatureSLC1A3SLC1A2SLC1A1SLC1A6SLC1A7Common abbreviationEAAT1EAAT2EAAT3EAAT4EAAT5HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10941](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10941), <http://www.uniprot.org/uniprot/P43003>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10940](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10940), <http://www.uniprot.org/uniprot/P43004>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10939](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10939), <http://www.uniprot.org/uniprot/P43005>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10944](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10944), <http://www.uniprot.org/uniprot/P48664>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10945](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10945), <http://www.uniprot.org/uniprot/O00341>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4497> (*K* ~i~ 5.8×10^‐5^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/9463476?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6511>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4516><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6511>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4497>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4516> \[<http://www.ncbi.nlm.nih.gov/pubmed/10570036?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4516>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4497>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6511><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6511>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4497>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4516><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6511>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4516>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4497>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782> \[<http://www.ncbi.nlm.nih.gov/pubmed/8782106?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>StoichiometryProbably 3 Na^+^: 1 H^+^: 1 glutamate (in): 1 K^+^ (out)3 Na^+^: 1 H^+^: 1 glutamate (in): 1 K^+^ (out) \[<http://www.ncbi.nlm.nih.gov/pubmed/9822723?dopt=AbstractPlus>\]3 Na^+^: 1 H^+^: 1 glutamate (in): 1 K^+^ (out) \[<http://www.ncbi.nlm.nih.gov/pubmed/8857541?dopt=AbstractPlus>\]Probably 3 Na^+^: 1 H^+^: 1 glutamate (in): 1 K^+^(out)Probably 3 Na^+^: 1 H^+^: 1 glutamate (in): 1 K^+^ (out)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4609> (membrane potential assay) (pIC~50~ 6.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/19161278?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4631> (p*K* ~B~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/9463476?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4531> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/16014807?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4631> (p*K* ~B~ 6.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/9463476?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317> (p*K* ~B~ 5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/9145919?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4571> (p*K* ~B~ 5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4573> (p*K* ~B~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/9145919?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4626> (pIC50 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/17017964?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4625> (\[^3^H\]D‐aspartate uptake assay) (p*K* ~i~ 6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/16183084?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4631> (pIC~50~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/11078189?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4631> (p*K* ~i~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/11677257?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4573> (p*K* ~i~ 4.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/11299317?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4631> (p*K* ~i~ 5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/11677257?dopt=AbstractPlus>\]Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4492> (Binding) (p*K* ~d~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/17047096?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4698>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4534>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4075><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4492> (Binding) (p*K* ~d~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/17047096?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4534>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4534>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4075><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4492> (Binding) (p*K* ~d~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17047096?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4698>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4534><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4492> (Binding) (p*K* ~d~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/17047096?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4698>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4534><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4492> (Binding) (p*K* ~d~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/17047096?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4698>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4534>

Comments {#bph14753-sec-0052}
--------

The K~B~ (or K~i~) values reported, unless indicated otherwise, are derived from transporter currents mediated by EAATs expressed in voltage‐clamped *Xenopus* laevis oocytes \[<http://www.ncbi.nlm.nih.gov/pubmed/11299317?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11677257?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9463476?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9145919?dopt=AbstractPlus>\]. K~B~ (or K~i~) values derived in uptake assays are generally higher (*e.g*. \[<http://www.ncbi.nlm.nih.gov/pubmed/9463476?dopt=AbstractPlus>\]). In addition to acting as a poorly transportable inhibitor of EAAT2, (2S,4R)‐4‐methylglutamate, also known as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317>, is a competitive substrate for EAAT1 (K~M~ = 54μM; \[<http://www.ncbi.nlm.nih.gov/pubmed/19074430?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9145919?dopt=AbstractPlus>\]) and additionally is a potent kainate receptor agonist \[<http://www.ncbi.nlm.nih.gov/pubmed/8996224?dopt=AbstractPlus>\] which renders the compound unsuitable for autoradiographic localisation of EAATs \[<http://www.ncbi.nlm.nih.gov/pubmed/17590480?dopt=AbstractPlus>\]. Similarly, at concentrations that inhibit EAAT2, dihydrokainate binds to kainate receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/9463476?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5327> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4531> are both non‐substrate inhibitors with a preference for EAAT2 over EAAT3 and EAAT1 \[<http://www.ncbi.nlm.nih.gov/pubmed/14517179?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16014807?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4626> is a non‐substrate inhibitor with modest selectivity for EAAT3 over EAAT1 (\>10‐fold) and EAAT2 (5‐fold) \[126, <http://www.ncbi.nlm.nih.gov/pubmed/16368269?dopt=AbstractPlus>\]. Analogously, L‐β‐*threo*‐benzyl‐aspartate (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4625>) is a competitive nonsubstrate inhibitor that preferentially blocks EAAT3 versus EAAT1, or EAAT2 \[<http://www.ncbi.nlm.nih.gov/pubmed/16183084?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4075> demonstrates low affinity binding (K~D~≅6.0 μM) to EAAT1 and EAAT2 in rat brain homogenates \[<http://www.ncbi.nlm.nih.gov/pubmed/11389172?dopt=AbstractPlus>\] and EAAT1 in murine astrocyte membranes \[<http://www.ncbi.nlm.nih.gov/pubmed/14994336?dopt=AbstractPlus>\], whereas <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4492> binds with high affinity to all EAATs other than EAAT3 \[<http://www.ncbi.nlm.nih.gov/pubmed/17047096?dopt=AbstractPlus>\]. The novel isoxazole derivative <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5328> may interact at the same site as TBOA and preferentially inhibit reverse transport of glutamate \[<http://www.ncbi.nlm.nih.gov/pubmed/18451317?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4573> induces substrate‐like currents at EAAT4, but does not elicit heteroexchange of \[^3^H\]‐aspartate in synaptosome preparations, inconsistentwith the behaviour of a substrate inhibitor \[<http://www.ncbi.nlm.nih.gov/pubmed/11299317?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5352>, a compound isolated from the venom from the spider *Parawixia bistriata* is a selective enhancer of the glutamate uptake through EAAT2 but not through EAAT1 or EAAT3 \[<http://www.ncbi.nlm.nih.gov/pubmed/17646426?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12890709?dopt=AbstractPlus>\]. In addition to the agents listed in the table, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4497> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4516> act as non‐selective competitive substrate inhibitors of all EAATs. Zn^2+^ and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> are putative endogenous modulators of EAATs with actions that differ across transporter subtypes (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/15324920?dopt=AbstractPlus>\]).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=164> {#bph14753-sec-0053}
===========================================================================

Overview {#bph14753-sec-0054}
--------

ASC transporters mediate Na^+^‐dependent exchange of small neutral amino acids such as Ala, Ser, Cys and Thr and their structure is predicted to be similar to that of the glutamate transporters \[<http://www.ncbi.nlm.nih.gov/pubmed/8101838?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8662767?dopt=AbstractPlus>\]. ASCT1 and ASCT2 also exhibit thermodynamically uncoupled chloride channel activity associated with substrate transport \[<http://www.ncbi.nlm.nih.gov/pubmed/10698697?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8910405?dopt=AbstractPlus>\]. Whereas EAATs counter‐transport K^+^ (see above) ASCTs do not and their function is independent of the intracellular concentration of K^+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/8910405?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=873><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=874>Systematic nomenclatureSLC1A4SLC1A5Common abbreviationASCT1ASCT2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10942](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10942), <http://www.uniprot.org/uniprot/P43007>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10943](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10943), <http://www.uniprot.org/uniprot/Q15758>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4785><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782> (low Vmax) = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4785> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4533> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4814> ≅ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> ≅ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3312> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4794> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369> (enhanced at low pH)Stoichiometry1 Na^+^: 1 amino acid (in): 1 Na^+^: 1 amino acid (out); (homo‐, or hetero‐exchange; \[<http://www.ncbi.nlm.nih.gov/pubmed/8857541?dopt=AbstractPlus>\])1 Na^+^: 1 amino acid (in): 1 Na^+^: 1 amino acid (out); (homo‐, or hetero‐exchange; \[<http://www.ncbi.nlm.nih.gov/pubmed/10537079?dopt=AbstractPlus>\])Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4508> (p*K* ~i~ 4.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/15670919?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4501> (p*K* ~i~ 3.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/15107471?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4500> (p*K* ~i~ 3) \[<http://www.ncbi.nlm.nih.gov/pubmed/15107471?dopt=AbstractPlus>\]

Comments {#bph14753-sec-0055}
--------

The substrate specificity of ASCT1 may extend to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4704> \[<http://www.ncbi.nlm.nih.gov/pubmed/14502423?dopt=AbstractPlus>\]. At low pH (5.5) both ASCT1 and ASCT2 are able to exchange acidic amino acids such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5329> and glutamate \[<http://www.ncbi.nlm.nih.gov/pubmed/8603078?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8662767?dopt=AbstractPlus>\]. In addition to the inhibitors tabulated above, HgCl~2~, methylmercury and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5331>, at low micromolar concentrations, non‐competitively inhibit ASCT2 by covalent modificiation of cysteine residues \[<http://www.ncbi.nlm.nih.gov/pubmed/20599776?dopt=AbstractPlus>\].

Further reading on SLC1 family of amino acid transporters {#bph14753-sec-0056}
---------------------------------------------------------
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Kanai Y *et al*. (2013) The SLC1 high‐affinity glutamate and neutral amino acid transporter family. *Mol. Aspects Med*. **34**: 108--20 <https://www.ncbi.nlm.nih.gov/pubmed/23506861?dopt=AbstractPlus>

Takahashi K *et al*. (2015) Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease. *Cell. Mol. Life Sci*. **72**: 3489--506 <https://www.ncbi.nlm.nih.gov/pubmed/26033496?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=140> {#bph14753-sec-0057}
===========================================================================

Overview {#bph14753-sec-0058}
--------

The SLC2 family transports <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4654>, inositol (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4495>) and related hexoses. Three classes of glucose transporter can be identified, separating GLUT1‐4 and 14, GLUT6, 8, 10 and 12; and GLUT5, 7, 9 and 11. Modelling suggests a 12 TM membrane topology, with intracellular termini, with functional transporters acting as homodimers or homotetramers.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=165> {#bph14753-sec-0059}
===========================================================================

Overview {#bph14753-sec-0060}
--------

Class I transporters are able to transport <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536>, but not <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4654>, in the direction of the concentration gradient and may be inhibited non‐selectively by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4285> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5334>. GLUT1 is the major glucose transporter in brain, placenta and erythrocytes, GLUT2 is found in the pancreas, liver and kidneys, GLUT3 is neuronal and placental, while GLUT4 is the insulin‐responsive transporter found in skeletal muscle, heart and adipose tissue. GLUT14 appears to result from gene duplication of GLUT3 and is expressed in the testes \[<http://www.ncbi.nlm.nih.gov/pubmed/12504846?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=875><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=876><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=877><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=878><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=879>Systematic nomenclatureSLC2A1SLC2A2SLC2A3SLC2A4SLC2A14Common abbreviationGLUT1GLUT2GLUT3GLUT4GLUT14HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11005](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11005), <http://www.uniprot.org/uniprot/P11166>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11006](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11006), <http://www.uniprot.org/uniprot/P11168>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11007](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11007), <http://www.uniprot.org/uniprot/P11169>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11009](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11009), <http://www.uniprot.org/uniprot/P14672>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18301](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18301), <http://www.uniprot.org/uniprot/Q8TDB8>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4535> (D‐glucose = D‐glucosamine) \[<http://www.ncbi.nlm.nih.gov/pubmed/12135767?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4733> \[<http://www.ncbi.nlm.nih.gov/pubmed/3945643?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> (D‐glucose = D‐glucosamine) \[<http://www.ncbi.nlm.nih.gov/pubmed/12135767?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4535> (D‐glucosamine \> D‐glucose) \[<http://www.ncbi.nlm.nih.gov/pubmed/12135767?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> (D‐glucosamine \> D‐glucose) \[<http://www.ncbi.nlm.nih.gov/pubmed/12135767?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4535> (D‐glucosamine ≥ D‐glucose) \[<http://www.ncbi.nlm.nih.gov/pubmed/12135767?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> (D‐glucosamine ≥ D‐glucose) \[<http://www.ncbi.nlm.nih.gov/pubmed/12135767?dopt=AbstractPlus>\]--Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4643><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4643><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4643><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4643>--CommentsGLUT1 is a class I facilitative sugar transporter. GLUT1 functions to maintain basal glucose import which is required for cellular respiration.--------

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=166> {#bph14753-sec-0061}
===========================================================================

Overview {#bph14753-sec-0062}
--------

Class II transporters transport <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4654> and appear to be insensitive to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5334>. Class II transporters appear to be predominantly intracellularly located.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=880><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=881><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=882>Systematic nomenclatureSLC2A5SLC2A7SLC2A9Common abbreviationGLUT5GLUT7GLUT9HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11010](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11010), <http://www.uniprot.org/uniprot/P22732>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13445](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13445), <http://www.uniprot.org/uniprot/Q6PXP3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13446](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13446), <http://www.uniprot.org/uniprot/Q9NRM0>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4654> (D‐fructose \> D‐glucose) \[<http://www.ncbi.nlm.nih.gov/pubmed/1634504?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> (D‐fructose \> D‐glucose) \[<http://www.ncbi.nlm.nih.gov/pubmed/1634504?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4654> \[<http://www.ncbi.nlm.nih.gov/pubmed/18477702?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> \[<http://www.ncbi.nlm.nih.gov/pubmed/18477702?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4654> \[<http://www.ncbi.nlm.nih.gov/pubmed/18842065?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4731> \[<http://www.ncbi.nlm.nih.gov/pubmed/18842065?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=883><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=884><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=885><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=886><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=887>Systematic nomenclatureSLC2A11SLC2A6SLC2A8SLC2A10SLC2A12Common abbreviationGLUT11GLUT6GLUT8GLUT10GLUT12HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14239](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14239), <http://www.uniprot.org/uniprot/Q9BYW1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11011](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11011), <http://www.uniprot.org/uniprot/Q9UGQ3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13812](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13812), <http://www.uniprot.org/uniprot/Q9NY64>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13444](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13444), <http://www.uniprot.org/uniprot/O95528>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18067](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18067), <http://www.uniprot.org/uniprot/Q8TD20>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4654> \[<http://www.ncbi.nlm.nih.gov/pubmed/17710649?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> \[<http://www.ncbi.nlm.nih.gov/pubmed/11583593?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> \[<http://www.ncbi.nlm.nih.gov/pubmed/10671487?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4733> \[<http://www.ncbi.nlm.nih.gov/pubmed/20639396?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> \[<http://www.ncbi.nlm.nih.gov/pubmed/20639396?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> \[<http://www.ncbi.nlm.nih.gov/pubmed/12914765?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=167> {#bph14753-sec-0063}
===========================================================================

Overview {#bph14753-sec-0064}
--------

Proton‐coupled inositol transporters are expressed predominantly in the brain and can be inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4285> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5334> \[<http://www.ncbi.nlm.nih.gov/pubmed/12135767?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=888>Systematic nomenclatureSLC2A13Common abbreviationHMITHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15956](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15956), <http://www.uniprot.org/uniprot/Q96QE2>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4645> \[<http://www.ncbi.nlm.nih.gov/pubmed/12135767?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4495> \[<http://www.ncbi.nlm.nih.gov/pubmed/12135767?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4649> \[<http://www.ncbi.nlm.nih.gov/pubmed/12135767?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4648> \[<http://www.ncbi.nlm.nih.gov/pubmed/12135767?dopt=AbstractPlus>\]Stoichiometry1 H^+^: 1 inositol (in) \[<http://www.ncbi.nlm.nih.gov/pubmed/19607714?dopt=AbstractPlus>\]

Further reading on SLC2 family of hexose and sugar alcohol transporters {#bph14753-sec-0065}
-----------------------------------------------------------------------

Augustin R. (2010) The protein family of glucose transport facilitators: It\'s not only about glucose after all. *IUBMB Life* **62**: 315--33 <https://www.ncbi.nlm.nih.gov/pubmed/20209635?dopt=AbstractPlus>

Klip A *et al*. (2014) Signal transduction meets vesicle traffic: the software and hardware of GLUT4 translocation. *Am. J. Physiol., Cell Physiol*. **306**: C879--86 <https://www.ncbi.nlm.nih.gov/pubmed/24598362?dopt=AbstractPlus>

Leney SE *et al*. (2009) Themolecular basis of insulin‐stimulated glucose uptake: signalling, trafficking and potential drug targets. *J. Endocrinol*. **203**: 1--18 <https://www.ncbi.nlm.nih.gov/pubmed/19389739?dopt=AbstractPlus>

Mueckler M *et al*. (2013) The SLC2 (GLUT) family of membrane transporters. Mol. Aspects Med. 34: 121‐38 <https://www.ncbi.nlm.nih.gov/pubmed/23506862?dopt=AbstractPlus>

Uldry M *et al*. (2004) The SLC2 family of facilitated hexose and polyol transporters. *Pflugers Arch*. 447: 480‐9 <https://www.ncbi.nlm.nih.gov/pubmed/12750891?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=141> {#bph14753-sec-0066}
===========================================================================

Overview {#bph14753-sec-0067}
--------

The SLC3 and SLC7 families combine to generate functional transporters, where the subunit composition is a disulphide‐linked combination of a heavy chain (SLC3 family) with a light chain (SLC7 family).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=168> {#bph14753-sec-0068}
===========================================================================

Overview {#bph14753-sec-0069}
--------

SLC3 family members are single TM proteins with extensive glycosylation of the exterior C‐terminus, which heterodimerize with SLC7 family members in the endoplasmic reticulum and assist in the plasma membrane localization of the transporter.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=168>.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=169> {#bph14753-sec-0070}
===========================================================================

Overview {#bph14753-sec-0071}
--------

SLC7 family members may be divided into two major groups: cationic amino acid transporters (CATs) and glycoprotein‐associated amino acid transporters (gpaATs). Cationic amino acid transporters are 14 TM proteins, which mediate pH^‐^ and sodium‐independent transport of cationic amino acids (system y^+^), apparently as an exchange mechanism. These transporters are sensitive to inhibition by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5335>.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=891><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=892><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=893><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=896><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=897>Systematic nomenclatureSLC7A1SLC7A2SLC7A3SLC7A5SLC7A8Common abbreviationCAT1CAT2CAT3LAT1LAT2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11057](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11057), <http://www.uniprot.org/uniprot/P30825>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11060](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11060), <http://www.uniprot.org/uniprot/P52569>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11061](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11061), <http://www.uniprot.org/uniprot/Q8WY07>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11063](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11063), <http://www.uniprot.org/uniprot/Q01650>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11066](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11066), <http://www.uniprot.org/uniprot/Q9UHI5>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=724>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=724>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=724>----Selective inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9347> \[<http://www.ncbi.nlm.nih.gov/pubmed/19900191?dopt=AbstractPlus>\]--

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=898><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=899><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=900><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=901><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=902><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=903>Systematic nomenclatureSLC7A7SLC7A6SLC7A9SLC7A10SLC7A11SLC7A13Common abbreviationy+LAT1y+LAT2b^0,+^ATAsc‐1xCT--HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11065](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11065), <http://www.uniprot.org/uniprot/Q9UM01>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11064](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11064), <http://www.uniprot.org/uniprot/Q92536>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11067](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11067), <http://www.uniprot.org/uniprot/P82251>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11058](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11058), <http://www.uniprot.org/uniprot/Q9NS82>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11059](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11059), <http://www.uniprot.org/uniprot/Q9UPY5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23092](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23092), <http://www.uniprot.org/uniprot/Q8TCU3>Inhibitors--------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1372> (pIC50 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/20303751?dopt=AbstractPlus>\]--

Comments {#bph14753-sec-0072}
--------

CAT4 appears to be non‐functional in heterologous expression \[<http://www.ncbi.nlm.nih.gov/pubmed/12049641?dopt=AbstractPlus>\], while SLC7A14 has yet to be characterized. Glycoprotein‐associated amino acid transporters are 12 TM proteins, which heterodimerize with members of the SLC3 family to act as cell‐surface amino acid exchangers.

Heterodimers between 4F2hc and LAT1 or LAT2 generate sodium‐independent system L transporters. LAT1 transports large neutral amino acids including branched‐chain and aromatic amino acids as well as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4841>, whereas LAT2 transports most of the neutral amino acids.

Heterodimers between 4F2hc and y^+^LAT1 or y^+^LAT2 generate transporters similar to the system y^+^L , which transport cationic (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=724>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725>) amino acids independent of sodium and neutral (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3312>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3311>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4814>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723>) amino acids in a partially sodium‐dependent manner. These transporters are <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5335>‐insensitive. Heterodimers between rBAT and b^0,+^AT appear to mediate sodium‐independent system b^0,+^ transport of most of the neutral amino acids and cationic amino acids (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=724> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725>).

Asc‐1 appears to heterodimerize with 4F2hc to allow the transport of small neutral amino acids (such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4785>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727>), as well as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4171>, in a sodium‐independent manner.

xCT generates a heterodimer with 4F2hc for a system x^‐^ ~e‐c~ transporter that mediates the sodium‐independent exchange of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5413> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>.

AGT has been conjugated with SLC3 members as fusion proteins to generate functional transporters, but the identity of a native heterodimer has yet to be ascertained.

Further reading on SLC3 and SLC7 families of heteromeric amino acid transporters (HATs) {#bph14753-sec-0073}
---------------------------------------------------------------------------------------

Bhutia YD *et al*. (2015) Amino Acid transporters in cancer and their relevance to \"glutamine addiction\": novel targets for the design of a new class of anticancer drugs. *Cancer Res*. **75**: 1782--8 <https://www.ncbi.nlm.nih.gov/pubmed/25855379?dopt=AbstractPlus>

Fotiadis D *et al*. (2013) The SLC3 and SLC7 families of amino acid transporters. *Mol. Aspects Med*. **34**: 139--58 <https://www.ncbi.nlm.nih.gov/pubmed/23506863?dopt=AbstractPlus>

Palacín M *et al*. (2004) The ancillary proteins of HATs: SLC3 family of amino acid transporters. *Pflugers Arch*. **447**: 490--4 <https://www.ncbi.nlm.nih.gov/pubmed/14770309?dopt=AbstractPlus>

Palacín M *et al*. (2005) The genetics of heteromeric amino acid transporters. *Physiology (Bethesda)* **20**: 112--24 <https://www.ncbi.nlm.nih.gov/pubmed/15772300?dopt=AbstractPlus>

Verrey F *et al*. (2004) CATs and HATs: the SLC7 family of amino acid transporters. *Pflugers Arch*. **447**: 532--42 <https://www.ncbi.nlm.nih.gov/pubmed/14770310?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=142> {#bph14753-sec-0074}
===========================================================================

Overview {#bph14753-sec-0075}
--------

Together with the SLC26 family, the SLC4 family of transporters subserve anion exchange, principally of chloride and bicarbonate (HCO~3~ ^‐^), but also carbonate and hydrogen sulphate (HSO~4~ ^‐^). SLC4 family members regulate bicarbonate fluxes as part of carbon dioxidemovement, chyme neutralization and reabsorption in the kidney.

Within the family, subgroups of transporters are identifiable: the electroneutral sodium‐independent Cl^‐^/HCO~3~ ^‐^ transporters (AE1, AE2 and AE3), the electrogenic sodium‐dependent HCO~3~ ^‐^ transporters (NBCe1 and NBCe2) and the electroneutral HCO~3~ ^‐^ transporters (NBCn1 and NBCn2). Topographical information derives mainly from study of AE1, abundant in erythrocytes, which suggests a dimeric or tetrameric arrangement, with subunits made up of 13 TM domains and re‐entrant loops at TM9/10 and TM11/12. The N terminus exhibits sites for interaction with multiple proteins, including glycolytic enzymes, haemoglobin and cytoskeletal elements.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=170> {#bph14753-sec-0076}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=904><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=905><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=906><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=907>Systematic nomenclatureSLC4A1SLC4A2SLC4A3SLC4A9Common abbreviationAE1AE2AE3AE4HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11027](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11027), <http://www.uniprot.org/uniprot/P02730>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11028](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11028), <http://www.uniprot.org/uniprot/P04920>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11029](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11029), <http://www.uniprot.org/uniprot/P48751>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11035](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11035), <http://www.uniprot.org/uniprot/Q96Q91>Endogenous substratesHCO~3~ ^‐^, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2339><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2339>, HCO~3~ ^‐^<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2339>, HCO~3~ ^‐^--Stoichiometry1 Cl^‐^ (in) : 1 HCO~3~ ^‐^ (out)1 Cl^‐^ (in) : 1 HCO~3~ ^‐^ (out)1 Cl^‐^ (in) : 1 HCO~3~ ^‐^ (out)--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=171> {#bph14753-sec-0077}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=908><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=909><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=910><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=911><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=912><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=913>Systematic nomenclatureSLC4A4SLC4A5SLC4A7SLC4A10SLC4A8SLC4A11Common abbreviationNBCe1NBCe2NBCn1NBCn2NDCBEBTR1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11030](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11030), <http://www.uniprot.org/uniprot/Q9Y6R1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18168](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18168), <http://www.uniprot.org/uniprot/Q9BY07>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11033](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11033), <http://www.uniprot.org/uniprot/Q9Y6M7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13811](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13811), <http://www.uniprot.org/uniprot/Q6U841>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11034](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11034), <http://www.uniprot.org/uniprot/Q2Y0W8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16438](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16438), <http://www.uniprot.org/uniprot/Q8NBS3>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4507><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4507><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4507><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4507><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4507>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2339><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2339>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4507>Stoichiometry1 Na^+^ : 2/3 HCO~3~ ^‐^ (out) or 1 Na^+^ : CO~3~ ^2\*^1 Na^+^ : 2/3 HCO~3~ ^‐^ (out) or 1 Na^+^ : CO~3~ ^2\*^1 Na^+^ : 1 HCO~3~ ^‐^ (out) or 1 Na^+^ : CO~3~ ^2\*^1 Na^+^ : 1 HCO~3~ ^‐^ (out) or 1 Na : CO~3~ ^2\*^1 Na^+^ : 2HCO~3~ ^‐^ (in) : 1 Cl^‐^ (out)--

Further reading on SLC4 family of bicarbonate transporters {#bph14753-sec-0078}
----------------------------------------------------------

Majumdar D *et al*. (2010) Na‐coupled bicarbonate transporters of the solute carrier 4 family in the nervous system: function, localization, and relevance to neurologic function. *Neuroscience* **171**: 951‐72 \[<https://www.ncbi.nlm.nih.gov/pubmed/20884330?dopt=AbstractPlus>\]

Parker MD *et al*. (2013) The divergence, actions, roles, and relatives of sodium‐coupled bicarbonate transporters. *Physiol. Rev*. **93**: 803‐959 \[<https://www.ncbi.nlm.nih.gov/pubmed/23589833?dopt=AbstractPlus>\]

Reithmeier RA *et al*. (2016) Band 3, the human red cell chloride/bicarbonate anion exchanger (AE1, SLC4A1), in a structural context. *Biochim. Biophys. Acta* **1858**: 1507‐32 \[<https://www.ncbi.nlm.nih.gov/pubmed/27058983?dopt=AbstractPlus>\]
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=143> {#bph14753-sec-0079}
===========================================================================

Overview {#bph14753-sec-0080}
--------

The SLC5 family of sodium‐dependent glucose transporters includes, in mammals, the Na^+^/substrate co‐transporters for glucose (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536>, monocarboxylates, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4495> and I^‐^ \[<http://www.ncbi.nlm.nih.gov/pubmed/14993474?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18446519?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21527736?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12748858?dopt=AbstractPlus>\]. Members of the SLC5 and SLC6 families, along with other unrelated Na^+^ cotransporters (*i.e*. Mhp1 and BetP), share a common structural core that contains an inverted repeat of 5TM α‐helical domains \[<http://www.ncbi.nlm.nih.gov/pubmed/19631523?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=173> {#bph14753-sec-0081}
===========================================================================

Overview {#bph14753-sec-0082}
--------

Detailed characterisation of members of the hexose transporter family is limited to SGLT1, 2 and 3, which are all inhibited in a competitive manner by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4757>, a natural dihydrocholine glucoside, that exhibits modest selectivity towards SGLT2 (see \[<http://www.ncbi.nlm.nih.gov/pubmed/21527736?dopt=AbstractPlus>\] for an extensive review). SGLT1 is predominantly expressed in the small intestine, mediating the absorption of glucose (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536>), but also occurs in the brain, heart and in the late proximal straight tubule of the kidney. The expression of SGLT2 is almost exclusively restricted to the early proximal convoluted tubule of the kidney, where it is largely responsible for the renal reabsorption of glucose. SGLT3 is not a transporter but instead acts as a glucosensor generating an inwardly directed flux of Na^+^ that causes membrane depolarization \[<http://www.ncbi.nlm.nih.gov/pubmed/13130073?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=915><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=916><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=917><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=918><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=919>Systematic nomenclatureSLC5A1SLC5A2SLC5A4SLC5A9SLC5A10Common abbreviationSGLT1SGLT2SGLT3SGLT4SGLT5HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11036](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11036), <http://www.uniprot.org/uniprot/P13866>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11037](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11037), <http://www.uniprot.org/uniprot/P31639>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11039](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11039), <http://www.uniprot.org/uniprot/Q9NY91>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:22146](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:22146), <http://www.uniprot.org/uniprot/Q2M3M2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23155](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23155), <http://www.uniprot.org/uniprot/A0PJK1>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4646> \[<http://www.ncbi.nlm.nih.gov/pubmed/17110502?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4640> \[<http://www.ncbi.nlm.nih.gov/pubmed/17110502?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> \[<http://www.ncbi.nlm.nih.gov/pubmed/17110502?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4640>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> \[<http://www.ncbi.nlm.nih.gov/pubmed/17110502?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4744> \[<http://www.ncbi.nlm.nih.gov/pubmed/17110502?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4586> \[<http://www.ncbi.nlm.nih.gov/pubmed/17110502?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4841> \[<http://www.ncbi.nlm.nih.gov/pubmed/17110502?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4842> \[<http://www.ncbi.nlm.nih.gov/pubmed/17110502?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4642> \[<http://www.ncbi.nlm.nih.gov/pubmed/17110502?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4650>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4640><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4646>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536>Stoichiometry2 Na^+^ : 1 glucose \[<http://www.ncbi.nlm.nih.gov/pubmed/8282810?dopt=AbstractPlus>\]1 Na^+^ : 1 glucose \[<http://www.ncbi.nlm.nih.gov/pubmed/20980548?dopt=AbstractPlus>\]------Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9547> (p*K* ~i~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/28410751?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4594> (pIC~50~ 9.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/20637636?dopt=AbstractPlus>\]------Comments----SGLT3 acts as a glucosensor.----

Comments {#bph14753-sec-0083}
--------

Recognition and transport of substrate by SGLTs requires that the sugar is a pyranose. De‐oxyglucose derivatives have reduced affinity for SGLT1, but the replacement of the sugar equatorial hydroxyl group by fluorine at some positions, excepting C2 and C3, is tolerated (see \[<http://www.ncbi.nlm.nih.gov/pubmed/21527736?dopt=AbstractPlus>\] for a detailed quantification). Although SGLT1 and SGLT2 have been described as high‐ and lowaffinity sodium glucose co‐transporters, respectively, recent work suggests that they have a similar affinity for glucose under physiological conditions \[<http://www.ncbi.nlm.nih.gov/pubmed/20980548?dopt=AbstractPlus>\]. Selective blockers of SGLT2, and thus blocking 50% of renal glucose reabsorption, are in development for the treatment of diabetes (*e.g*. \[<http://www.ncbi.nlm.nih.gov/pubmed/20508640?dopt=AbstractPlus>\]).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=172> {#bph14753-sec-0084}
===========================================================================

Overview {#bph14753-sec-0085}
--------

The high affinity, hemicholinium‐3‐sensitive, choline transporter (CHT) is expressed mainly in cholinergic neurones on nerve cell terminals and synaptic vesicles (keratinocytes being an additional location). In autonomic neurones, expression of CHT requires an activity‐dependent retrograde signal from postsynaptic neurones \[<http://www.ncbi.nlm.nih.gov/pubmed/19186169?dopt=AbstractPlus>\]. Through recapture of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551> generated by the hydrolysis of ACh by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294>sterase, CHT serves to maintain acetylcholine synthesis within the presynaptic terminal \[<http://www.ncbi.nlm.nih.gov/pubmed/14993474?dopt=AbstractPlus>\]. Homozygous mice engineered to lack CHT die within one hour of birth as a result of hypoxia arising from failure of transmission at the neuromuscular junction of the skeletal muscles that support respiration \[<http://www.ncbi.nlm.nih.gov/pubmed/15173594?dopt=AbstractPlus>\]. A low affinity choline uptake mechanism that remains to be identified at the molecular level may involve multiple transporters. In addition, a family of choline transporter‐like (CTL) proteins, (which are members of the SLC44 family) with weak Na^+^ dependence have been described \[<http://www.ncbi.nlm.nih.gov/pubmed/15715662?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=914>Systematic nomenclatureSLC5A7HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14025](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14025), <http://www.uniprot.org/uniprot/Q9GZV3>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4760>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551>StoichiometryNa^+^ : choline (variable stoichimetry); modulated by extracellular Cl^‐^ \[<http://www.ncbi.nlm.nih.gov/pubmed/17005849?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4494> (p*K* ~i~ 7--8) \[<http://www.ncbi.nlm.nih.gov/pubmed/12675135?dopt=AbstractPlus>\]Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4493> (p*K* ~d~ 8.2--8.4)

Comments {#bph14753-sec-0086}
--------

K~i~ and K~D~ values for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4494> listed in the table are for human CHT expressed in *Xenopus laevis* oocytes \[<http://www.ncbi.nlm.nih.gov/pubmed/11068039?dopt=AbstractPlus>\], or COS‐7 cells \[<http://www.ncbi.nlm.nih.gov/pubmed/11027560?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5502> is a substrate for CHT that causes covalent modification and irreversible inactivation of the transporter. Several exogenous substances (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4760>) that are substrates for CHT act as precursors to cholinergic false transmitters.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=174> {#bph14753-sec-0087}
===========================================================================

Overview {#bph14753-sec-0088}
--------

The sodium‐iodide symporter (NIS) is an iodide transporter found principally in the thyroid gland where it mediates the accumulation of I^‐^ within thyrocytes. Transport of I^‐^ by NIS from the blood across the basolateral membrane followed by apical efflux into the colloidal lumen, mediated at least in part by pendrin (SLC22A4), and most likely not SMCT1 (SLC5A8) as once thought, provides the I^‐^ required for the synthesis of the thyroid hormones triiodothyronine (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634>) and thyroxine (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635>) \[<http://www.ncbi.nlm.nih.gov/pubmed/19196800?dopt=AbstractPlus>\]. NIS is also expressed in the salivary glands, gastric mucosa, intestinal enterocytes and lactating breast. NIS mediates I^‐^ absorption in the intestine and I^‐^ secretion into the milk. SMVT is expressed on the apical membrane of intestinal enterocytes and colonocytes and is the main system responsible for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787> (vitamin H) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4668> (vitamin B~5~) uptake in humans \[<http://www.ncbi.nlm.nih.gov/pubmed/19056639?dopt=AbstractPlus>\]. SMVT located in kidney proximal tubule epithelial cells mediates the reabsorption of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4668>. SMCT1 (SLC5A8), which transports a wide range of monocarboxylates, is expressed in the apical membrane of epithelia of the small intestine, colon, kidney, brain neurones and the retinal pigment epithelium \[<http://www.ncbi.nlm.nih.gov/pubmed/18446519?dopt=AbstractPlus>\]. SMCT2 (SLC5A12) also localises to the apical membrane of kidney, intestine, and colon, but in the brain and retina is restricted to astrocytes and Müller cells, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/18446519?dopt=AbstractPlus>\]. SMCT1 is a high‐affinity transporter whereas SMCT2 is a lowaffinity transporter. The physiological substrates for SMCT1 and SMCT2 are lactate (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2934>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1062>, and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1588> in non‐colonic tissues such as the kidney. SMCT1 is also likely to be the principal transporter for the absorption of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1588> (vitamin B3) in the intestine and kidney \[<http://www.ncbi.nlm.nih.gov/pubmed/15651982?dopt=AbstractPlus>\]. In the small intestine and colon, the physiological substrates for these transporters are <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1588> and the shortchain fatty acids <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1062>, and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059> that are produced by bacterial fermentation of dietary fiber \[<http://www.ncbi.nlm.nih.gov/pubmed/14966140?dopt=AbstractPlus>\]. In the kidney, SMCT2 is responsible for the bulk absorption of lactate because of its low‐affinity/high‐capacity nature. Absence of both transporters in the kidney leads to massive excretion of lactate in urine and consequently drastic decrease in the circulating levels of lactate in blood \[<http://www.ncbi.nlm.nih.gov/pubmed/16873376?dopt=AbstractPlus>\]. SMCT1 also functions as a tumour suppressor in the colon as well as in various other non‐colonic tissues \[<http://www.ncbi.nlm.nih.gov/pubmed/18992769?dopt=AbstractPlus>\]. The tumour‐suppressive function of SMCT1 is based on its ability to transport <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809>, an inhibitor of histone deacetylases, into cells in non‐colonic tissues \[<http://www.ncbi.nlm.nih.gov/pubmed/17178845?dopt=AbstractPlus>\]; in the colon, the ability of SMCT1 to transport <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1062>, also inhibitors of histone deacetylases, underlies the tumour‐suppressive function of this transporter \[<http://www.ncbi.nlm.nih.gov/pubmed/18446519?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18992769?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16375929?dopt=AbstractPlus>\]. The ability of SMCT1 to promote histone acetylase inhibition through accumulation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1062> in immune cells is also responsible for suppression of dendritic cell development in the colon \[<http://www.ncbi.nlm.nih.gov/pubmed/20601425?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=920><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=921><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=922><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=923>Systematic nomenclatureSLC5A5SLC5A6SLC5A8SLC5A12HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11040](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11040), <http://www.uniprot.org/uniprot/Q92911>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11041](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11041), <http://www.uniprot.org/uniprot/Q9Y289>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19119](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19119), <http://www.uniprot.org/uniprot/Q8N695>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:28750](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28750), <http://www.uniprot.org/uniprot/Q1EHB4>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4524>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4529>, I^‐^, NO~3~ ^‐^, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4515><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4822> \[<http://www.ncbi.nlm.nih.gov/pubmed/20980265?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4668> \[<http://www.ncbi.nlm.nih.gov/pubmed/20980265?dopt=AbstractPlus>\], I^‐^ \[<http://www.ncbi.nlm.nih.gov/pubmed/20980265?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787> \[<http://www.ncbi.nlm.nih.gov/pubmed/20980265?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1062>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4517>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4703>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1588>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2934>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1593>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4306>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4518>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4656>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4522>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4565>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4711>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4521>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4699>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4655><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1588>Stoichiometry2Na^+^ : 1I^‐^ \[<http://www.ncbi.nlm.nih.gov/pubmed/9341168?dopt=AbstractPlus>\]; 1Na^+^ : 1 ClO~4~ ^‐^ \[<http://www.ncbi.nlm.nih.gov/pubmed/18077370?dopt=AbstractPlus>\]2Na^+^ : 1 biotin (or pantothenic acid) \[<http://www.ncbi.nlm.nih.gov/pubmed/10772912?dopt=AbstractPlus>\]2Na^+^ : 1 monocarboxylate \[<http://www.ncbi.nlm.nih.gov/pubmed/17526579?dopt=AbstractPlus>\]--Inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4820> (pIC~50~ 4.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/16729224?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2713> (pIC~50~ 4.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/16729224?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4795> (pIC~50~ 3.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/16729224?dopt=AbstractPlus>\]--

Comments {#bph14753-sec-0089}
--------

I^‐^, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4524>, thiocyanate and NO~3~ ^‐^ are competitive substrate inhibitors of NIS \[<http://www.ncbi.nlm.nih.gov/pubmed/18077370?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4822> appears to act as a competitive substrate inhibitor of SMVT \[<http://www.ncbi.nlm.nih.gov/pubmed/10329687?dopt=AbstractPlus>\] and the anticonvulsant drugs <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5338> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5339> competitively block the transport of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787> by brush border vesicles prepared from human intestine \[<http://www.ncbi.nlm.nih.gov/pubmed/2911998?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=175> {#bph14753-sec-0090}
===========================================================================

Overview {#bph14753-sec-0091}
--------

Three different mammalian myo‐inositol cotransporters are currently known; two are the Na^+^‐coupled SMIT1 and SMIT2 tabulated below and the third is proton‐coupled HMIT (SLC2A13). SMIT1 and SMIT2 have a widespread and overlapping tissue location but in polarized cells, such as the Madin‐ Darby canine kidney cell line, they segregate to the basolateral and apical membranes, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/15181167?dopt=AbstractPlus>\]. In the nephron, SMIT1 mediates <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4495> uptake as a 'compatible osmolyte' when inner medullary tubules are exposed to increases in extracellular osmolality, whilst SMIT2 mediates the reabsorption of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4495> from the filtrate. In some species (*e.g.* rat, but not rabbit) apically located SMIT2 is responsible for the uptake of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4495> from the intestinal lumen \[<http://www.ncbi.nlm.nih.gov/pubmed/17932225?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=924><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=925>Systematic nomenclatureSLC5A3SLC5A11Common abbreviationSMIT1SMIT2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11038](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11038), <http://www.uniprot.org/uniprot/P53794>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23091](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23091), <http://www.uniprot.org/uniprot/Q8WWX8>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4495>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4649> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4721> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4720> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4719>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4640> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4646>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4722> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4724> \[<http://www.ncbi.nlm.nih.gov/pubmed/7537337?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4495> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4645> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4724> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4720> \[<http://www.ncbi.nlm.nih.gov/pubmed/12133831?dopt=AbstractPlus>\]Stoichiometry2 Na^+^ :1 *myo*‐inositol \[<http://www.ncbi.nlm.nih.gov/pubmed/7537337?dopt=AbstractPlus>\]2Na^+^ :1 *myo*‐inositol \[<http://www.ncbi.nlm.nih.gov/pubmed/15613375?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4757> \[<http://www.ncbi.nlm.nih.gov/pubmed/12133831?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4757> (p*K* ~i~ 4.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/12133831?dopt=AbstractPlus>\]

Comments {#bph14753-sec-0092}
--------

The data tabulated are those for dog SMIT1 and rabbit SMIT2. SMIT2 transports <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4645>, but SMIT1 does not. In addition, whereas SMIT1 transports both <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4724> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4720> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4722> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4721>, SMIT2 transports only the D‐isomers of these sugars \[<http://www.ncbi.nlm.nih.gov/pubmed/12133831?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7537337?dopt=AbstractPlus>\]. Thus the substrate specificities of SMIT1 (for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4721>) and SMIT2 (for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4645>) allow discrimination between the two SMITs. Human SMIT2 appears not to transport glucose \[<http://www.ncbi.nlm.nih.gov/pubmed/19032932?dopt=AbstractPlus>\].

Further reading on SLC5 family of sodium‐dependent glucose transporters {#bph14753-sec-0093}
-----------------------------------------------------------------------

DeFronzo RA *et al*. (2017) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. *Nat Rev Nephrol* **13**: 11‐26 <https://www.ncbi.nlm.nih.gov/pubmed/27941935?dopt=AbstractPlus>

Koepsell H. (2017) The Na^+^‐D‐glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. *Pharmacol. Ther*. **170**: 148‐165 <https://www.ncbi.nlm.nih.gov/pubmed/27773781?dopt=AbstractPlus>

Lehmann A *et al*. (2016) Intestinal SGLT1 inmetabolic health and disease. *Am. J. Physiol. Gastrointest. Liver Physiol*. **310**: G887‐98 <https://www.ncbi.nlm.nih.gov/pubmed/27012770?dopt=AbstractPlus>

Wright EM. (2013) Glucose transport families SLC5 and SLC50. *Mol. Aspects Med*. **34**: 183‐96 <https://www.ncbi.nlm.nih.gov/pubmed/23506865?dopt=AbstractPlus>

Wright EM *et al*. (2011) Biology of human sodium glucose transporters. *Physiol. Rev*. **91**: 733‐94 <https://www.ncbi.nlm.nih.gov/pubmed/21527736?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=144> {#bph14753-sec-0094}
===========================================================================

Overview {#bph14753-sec-0095}
--------

Members of the solute carrier family 6 (SLC6) of sodium‐ and (sometimes chloride‐) dependent neurotransmitter transporters \[<http://www.ncbi.nlm.nih.gov/pubmed/16540203?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12719981?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21752877?dopt=AbstractPlus>\] are primarily plasma membrane located and may be divided into four subfamilies that transport monoamines, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> and neutral amino acids, plus the related bacterial NSS transporters \[<http://www.ncbi.nlm.nih.gov/pubmed/19022853?dopt=AbstractPlus>\]. The members of this superfamily share a structural motif of 10 TM segments that has been observed in crystal structures of the NSS bacterial homolog LeuT~Aa~, a Na^+^‐dependent amino acid transporter from *Aquiflex aeolicus* \[<http://www.ncbi.nlm.nih.gov/pubmed/16041361?dopt=AbstractPlus>\] and in several other transporter families structurally related to LeuT \[<http://www.ncbi.nlm.nih.gov/pubmed/19996368?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=176> {#bph14753-sec-0096}
===========================================================================

Overview {#bph14753-sec-0097}
--------

Monoamine neurotransmission is limited by perisynaptic transporters. Presynapticmonoamine transporters allow recycling of synaptically released <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=484>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5>.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=927><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=928>Systematic nomenclatureSLC6A2SLC6A3SLC6A4HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11048](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11048), <http://www.uniprot.org/uniprot/P23975>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11049](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11049), <http://www.uniprot.org/uniprot/Q01959>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11050](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11050), <http://www.uniprot.org/uniprot/P31645>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4568>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4803>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4804><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4568>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4803>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4804><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4574>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4592>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5>Stoichiometry1 noradrenaline: 1 Na^+^:1 Cl^‐^ \[<http://www.ncbi.nlm.nih.gov/pubmed/8636118?dopt=AbstractPlus>\]1 dopamine: 1^∪^2 Na^+^: 1 Cl^‐^ \[<http://www.ncbi.nlm.nih.gov/pubmed/8125921?dopt=AbstractPlus>\]1 5‐HT:1 Na^+^:1 Cl^‐^ (in), + 1 K^+^ (out) \[<http://www.ncbi.nlm.nih.gov/pubmed/6853478?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9880> (p*K* ~i~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/29615471?dopt=AbstractPlus>\] -- Rat--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9880> (p*K* ~i~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/29615471?dopt=AbstractPlus>\] -- RatSub/family‐selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2586> (p*K* ~i~ 5.2) \[[31](#bph14753-bib-0031){ref-type="ref"}\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2586> (p*K* ~i~ 6.3) \[[31](#bph14753-bib-0031){ref-type="ref"}\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2586> (p*K* ~i~ 6) \[[31](#bph14753-bib-0031){ref-type="ref"}\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4797> (p*K* ~i~ 8.9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7285> (pIC~50~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/22420844?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4637> (p*K* ~i~ 8.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7285> (p*K* ~i~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/18983139?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4792> (p*K* ~i~ 8.1), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4808> (p*K* ~i~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/10812041?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4797> (p*K* ~i~ 8), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4606> (p*K* ~i~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/8878059?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4639> (p*K* ~i~ 7.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7554> (p*K* ~i~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/21129986?dopt=AbstractPluss>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7236> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/17228864?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2398> (p*K* ~i~ 9.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/9537821?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4790> (p*K* ~i~ 9.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/9537821?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2398> (p*K* ~d~ 9.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/9537821?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4798> (p*K* ~i~ 9.1), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7177> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/19720528?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7901> (pIC~50~ 8.9) \[[233](#bph14753-bib-0233){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7189> (p*K* ~d~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/9537821?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=203> (p*K* ~i~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/9537821?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7547> (p*K* ~i~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/18487050?dopt=AbstractPlus>\]Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4591> (Inhibitor) (p*K* ~d~ 9.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/15300361?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4636> (Inhibitor) (p*K* ~d~ 8.4)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4638> (Inhibitor) (p*K* ~d~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/8302271?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4605> (Inhibitor) (p*K* ~d~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/8302271?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4561> (Inhibitor) (p*K* ~d~ 9.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4621> (Inhibitor) (p*K* ~d~ 8.3)

Comments {#bph14753-sec-0098}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5409> labels all three monoamine transporters (NET, DAT and SERT) with affinities between 0.5 and 5 nM. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2286> is an inhibitor of all three transporters with *p*K~i~ values between 6.5 and 7.2. Potential alternative splicing sites in non‐coding regions of SERT and NET have been identified. A bacterial homologue of SERT shows allosteric modulation by selected anti‐depressants \[<http://www.ncbi.nlm.nih.gov/pubmed/17687333?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=177> {#bph14753-sec-0099}
===========================================================================

Overview {#bph14753-sec-0100}
--------

The activity of GABA‐transporters located predominantly upon neurones (GAT‐1), glia (GAT‐3) or both (GAT‐2, BGT‐ 1) serves to terminate phasic GABA‐ergic transmission, maintain low ambient extracellular concentrations of GABA, and recycle GABA for reuse by neurones. Nonetheless, ambient concentrations of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067> are sufficient to sustain tonic inhibition mediated by high affinity GABAA receptors in certain neuronal populations \[<http://www.ncbi.nlm.nih.gov/pubmed/15111008?dopt=AbstractPlus>\]. GAT1 is the predominant GABA transporter in the brain and occurs primarily upon the terminals of presynaptic neurones and to a much lesser extent upon distal astocytic processes that are in proximity to axons terminals. GAT3 resides predominantly on distal astrocytic terminals that are close to the GABAergic synapse. By contrast, BGT1 occupies an extrasynaptic location possibly along with GAT2 which has limited expression in the brain \[<http://www.ncbi.nlm.nih.gov/pubmed/20026354?dopt=AbstractPlus>\]. TauT is a high affinity taurine transporter involved in osmotic balance that occurs in the brain and non‐neuronal tissues, such as the kidney, brush border membrane of the intestine and blood brain barrier \[<http://www.ncbi.nlm.nih.gov/pubmed/12719981?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16734743?dopt=AbstractPlus>\]. CT1, which transports <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4496>, has a ubiquitous expression pattern, often co‐localizing with creatine kinase \[<http://www.ncbi.nlm.nih.gov/pubmed/12719981?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=930><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=931><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=932><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=933><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=934>Systematic nomenclatureSLC6A1SLC6A13SLC6A11SLC6A12SLC6A6SLC6A8HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11042](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11042), <http://www.uniprot.org/uniprot/P30531>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11046](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11046), <http://www.uniprot.org/uniprot/Q9NSD5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11044](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11044), <http://www.uniprot.org/uniprot/P48066>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11045](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11045), <http://www.uniprot.org/uniprot/P48065>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11052](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11052), <http://www.uniprot.org/uniprot/P31641>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11055](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11055), <http://www.uniprot.org/uniprot/P48029>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4564>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4691><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4564>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4691><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4691>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4564>------Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2365>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2365>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4550><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2365>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2379>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067> \[<http://www.ncbi.nlm.nih.gov/pubmed/19074966?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4496>Stoichiometry2Na^+^: 1Cl^‐^: 1GABA2Na^+^: 1Cl^‐^: 1GABA≥ 2Na^+^: 2 Cl^‐^: 1GABA3Na^+^: 1 (or 2) Cl^‐^: 1GABA2Na^+^: 1Cl^‐^: 1 taurineProbably 2Na^+^: 1Cl^‐^: 1 creatineSelective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4669> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/7851497?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4818> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/7851497?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4705> (pIC~50~ 6.9) \[149\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4612> (pIC~50~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/7851497?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4583> (pIC~50~ 4.9--5.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6512> (pIC~50~ 5.1--5.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4756> (pIC~50~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/15550575?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6513> (pIC~50~ 3.6--3.9)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4677> (pIC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/7874447?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4677> (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/7874447?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4610> (p*K* ~i~ 5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/9134205?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4583> (pIC~50~ 4.9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6512> (pIC~50~ 3.7--4.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6513> (pIC~50~ 3.6--4.5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4756> (pIC~50~ 4) \[<http://www.ncbi.nlm.nih.gov/pubmed/15550575?dopt=AbstractPlus>\] -- Mouse----Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4685> (Inhibitor)----------

Comments {#bph14753-sec-0101}
--------

The IC50 values for GAT1‐4 reported in the table reflect the range reported in the literature from studies of both human and mouse transporters. There is a tendency towards lower IC~50~ values for the human orthologue \[<http://www.ncbi.nlm.nih.gov/pubmed/19275529?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4677> is only weakly selective for GAT 2 and GAT3, with IC~50~ values in the range 22 to \>30 *μ*M at GAT1 and BGT1, whereas <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4610> has at least an order of magnitude selectivity for BGT1 \[see \[<http://www.ncbi.nlm.nih.gov/pubmed/17175818?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15451399?dopt=AbstractPlus>\] for reviews\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5489> is a recently described compound that displays 20‐fold selectivity for GAT3 over GAT1 \[<http://www.ncbi.nlm.nih.gov/pubmed/16766089?dopt=AbstractPlus>\]. In addition to the inhibitors listed, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5490> is a moderately potent, though non‐selective, inhibitor of all cloned GABA transporters (IC~50~ = 26‐46 *μ*M; \[<http://www.ncbi.nlm.nih.gov/pubmed/8057281?dopt=AbstractPlus>\]). Diaryloxime and diarylvinyl ether derivatives of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4564> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4691> that potently inhibit the uptake of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5410> into rat synaptosomes have been described \[<http://www.ncbi.nlm.nih.gov/pubmed/10479278?dopt=AbstractPlus>\]. Several derivatives of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5418> (*e.g.* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5419> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5420>) demonstrate selectivity as blockers of astroglial, versus neuronal, uptake of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067> \[see \[<http://www.ncbi.nlm.nih.gov/pubmed/17175818?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21428813?dopt=AbstractPlus>\] for reviews\]. GAT3 is inhibited by physiologically relevant concentrations of Zn^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/15829583?dopt=AbstractPlus>\]. Taut transports <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067>, but with low affinity, but CT1 does not, although it can be engineered to do so by mutagenesis guided by LeuT as a structural template \[<http://www.ncbi.nlm.nih.gov/pubmed/17400549?dopt=AbstractPlus>\]. Although inhibitors of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4496> transport by CT1 (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4707>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5491>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5492>) are known (*e.g*. \[<http://www.ncbi.nlm.nih.gov/pubmed/9882430?dopt=AbstractPlus>\]) they insufficiently characterized to be included in the table.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=178> {#bph14753-sec-0102}
===========================================================================

Overview {#bph14753-sec-0103}
--------

Two gene products, GlyT1 and GlyT2, are known that give rise to transporters that are predominantly located on glia and neurones, respectively. Five variants of GlyT1 (a,b,c,d & e) differing in their N‐ and C‐termini are generated by alternative promoter usage and splicing, and three splice variants of GlyT2 (a,b & c) have also been identified (see \[<http://www.ncbi.nlm.nih.gov/pubmed/16417482?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15950877?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16722246?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12354619?dopt=AbstractPlus>\] for reviews). GlyT1 transporter isoforms expressed in glia surrounding glutamatergic synapses regulate synaptic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> concentrations influencing NMDA receptor‐mediated neurotransmission \[<http://www.ncbi.nlm.nih.gov/pubmed/9861038?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15555781?dopt=AbstractPlus>\], but also are important, in early neonatal life, for regulating glycine concentrations at inhibitory glycinergic synapses \[<http://www.ncbi.nlm.nih.gov/pubmed/14622582?dopt=AbstractPlus>\]. Homozygous mice engineered to totally lack GlyT1 exhibit severe respiratory and motor deficiencies due to hyperactive glycinergic signalling and die within the first postnatal day \[<http://www.ncbi.nlm.nih.gov/pubmed/14622582?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15159536?dopt=AbstractPlus>\]. Disruption of GlyT1 restricted to forebrain neurones is associated with enhancement of EPSCs mediated by NMDA receptors and behaviours that are suggestive of a promnesic action \[<http://www.ncbi.nlm.nih.gov/pubmed/16554468?dopt=AbstractPlus>\]. GlyT2 transporters localised on the axons and boutons of glycinergic neurones appear crucial for efficient transmitter loading of synaptic vesicles but may not be essential for the termination of inhibitory neurotransmission \[<http://www.ncbi.nlm.nih.gov/pubmed/14622583?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18815261?dopt=AbstractPlus>\]. Mice in which GlyT2 has been deleted develop a fatal hyperekplexia phenotype during the second postnatal week \[<http://www.ncbi.nlm.nih.gov/pubmed/14622583?dopt=AbstractPlus>\] and mutations in the human gene encoding GlyT2 (SLC6A5) have been identified in patients with hyperekplexia (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/18707791?dopt=AbstractPlus>\]). ATB^0+^ (SLC6A14) is a transporter for numerous dipolar and cationic amino acids and thus has a much broader substrate specificity than the glycine transporters alongside which it is grouped on the basis of structural similarity \[<http://www.ncbi.nlm.nih.gov/pubmed/12719981?dopt=AbstractPlus>\]. ATB^0+^ is expressed in various peripheral tissues \[<http://www.ncbi.nlm.nih.gov/pubmed/12719981?dopt=AbstractPlus>\]. By contrast PROT (SLC6A7), which is expressed only in brain in association with a subset of excitatory nerve terminals, shows specificity for the transport of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314>.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=936><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=937><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=938>Systematic nomenclatureSLC6A9SLC6A5SLC6A14SLC6A7HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11056](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11056), <http://www.uniprot.org/uniprot/P48067>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11051](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11051), <http://www.uniprot.org/uniprot/Q9Y345>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11047](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11047), <http://www.uniprot.org/uniprot/Q9UN76>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11054](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11054), <http://www.uniprot.org/uniprot/Q99884>Substrates----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4700>, zwitterionic or cationic NOS inhibitors \[<http://www.ncbi.nlm.nih.gov/pubmed/11306607?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4694> \[<http://www.ncbi.nlm.nih.gov/pubmed/18522536?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4716> \[<http://www.ncbi.nlm.nih.gov/pubmed/15290873?dopt=AbstractPlus>\]--Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4713>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2365> \[<http://www.ncbi.nlm.nih.gov/pubmed/18599538?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19074966?dopt=AbstractPlus>\] <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3311> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3312>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4814> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4794> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726> \[<http://www.ncbi.nlm.nih.gov/pubmed/10446133?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314>Stoichiometry2 Na^+^: 1 Cl^‐^: 1 glycine3 Na^+^: 1 Cl^‐^: 1 glycine2‐3 Na^+^: 1 Cl^‐^: 1 amino acid \[<http://www.ncbi.nlm.nih.gov/pubmed/10446133?dopt=AbstractPlus>\]Probably 2 Na^+^: 1 Cl^‐^: 1 L‐prolineInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9057> (p*K* ~i~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/19410451?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7546> (pEC~50~ \<4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/20491477?dopt=AbstractPlus>\]----Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4618> (pIC~50~ 8.5--9.1), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4778> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/18621075?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4604> (pIC~50~ 8.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4712> (pIC~50~ 7.8), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4598> (pIC~50~ 7.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7546> (pEC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/20491477?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4667> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/11495577?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4622>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4767><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4693> (pIC~50~ 3.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/18522536?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8520> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/25037917?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4576> (pIC~50~ 7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19159658?dopt=AbstractPlus>\]Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4602> (Binding) (p*K* ~d~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/12657266?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4490> (Binding) (p*K* ~d~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20691713?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4584> (Binding) (p*K* ~d~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/18355687?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4491> (Binding) (p*K* ~d~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/20691713?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4603> (p*K* ~d~ 8.1--8.5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4619> (p*K* ~d~ 7.7--8.2)------Comments--N‐Oleoyl‐L‐carnitine (0.3*μ*M, \[<http://www.ncbi.nlm.nih.gov/pubmed/22978602?dopt=AbstractPlus>\]) and and N‐arachidonoylglycine (IC~50~ 5‐8 *μ*M, \[<http://www.ncbi.nlm.nih.gov/pubmed/16899062?dopt=AbstractPlus>) have been described as potential endogenous selective GlyT2 inhibitors----

Comments {#bph14753-sec-0104}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4713> is a selective transportable inhibitor of GlyT1 and also a weak agonist at the <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> binding site of the NMDA receptor \[<http://www.ncbi.nlm.nih.gov/pubmed/19433577?dopt=AbstractPlus>\], but has no effect on GlyT2. This difference has been attributed to a single glycine residue in TM6 (serine residue in GlyT2) \[<http://www.ncbi.nlm.nih.gov/pubmed/17383967?dopt=AbstractPlus>\]. Inhibition of GLYT1 by the sarcosine derivatives <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4620>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4601> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4600> is non‐competitive \[<http://www.ncbi.nlm.nih.gov/pubmed/12941372?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18815213?dopt=AbstractPlus>\]. IC~50~ values for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4600> reported in the literature vary, most likely due to differences in assay conditions \[<http://www.ncbi.nlm.nih.gov/pubmed/11454468?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12941372?dopt=AbstractPlus>\]. The tricyclic antidepressant <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=201> weakly inhibits GlyT2 (IC~50~ 92 *μ*M) with approximately 10‐fold selectivity over GlyT1 \[<http://www.ncbi.nlm.nih.gov/pubmed/10694221?dopt=AbstractPlus>\]. The endogenous lipids <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> exert opposing effects upon GlyT1a, inhibiting (IC~50~ 2 *μ*M) and potentiating (EC~50~ 13 *μ*M) transport currents, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/12558979?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5493>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5494> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5495> have been described as endogenous non‐competitive inhibitors of GlyT2a, but not GlyT1b \[<http://www.ncbi.nlm.nih.gov/pubmed/19875446?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20860669?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16899062?dopt=AbstractPlus>\]. Protons \[<http://www.ncbi.nlm.nih.gov/pubmed/10860934?dopt=AbstractPlus>\] and Zn^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/15031290?dopt=AbstractPlus>\] act as non‐competitive inhibitors of GlyT1b, with IC~50~ values of 100 nM and 10 *μ*M respectively, but neither ion affects GlyT2 (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/15324920?dopt=AbstractPlus>\]). Glycine transport by GLYT1 is inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5212>, whereas GLYT2 transport is stimulated (both in the presence of Na^+^) \[<http://www.ncbi.nlm.nih.gov/pubmed/21574997?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=179> {#bph14753-sec-0105}
===========================================================================

Overview {#bph14753-sec-0106}
--------

Certain members of neutral amino acid transport family are expressed upon the apical surface of epithelial cells and are important for the absorption of amino acids from the duodenum, jejunum and ileum and their reabsorption within the proximal tubule of the nephron (i.e. B^0^AT1 (SLC6A19), SLC6A18, SLC6A20). Others may function as transporters for neurotransmitters or their precursors (i.e. B^0^AT2, SLC6A17) \[<http://www.ncbi.nlm.nih.gov/pubmed/18400692?dopt=AbstractPlus>\]. B^0^AT1 has been proposed as a drug target to treat phenylketonuria \[<http://www.ncbi.nlm.nih.gov/pubmed/30046012?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=939><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=940><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=941><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=942><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=943><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=944>Systematic nomenclatureSLC6A19SLC6A15SLC6A18SLC6A16SLC6A17SLC6A20HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:27960](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:27960), <http://www.uniprot.org/uniprot/Q695T7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13621](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13621), <http://www.uniprot.org/uniprot/Q9H2J7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:26441](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26441), <http://www.uniprot.org/uniprot/Q96N87>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13622](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13622), <http://www.uniprot.org/uniprot/Q9GZN6>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:31399](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:31399), <http://www.uniprot.org/uniprot/Q9H1V8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30927](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30927), <http://www.uniprot.org/uniprot/Q9NP91>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3312>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4814>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3311>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4794> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4533>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4785>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314> \[<http://www.ncbi.nlm.nih.gov/pubmed/16540203?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4794>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4814>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3312> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3311>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4785>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4533>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> \[<http://www.ncbi.nlm.nih.gov/pubmed/16540203?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4814>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3312>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723> \[<http://www.ncbi.nlm.nih.gov/pubmed/20377526?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3312>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4814>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> \[<http://www.ncbi.nlm.nih.gov/pubmed/19147495?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314>Stoichiometry1 Na^+^: 1 amino acid \[<http://www.ncbi.nlm.nih.gov/pubmed/15804236?dopt=AbstractPlus>\]1Na^+^ : 1 amino acid \[<http://www.ncbi.nlm.nih.gov/pubmed/16185194?dopt=AbstractPlus>\]Na^+^‐ and Cl^‐^ ‐dependent transport \[<http://www.ncbi.nlm.nih.gov/pubmed/19478081?dopt=AbstractPlus>\]--Na^+^‐dependent, Cl^‐^‐independent transport \[<http://www.ncbi.nlm.nih.gov/pubmed/19147495?dopt=AbstractPlus>\]2 Na^+^: 1 Cl^‐^: 1 imino acid \[<http://www.ncbi.nlm.nih.gov/pubmed/19657969?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10256> (pIC~50~ 6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/30589598?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7401> (pIC~50~ 4.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/24704252?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7601> (pIC~50~ 4.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/28176326?dopt=AbstractPlus>\]----------Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7216> (pIC~50~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/25318072?dopt=AbstractPlus>\]--------CommentsMutations in B^0^AT1 are associated with Hartnup disorder--SLC6A18 is a functional transporter in mouse, but not in humans.------

Further reading on SLC6 neurotransmitter transporter family {#bph14753-sec-0107}
-----------------------------------------------------------

Bermingham DP *et al*. (2016) Kinase‐dependent Regulation of Monoamine Neurotransmitter Transporters. *Pharmacol. Rev*. **68**: 888‐953 \[<https://www.ncbi.nlm.nih.gov/pubmed/27591044?dopt=AbstractPlus>\]

Bröer S *et al*. (2012) The solute carrier 6 family of transporters. *Br. J. Pharmacol*. **167**: 256‐78 \[<https://www.ncbi.nlm.nih.gov/pubmed/22519513?dopt=AbstractPlus>\]

Joncquel‐Chevalier Curt M *et al*. (2015) Creatine biosynthesis and transport in health and disease. *Biochimie* **119**: 146‐65 \[<https://www.ncbi.nlm.nih.gov/pubmed/26542286?dopt=AbstractPlus>\]

Lohr KM *et al*. (2017) Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease. *Eur. J. Neurosci*. **45**: 20‐33 \[<https://www.ncbi.nlm.nih.gov/pubmed/27520881?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=180> {#bph14753-sec-0108}
===========================================================================

Overview {#bph14753-sec-0109}
--------

The sodium/calcium exchangers (NCX) use the extracellular sodium concentration to facilitate the extrusion of calcium out of the cell. Alongside the plasma membrane Ca^2+^‐ATPase (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=138#159_overview>) and sarcoplasmic/endoplasmic reticulum Ca^2+^‐ATPase (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=138>), as well as the sodium/potassium/calcium exchangers (NKCX, <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=202>), NCX allow recovery of intracellular calcium back to basal levels after cellular stimulation. When intracellular sodium ion levels rise, for example, following depolarisation, these transporters can operate in the reverse direction to allow calcium influx and sodium efflux, as an electrogenic mechanism. Structural modelling suggests the presence of 9 TM segments, with a large intracellular loop between the fifth and sixth TM segments.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=945><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=946><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=947>Systematic nomenclatureSLC8A1SLC8A2SLC8A3Common abbreviationNCX1NCX2NCX3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11068](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11068), <http://www.uniprot.org/uniprot/P32418>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11069](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11069), <http://www.uniprot.org/uniprot/Q9UPR5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11070](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11070), <http://www.uniprot.org/uniprot/P57103>Stoichiometry3 Na^+^ (in) : 1 Ca^2+^ (out) or 4 Na^+^ (in) : 1 Ca^2+^ (out) \[<http://www.ncbi.nlm.nih.gov/pubmed/11916852?dopt=AbstractPlus>\]; Reverse mode 1 Ca^2+^ (in): 1 Na^+^ (out)----Selective inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9484> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16973719?dopt=AbstractPlus>\]

Comments {#bph14753-sec-0110}
--------

Although subtype‐selective inhibitors of NCX function are not widely available, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4597> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4593> act as non‐selective NCX inhibitors, while <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4617>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4232>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4666>, and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6481> \[<http://www.ncbi.nlm.nih.gov/pubmed/23647096?dopt=AbstractPlus>\] act to inhibit NCX function with varying degrees of selectivity. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8438> is a selective NCX3 inhibitor \[<http://www.ncbi.nlm.nih.gov/pubmed/25942323?dopt=AbstractPlus>\] and and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9484> inhibits NCX3 preferentially over other isoforms \[<http://www.ncbi.nlm.nih.gov/pubmed/16973719?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27480939?dopt=AbstractPlus>\].

Further reading on SLC8 family of sodium/calcium exchangers {#bph14753-sec-0111}
-----------------------------------------------------------

Giladi M *et al*. (2016) Structure‐Functional Basis of Ion Transport in Sodium‐Calcium Exchanger (NCX) Proteins. *Int J Mol Sci* **17**: \[<https://www.ncbi.nlm.nih.gov/pubmed/27879668?dopt=AbstractPlus>\]

Khananshvili D. (2013) The SLC8 gene family of sodium‐calcium exchangers (NCX) ‐ structure, function, and regulation in health and disease. *Mol. Aspects Med*. **34**: 220‐35 \[<https://www.ncbi.nlm.nih.gov/pubmed/23506867?dopt=AbstractPlus>\]

Sekler I. (2015) Standing of giants shoulders the story of the mitochondrial Na(+)Ca(2+) exchanger. *Biochem. Biophys. Res. Commun*. **460**: 50‐2 \[<https://www.ncbi.nlm.nih.gov/pubmed/25998733?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=181> {#bph14753-sec-0112}
===========================================================================

Overview {#bph14753-sec-0113}
--------

Sodium/hydrogen exchangers or sodium/proton antiports are a family of transporters that maintain cellular pH by utilising the sodium gradient across the plasma membrane to extrude protons produced by metabolism, in a stoichiometry of 1 Na^+^ (in) : 1 H^+^ (out). Several isoforms, NHE6, NHE7, NHE8 and NHE9 appear to locate on intracellularmembranes \[<http://www.ncbi.nlm.nih.gov/pubmed/11641397?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15522866?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11279194?dopt=AbstractPlus>\]. Li^+^ and NH~4~ ^+^, but not K^+^, ions may also be transported by some isoforms. Modelling of the topology of these transporters indicates 12 TM regions with an extended intracellular C‐terminus containing multiple regulatory sites. NHE1 is considered to be a ubiquitously‐expressed 'housekeeping' transporter. NHE3 is highly expressed in the intestine and kidneys and regulate sodium movements in those tissues. NHE10 is present in sperm \[<http://www.ncbi.nlm.nih.gov/pubmed/14634667?dopt=AbstractPlus>\] and osteoclasts \[<http://www.ncbi.nlm.nih.gov/pubmed/18269914?dopt=AbstractPlus>\]; gene disruption results in infertile male mice \[<http://www.ncbi.nlm.nih.gov/pubmed/14634667?dopt=AbstractPlus>\].

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=181>.

Comments {#bph14753-sec-0114}
--------

Analogues of the non‐selective cation transport inhibitor amiloride appear to inhibit NHE function through competitive inhibition of the extracellular Na^+^ binding site. The more selective amiloride analogues <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4595> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4186> exhibit a rank order of affinity of inhibition of NHE1 \> NHE2 \> NHE3 \[<http://www.ncbi.nlm.nih.gov/pubmed/8246907?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8415663?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7685025?dopt=AbstractPlus>\].

Further reading on SLC9 family of sodium/hydrogen exchangers {#bph14753-sec-0115}
------------------------------------------------------------

Donowitz M *et al*. (2013) SLC9/NHE gene family, a plasma membrane and organellar family of Na^+^/H^+^ exchangers. *Mol. Aspects Med*. **34**: 236‐51 \[<https://www.ncbi.nlm.nih.gov/pubmed/23506868?dopt=AbstractPlus>\]

Kato A *et al*. (2011) Regulation of electroneutral NaCl absorption by the small intestine. *Annu. Rev. Physiol*. **73**: 261‐81 \[<https://www.ncbi.nlm.nih.gov/pubmed/21054167?dopt=AbstractPlus>\]

Ohgaki R *et al*. (2011) Organellar Na+/H+ exchangers: novel players in organelle pH regulation and their emerging functions. *Biochemistry* **50**: 443‐50 \[<https://www.ncbi.nlm.nih.gov/pubmed/21171650?dopt=AbstractPlus>\]

Parker MD *et al*. (2015) Na+‐H+ exchanger‐1 (NHE1) regulation in kidney proximal tubule. *Cell. Mol. Life Sci*. **72**: 2061‐74 \[<https://www.ncbi.nlm.nih.gov/pubmed/25680790?dopt=AbstractPlus>\]

Ruffin VA *et al*. (2014) Intracellular pH regulation by acid‐base transporters in mammalian neurons. *Front Physiol* **5**: 43 \[<https://www.ncbi.nlm.nih.gov/pubmed/24592239?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=182> {#bph14753-sec-0116}
===========================================================================

Overview {#bph14753-sec-0117}
--------

The SLC10 family transport bile acids, sulphated solutes, and other xenobiotics in a sodium‐dependent manner. The founding members, SLC10A1 (NTCP) and SLC10A2 (ASBT) function, along with members of the ABC transporter family (MDR1/ABCB1, BSEP/ABCB11 andMRP2/ABCC2) and the organic solute transporter obligate heterodimer OSTa:OSTß (SLC51), to maintain the enterohepatic circulation of bile acids \[<http://www.ncbi.nlm.nih.gov/pubmed/19498215?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20103563?dopt=AbstractPlus>\]. SLC10A6 (SOAT) functions as a sodium‐dependent transporter of sulphated solutes including sulfphated steroids and bile acids \[<http://www.ncbi.nlm.nih.gov/pubmed/17491011?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15020217?dopt=AbstractPlus>\]. Transport function has not yet been demonstrated for the 4 remaining members of the SLC10 family, SLC10A3 (P3), SLC10A4 (P4), SLC10A5 (P5), and SLC10A7 (P7), and the identity of their endogenous substrates remain unknown \[<http://www.ncbi.nlm.nih.gov/pubmed/17632081?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15020217?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17628207?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19682536?dopt=AbstractPlus>\]. Members of the SLC10 family are predicted to have seven transmembrane domains with an extracellular N‐terminus and cytoplasmic C‐terminus \[<http://www.ncbi.nlm.nih.gov/pubmed/16411770?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10471288?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=959><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=960><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=961>Systematic nomenclatureSLC10A1SLC10A2SLC10A6Common abbreviationNTCPASBTSOATHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10905](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10905), <http://www.uniprot.org/uniprot/Q14973>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10906](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10906), <http://www.uniprot.org/uniprot/Q12908>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30603](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30603), <http://www.uniprot.org/uniprot/Q3KNW5>Substrates--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4714> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4715>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4545> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4547> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=609> \> cholic acid \[<http://www.ncbi.nlm.nih.gov/pubmed/9458785?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4290> \[<http://www.ncbi.nlm.nih.gov/pubmed/17491011?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4749>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4528> \[<http://www.ncbi.nlm.nih.gov/pubmed/15020217?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4548>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4528> \[<http://www.ncbi.nlm.nih.gov/pubmed/9458785?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17632081?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9398014?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4749>, iodothyronine sulphates \[<http://www.ncbi.nlm.nih.gov/pubmed/19682536?dopt=AbstractPlus>\] <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4746>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4547>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4747> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4544> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=609> \[<http://www.ncbi.nlm.nih.gov/pubmed/9398014?dopt=AbstractPlus>\]----Stoichiometry2 Na^+^: 1 bile acid \[<http://www.ncbi.nlm.nih.gov/pubmed/16411770?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17491011?dopt=AbstractPlus>\]\>1 Na^+^: 1 bile acid \[<http://www.ncbi.nlm.nih.gov/pubmed/9458785?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9856990?dopt=AbstractPlus>\]--Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=63> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/10565843?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1024> (pIC~50~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/10565843?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7596> (pIC~50~ 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/10565843?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1024> (p*K* ~i~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/23339484?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=589> (p*K* ~i~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/23339484?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9996>t (pIC~50~ 8.9) \[[237](#bph14753-bib-0237){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6530> (pIC~50~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/12810816?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6529> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/14552767?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23678871?dopt=AbstractPlus>\]--Labelled ligands--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4546> \[<http://www.ncbi.nlm.nih.gov/pubmed/9458785?dopt=AbstractPlus>\]--Comments--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4770> is a fluorescent bile acid analogue used as a probe \[<http://www.ncbi.nlm.nih.gov/pubmed/9856990?dopt=AbstractPlus>\].--

Comments {#bph14753-sec-0118}
--------

Heterologously expressed SLC10A4 \[<http://www.ncbi.nlm.nih.gov/pubmed/18355966?dopt=AbstractPlus>\] or SLC10A7 \[<http://www.ncbi.nlm.nih.gov/pubmed/17628207?dopt=AbstractPlus>\] failed to exhibit significant transport of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4547>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4290>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4528> or <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551>. SLC10A4 has recently been suggested to associate with neuronal vesicles \[<http://www.ncbi.nlm.nih.gov/pubmed/21742018?dopt=AbstractPlus>\].

Further reading on SLC10 family of sodium‐bile acid co‐transporters {#bph14753-sec-0119}
-------------------------------------------------------------------

Anwer MS *et al*. (2014) Sodium‐dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. *Pflugers Arch*. **466**: 77‐89 \[<https://www.ncbi.nlm.nih.gov/pubmed/24196564?dopt=AbstractPlus>\]

Claro da Silva T *et al*. (2013) The solute carrier family 10 (SLC10): beyond bile acid transport. *Mol. Aspects Med*. **34**: 252‐69 \[<https://www.ncbi.nlm.nih.gov/pubmed/23506869?dopt=AbstractPlus>\]

Dawson PA. (2017) Roles of Ileal ASBT and OSTa‐OSTß in Regulating Bile Acid Signaling. *Dig Dis* 35: 261‐266 \[<https://www.ncbi.nlm.nih.gov/pubmed/28249269?dopt=AbstractPlus>\]

Zwicker BL *et al*. (2013) Transport and biological activities of bile acids. *Int. J. Biochem. Cell Biol*. **45**: 1389‐98 \[<https://www.ncbi.nlm.nih.gov/pubmed/23603607?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=183> {#bph14753-sec-0120}
===========================================================================

Overview {#bph14753-sec-0121}
--------

The family of proton‐coupled metal ion transporters are responsible for movements of divalent cations, particularly ferrous and manganese ions, across the cell membrane (SLC11A2/DMT1) and across endosomal (SLC11A2/DMT1) or lysosomal/phagosomal membranes (SLC11A1/NRAMP1), dependent on proton transport. Both proteins appear to have 12 TM regions and cytoplasmic N‐ and C‐ termini. NRAMP1 is involved in antimicrobial action in macrophages, although its precise mechanism is undefined. Facilitated diffusion of divalent cations into phagosomes may increase intravesicular free radicals to damage the pathogen. Alternatively, export of divalent cations from the phagosome may deprive the pathogen of essential enzyme cofactors. SLC11A2/DMT1 is more widely expressed and appears to assist in divalent cation assimilation from the diet, as well as in phagocytotic cells.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=966><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=967>Systematic nomenclatureSLC11A1SLC11A2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10907](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10907), <http://www.uniprot.org/uniprot/P49279>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10908](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10908), <http://www.uniprot.org/uniprot/P49281>Endogenous substratesFe^2+^, Mn^2+^<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4164>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4160>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440>, Fe^2+^, Mn^2+^Stoichiometry1 H^+^ : 1 Fe^2+^ (out) or 1 Fe^2+^ (in) : 1 H^+^ (out)1 H^+^ : 1 Fe^2+^ (out) \[<http://www.ncbi.nlm.nih.gov/pubmed/9242408?dopt=AbstractPlus>\]Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8814> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22749870?dopt=AbstractPlus>\]

Comments {#bph14753-sec-0122}
--------

Loss‐of‐function mutations in NRAMP1 are associated with increased susceptibility to microbial infection (<http://omim.org/entry/607948>). Loss‐of‐function mutations in DMT1 are associated with microcytic anemia (<http://omim.org/entry/206100>).

Further reading on SLC11 family of proton‐coupled metal ion transporters {#bph14753-sec-0123}
------------------------------------------------------------------------

Codazzi F *et al*. (2015) Iron entry in neurons and astrocytes: a link with synaptic activity. *Front Mol Neurosci* **8**: 18 \[<https://www.ncbi.nlm.nih.gov/pubmed/26089776?dopt=AbstractPlus>\]

Montalbetti N *et al*. (2013) Mammalian iron transporters: families SLC11 and SLC40. *Mol. Aspects Med*. **34**: 270‐87 \[<https://www.ncbi.nlm.nih.gov/pubmed/23506870?dopt=AbstractPlus>\]

Wessling‐Resnick M. (2015) Nramp1 and Other Transporters Involved in Metal Withholding during Infection. *J. Biol. Chem*. **290**: 18984‐90 \[<https://www.ncbi.nlm.nih.gov/pubmed/26055722?dopt=AbstractPlus>\]

Zheng W *et al*. (2012) Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. *Pharmacol. Ther*. **133**: 177‐88 \[<https://www.ncbi.nlm.nih.gov/pubmed/22115751?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=184> {#bph14753-sec-0124}
===========================================================================

Overview {#bph14753-sec-0125}
--------

The SLC12 family of chloride transporters contribute to ion fluxes across a variety of tissues, particularly in the kidney and choroid plexus of the brain. Within this family, further subfamilies are identifiable: NKCC1, NKCC2 and NCC constitute a group of therapeutically‐relevant transporters, targets for loop and thiazide diuretics. These 12 TM proteins exhibit cytoplasmic termini and an extended extracellular loop at TM7/8 and are kidneyspecific (NKCC2 and NCC) or show a more widespread distribution (NKCC1). A second family, the K‐Cl co‐transporters are also 12 TM domain proteins with cytoplasmic termini, but with an extended extracellular loop at TM 5/6. CCC6 exhibits structural similarities with the K‐Cl co‐transporters, while CCC9 is divergent, with 11 TM domains and a cytoplasmic N‐terminus and extracellular C‐terminus.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=968><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=969><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=970><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=971><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=972>Systematic nomenclatureSLC12A1SLC12A2SLC12A3SLC12A4SLC12A5Common abbreviationNKCC2NKCC1NCCKCC1KCC2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10910](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10910), <http://www.uniprot.org/uniprot/Q13621>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10911](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10911), <http://www.uniprot.org/uniprot/P55011>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10912](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10912), <http://www.uniprot.org/uniprot/P55017>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10913](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10913), <http://www.uniprot.org/uniprot/Q9UP95>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13818](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13818), <http://www.uniprot.org/uniprot/Q9H2X9>Stoichiometry1 Na^+^ : 1 K^+^ : 2 Cl^‐^ (in)1 Na^+^ : 1 K^+^ : 2 Cl^‐^ (in)1 Na^+^ : 1 Cl^‐^ (in)1 K^+^ : 1 Cl^‐^ (out)1 K^+^ : 1 Cl^‐^ (out)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4837> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/11882915?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4742> (pIC~50~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/11882915?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4839> (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/11882915?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4742> (pIC~50~ 5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/11882915?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4837> (pIC~50~ 5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/11882915?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4839> (pIC~50~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/11882915?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4835>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4167>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4836>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4838><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4589><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4665> (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/19279215?dopt=AbstractPlus>\],<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4589>

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=973><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=974><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=975>Systematic nomenclatureSLC12A6SLC12A7SLC12A8Common abbreviationKCC3KCC4CCC9HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10914](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10914), <http://www.uniprot.org/uniprot/Q9UHW9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10915](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10915), <http://www.uniprot.org/uniprot/Q9Y666>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15595](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15595), <http://www.uniprot.org/uniprot/A0AV02>Substrates----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2390>Stoichiometry1 K^+^ : 1 Cl^‐^ (out)1 K^+^ : 1 Cl^‐^ (out)UnknownInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4589><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4589>--Comments----In mouse studies Slc12a8 has been shown to transport the nicotinamide adenine dinucleotide (NAD+) precursor, nicotinamide mononucleotide (NMN) in to cells, and administration of NMN produces anti‐ageing effects *in vivo* \[[261](#bph14753-bib-0261){ref-type="ref"}\].

Comments {#bph14753-sec-0126}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4589> is able to differentiate KCC isoforms from NKCC and NCC transporters, but also inhibits CFTR \[<http://www.ncbi.nlm.nih.gov/pubmed/11527541?dopt=AbstractPlus>\].

Further reading on SLC12 family of cation‐coupled chloride transporters {#bph14753-sec-0127}
-----------------------------------------------------------------------

Arroyo JP *et al*. (2013) The SLC12 family of electroneutral cation‐coupled chloride cotransporters. *Mol. Aspects Med*. **34**: 288‐98 \[<https://www.ncbi.nlm.nih.gov/pubmed/23506871?dopt=AbstractPlus>\]

Bachmann S *et al*. (2017) Regulation of renal Na‐(K)‐Cl cotransporters by vasopressin. *Pflugers Arch*. **469**: 889‐897 \[<https://www.ncbi.nlm.nih.gov/pubmed/28577072?dopt=AbstractPlus>\]

Bazúa‐Valenti S *et al*. (2016) Physiological role of SLC12 family members in the kidney. *Am. J. Physiol. Renal Physiol*. **311**: F131‐44 \[<https://www.ncbi.nlm.nih.gov/pubmed/27097893?dopt=AbstractPlus>\]

Huang X *et al*. (2016) Everything we always wanted to know about furosemide but were afraid to ask. *Am. J. Physiol. Renal Physiol*. **310**: F958‐71 \[<https://www.ncbi.nlm.nih.gov/pubmed/26911852?dopt=AbstractPlus>\]

Kahle KT *et al*. (2015) K‐Cl cotransporters, cell volume homeostasis, and neurological disease. *Trends Mol Med* **21**: 513‐23 \[<https://www.ncbi.nlm.nih.gov/pubmed/26142773?dopt=AbstractPlus>\]

Martín‐Aragón Baudel MA *et al*. (2017) Chloride co‐transporters as possible therapeutic targets for stroke. *J. Neurochem*. **140**: 195‐209 \[<https://www.ncbi.nlm.nih.gov/pubmed/27861901?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=185> {#bph14753-sec-0128}
===========================================================================

Overview {#bph14753-sec-0129}
--------

Within the SLC13 family, two groups of transporters may be differentiated on the basis of the substrates transported: NaS1 and NaS2 convey sulphate, while NaC1‐3 transport carboxylates. NaS1 and NaS2 transporters are made up of 13 TM domains, with an intracellular N terminus and are electrogenic with physiological roles in the intestine, kidney and placenta. NaC1, NaC2 and NaC3 are made up of 11 TM domains with an intracellular N terminus and are electrogenic, with physiological roles in the kidney and liver.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=977><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=978><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=979><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=980><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=981>Systematic nomenclatureSLC13A1SLC13A2SLC13A3SLC13A4SLC13A5Common abbreviationNaS1NaC1NaC3NaS2NaC2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10916](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10916), <http://www.uniprot.org/uniprot/Q9BZW2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10917](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10917), <http://www.uniprot.org/uniprot/Q13183>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14430](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14430), <http://www.uniprot.org/uniprot/Q8WWT9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15827](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15827), <http://www.uniprot.org/uniprot/Q9UKG4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23089](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23089), <http://www.uniprot.org/uniprot/Q86YT5>Endogenous substratesSeO~4~ ^2‐^, SO~4~ ^2‐^, S~2~O~3~ ^2‐^<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2478>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3637><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2478>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3637>SO~4~ ^2‐^<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2478>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809>Stoichiometry3 Na^+^ : 1 SO~4~ ^2‐^ (in)3 Na^+^ : 1 dicarboxylate^2‐^ (in)Unknown3 Na^+^ : SO~4~ ^2‐^ (in)Unknown

Further reading on SLC13 family of sodium‐dependent sulphate/carboxylate transporters {#bph14753-sec-0130}
-------------------------------------------------------------------------------------

Bergeron MJ *et al*. (2013) SLC13 family of Na^+^‐coupled di‐ and tri‐carboxylate/sulfate transporters. *Mol. Aspects Med*. **34**: 299‐312 \[<https://www.ncbi.nlm.nih.gov/pubmed/23506872?dopt=AbstractPlus>\]

Markovich D. (2014) Na^+^‐sulfate cotransporter SLC13A1. *Pflugers Arch*. **466**: 131‐7 \[<https://www.ncbi.nlm.nih.gov/pubmed/24193406?dopt=AbstractPlus>\]

Pajor AM. (2014) Sodium‐coupled dicarboxylate and citrate transporters from the SLC13 family. *Pflugers Arch*. **466**: 119‐30 \[<https://www.ncbi.nlm.nih.gov/pubmed/24114175?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=186> {#bph14753-sec-0131}
===========================================================================

Overview {#bph14753-sec-0132}
--------

As a product of protein catabolism, urea is moved around the body and through the kidneys for excretion. Although there is experimental evidence for concentrative urea transporters, these have not been defined at the molecular level. The SLC14 family are facilitative transporters, allowing <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4539> movement down its concentration gradient. Multiple splice variants of these transporters have been identified; for UT‐A transporters, in particular, there is evidence for cell‐specific expression of these variants with functional impact \[<http://www.ncbi.nlm.nih.gov/pubmed/21449978?dopt=AbstractPlus>\]. Topographical modelling suggests that the majority of the variants of SLC14 transporters have 10 TM domains, with a glycosylated extracellular loop at TM5/6, and intracellular C‐ and N‐termini. The UT‐A1 splice variant, exceptionally, has 20 TMdomains, equivalent to a combination of theUT‐A2 and UT‐A3 splice variants.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=982><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=983>Systematic nomenclatureSLC14A1SLC14A2Common abbreviationUT‐BUT‐AHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10918](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10918), <http://www.uniprot.org/uniprot/Q13336>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10919](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10919), <http://www.uniprot.org/uniprot/Q15849>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4661> \[<http://www.ncbi.nlm.nih.gov/pubmed/17506977?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4553> \[<http://www.ncbi.nlm.nih.gov/pubmed/17506977?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4662> \[<http://www.ncbi.nlm.nih.gov/pubmed/17506977?dopt=AbstractPlus>\]--Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4509> \[<http://www.ncbi.nlm.nih.gov/pubmed/17506977?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4539> \[<http://www.ncbi.nlm.nih.gov/pubmed/17506977?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4739> \[<http://www.ncbi.nlm.nih.gov/pubmed/17506977?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4539> \[<http://www.ncbi.nlm.nih.gov/pubmed/18256317?dopt=AbstractPlus>\]StoichiometryEquilibrativeEquilibrativeInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8881> (pIC~50~ \~8) \[<http://www.ncbi.nlm.nih.gov/pubmed/23597791?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8881> (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/23597791?dopt=AbstractPlus>\] --Mouse--

Further reading on SLC14 family of facilitative urea transporters {#bph14753-sec-0133}
-----------------------------------------------------------------

Esteva‐Font C *et al*. (2015) Urea transporter proteins as targets for small‐molecule diuretics. *Nat Rev Nephrol* **11**: 113‐23 \[<https://www.ncbi.nlm.nih.gov/pubmed/25488859?dopt=AbstractPlus>\]

LeMoine CM *et al*. (2015) Evolution of urea transporters in vertebrates: adaptation to urea\'s multiple roles and metabolic sources. *J. Exp. Biol*. **218**: 1936‐1945 \[<https://www.ncbi.nlm.nih.gov/pubmed/26085670?dopt=AbstractPlus>\]

Pannabecker TL. (2013) Comparative physiology and architecture associated with the mammalian urine concentrating mechanism: role of inner medullary water and urea transport pathways in the rodent medulla. *Am. J. Physiol. Regul. Integr. Comp. Physiol*. **304**: R488‐503 \[<https://www.ncbi.nlm.nih.gov/pubmed/23364530?dopt=AbstractPlus>\]

Shayakul C *et al*. (2013) The urea transporter family (SLC14): physiological, pathological and structural aspects. *Mol. Aspects Med*. **34**: 313‐22 \[<https://www.ncbi.nlm.nih.gov/pubmed/23506873?dopt=AbstractPlus>\]

Stewart G. (2011) The emerging physiological roles of the SLC14A family of urea transporters. *Br. J. Pharmacol*. **164**: 1780‐92 \[<https://www.ncbi.nlm.nih.gov/pubmed/21449978?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=187> {#bph14753-sec-0134}
===========================================================================

Overview {#bph14753-sec-0135}
--------

The Solute Carrier 15 (SLC15) family of peptide transporters, alias H^+^‐coupled oligopeptide cotransporter family, is a group of membrane transporters known for their key role in the cellular uptake of di‐ and tripeptides (di/tripeptides). Of its members, SLC15A1 (PEPT1) chiefly mediates intestinal absorption of luminal di/tripeptides from overall dietary protein digestion, SLC15A2 (PEPT2) mainly allows renal tubular reuptake of di/tripeptides from ultrafiltration and brain‐to‐blood efflux of di/tripeptides in the choroid plexus, SLC15A3 (PHT2) and SLC15A4 (PHT1) interact with both di/tripeptides and histidine, e.g. in certain immune cells, and SLC15A5 has unknown physiological function. In addition, the SLC15 family of peptide transporters variably interacts with a very large number of peptidomimetics and peptide‐like drugs. It is conceivable, based on the currently acknowledged structural and functional differences, to divide the SLC15 family of peptide transporters into two subfamilies.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=984><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=985>Systematic nomenclatureSLC15A1SLC15A2Common abbreviationPEPT1PEPT2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10920](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10920), <http://www.uniprot.org/uniprot/P46059>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10921](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10921), <http://www.uniprot.org/uniprot/Q16348>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1022> \[<http://www.ncbi.nlm.nih.gov/pubmed/14578196?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16568107?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11375948?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9835627?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23259992?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9502> \[<http://www.ncbi.nlm.nih.gov/pubmed/27543355?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5421> \[<http://www.ncbi.nlm.nih.gov/pubmed/28943923?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11518682?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24744852?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22950754?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9501> \[<http://www.ncbi.nlm.nih.gov/pubmed/21366347?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23822979?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24744852?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9503> \[<http://www.ncbi.nlm.nih.gov/pubmed/15128310?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5024> \[<http://www.ncbi.nlm.nih.gov/pubmed/17487240?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15521010?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5024> \[<http://www.ncbi.nlm.nih.gov/pubmed/29784761?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23442152?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9501> \[<http://www.ncbi.nlm.nih.gov/pubmed/21366347?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9888294?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24744852?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19913073?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16041713?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23442152?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20868728?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19612975?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5421> \[<http://www.ncbi.nlm.nih.gov/pubmed/24744852?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22950754?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9843719?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9504> \[<http://www.ncbi.nlm.nih.gov/pubmed/23442152?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18474668?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9503> \[<http://www.ncbi.nlm.nih.gov/pubmed/15128310?dopt=AbstractPlus>\]Endogenous substratesprotons, dipeptides \[<http://www.ncbi.nlm.nih.gov/pubmed/9637710?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4784> \[<http://www.ncbi.nlm.nih.gov/pubmed/19789362?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15901802?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9637710?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11454935?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12649372?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16627568?dopt=AbstractPlus>\], tripeptides \[<http://www.ncbi.nlm.nih.gov/pubmed/9637710?dopt=AbstractPlus>\]dipeptides, protons, tripeptides, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4784> \[<http://www.ncbi.nlm.nih.gov/pubmed/9637710?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11454935?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17034769?dopt=AbstractPlus>\]StoichiometryTransport is electrogenic and involves a variable proton‐to‐substrate stoichiometry for uptake of neutral and mono‐ or polyvalently charged peptides, as well as 5‐aminolevulic acid.Transport is electrogenic and involves a variable proton‐to‐substrate stoichiometry for uptake of neutral and mono‐ or polyvalently charged peptides, as well as 5‐aminolevulic acid.Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9486> (p*K* ~i~ 5.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/14706812?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4702> (p*K* ~i~ 5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/15930458?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9882198?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4498> (p*K* ~i~ 5--5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/11284702?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4499> (p*K* ~i~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/16868651?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11752223?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4498>Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4489> \[<http://www.ncbi.nlm.nih.gov/pubmed/18344442?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4599> \[<http://www.ncbi.nlm.nih.gov/pubmed/30135242?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9753615?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15974593?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7592745?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9610386?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9092716?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11454935?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18824524?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11284702?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18713951?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15567297?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27543355?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10578127?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9379359?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9374833?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8843163?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10748266?dopt=AbstractPlus>\], \[<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4659>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4659> \[<http://www.ncbi.nlm.nih.gov/pubmed/12538834?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11714740?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11602669?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8956326?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9706043?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20660104?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16434549?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27903454?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16627568?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22950754?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4489> \[<http://www.ncbi.nlm.nih.gov/pubmed/15781409?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4599> \[<http://www.ncbi.nlm.nih.gov/pubmed/14715149?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7592745?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9610386?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9092716?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24548120?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11454935?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18824524?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18713951?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7756356?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15567297?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10578127?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9374833?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10748266?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4659> \[<http://www.ncbi.nlm.nih.gov/pubmed/16434549?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26494147?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27903454?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18367661?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27836942?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22950754?dopt=AbstractPlus>\]CommentsA variety of dipeptides and drugs interact with PEPT1, including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4559> \[<http://www.ncbi.nlm.nih.gov/pubmed/15832510?dopt=AbstractPlus>\], D‐Phe‐Ala \[<http://www.ncbi.nlm.nih.gov/pubmed/9637710?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11284702?dopt=AbstractPlus>\], D‐Phe‐Gln \[<http://www.ncbi.nlm.nih.gov/pubmed/19789362?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4784> \[<http://www.ncbi.nlm.nih.gov/pubmed/12649372?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14600253?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16632403?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6833> \[<http://www.ncbi.nlm.nih.gov/pubmed/10748266?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2414> \[<http://www.ncbi.nlm.nih.gov/pubmed/10578127?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4824> \[<http://www.ncbi.nlm.nih.gov/pubmed/11180195?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9753615?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15901802?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10087037?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4831> \[<http://www.ncbi.nlm.nih.gov/pubmed/8627565?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4832> \[<http://www.ncbi.nlm.nih.gov/pubmed/7592745?dopt=AbstractPlus>\] and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4796> (benzylpenicillin) \[<http://www.ncbi.nlm.nih.gov/pubmed/15901802?dopt=AbstractPlus>\], as detected using \[^3^H\] and \[^14^C\] radio‐labelled probes.Other high‐affinity (non‐transported) inhibitors: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9486>l (K~i~ 2 *μ*M) \[<http://www.ncbi.nlm.nih.gov/pubmed/14706812?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11284702?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4498> (K~i~ 3‐7 *μ*M) \[<http://www.ncbi.nlm.nih.gov/pubmed/14706812?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11284702?dopt=AbstractPlus>\]; other low‐affinity, (non‐transported) inhibitors: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4702> (Ki 3 mM) \[<http://www.ncbi.nlm.nih.gov/pubmed/19789362?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15930458?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9882198?dopt=AbstractPlus>\]. Like PEPT1, PEPT2 interact with dipeptides and drugs including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4559> \[<http://www.ncbi.nlm.nih.gov/pubmed/17034769?dopt=AbstractPlus>\], D‐Phe‐Ala \[<http://www.ncbi.nlm.nih.gov/pubmed/9637710?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11752223?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4784> \[<http://www.ncbi.nlm.nih.gov/pubmed/9637710?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11454935?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12649372?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14600253?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16632403?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6833> \[<http://www.ncbi.nlm.nih.gov/pubmed/10748266?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2414> \[<http://www.ncbi.nlm.nih.gov/pubmed/10578127?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4831> \[<http://www.ncbi.nlm.nih.gov/pubmed/14600253?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4832> \[<http://www.ncbi.nlm.nih.gov/pubmed/7592745?dopt=AbstractPlus>\] and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4796> (benzylpenicillin) \[<http://www.ncbi.nlm.nih.gov/pubmed/14600253?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=986><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=987>Systematic nomenclatureSLC15A3SLC15A4Common abbreviationPHT2PHT1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18068](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18068), <http://www.uniprot.org/uniprot/Q8IY34>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23090](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23090), <http://www.uniprot.org/uniprot/Q8N697>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9506> \[<http://www.ncbi.nlm.nih.gov/pubmed/24695226?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5024> \[<http://www.ncbi.nlm.nih.gov/pubmed/24695226?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/29305856?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9507> \[<http://www.ncbi.nlm.nih.gov/pubmed/29305856?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9502> \[<http://www.ncbi.nlm.nih.gov/pubmed/27543355?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9507> \[<http://www.ncbi.nlm.nih.gov/pubmed/19570976?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21277849?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/29224352?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9508> \[<http://www.ncbi.nlm.nih.gov/pubmed/19570976?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9505> \[<http://www.ncbi.nlm.nih.gov/pubmed/16289537?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24548120?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/29224352?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22950754?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5024> \[<http://www.ncbi.nlm.nih.gov/pubmed/24695226?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/29224352?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4824> \[<http://www.ncbi.nlm.nih.gov/pubmed/16289537?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9506> \[<http://www.ncbi.nlm.nih.gov/pubmed/29784761?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24695226?dopt=AbstractPlus>\]Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310> \[<http://www.ncbi.nlm.nih.gov/pubmed/11336635?dopt=AbstractPlus>\], dipeptides, tripeptides, protons<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310> \[<http://www.ncbi.nlm.nih.gov/pubmed/16289537?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25238095?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27543355?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27845049?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9092568?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4559> \[<http://www.ncbi.nlm.nih.gov/pubmed/16289537?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9092568?dopt=AbstractPlus>\]StoichiometryPHT2 has not been analyzed systematically with respect to driving force, mode of transport, and substrate specificity. The pH dependence observed for transport of histidine \[<http://www.ncbi.nlm.nih.gov/pubmed/11336635?dopt=AbstractPlus>\] and the model peptides used, *i.e*., carnosine \[<http://www.ncbi.nlm.nih.gov/pubmed/11336635?dopt=AbstractPlus>\] and histidyl‐leucine \[<http://www.ncbi.nlm.nih.gov/pubmed/11336635?dopt=AbstractPlus>\], suggest a similar mode of operation as PEPT1 and PEPT2 proteins.PHT1 has not been analyzed systematically with respect to driving force, mode of transport, and substrate specificity. The pH dependence observed for transport of histidine \[<http://www.ncbi.nlm.nih.gov/pubmed/16289537?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25238095?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27543355?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27845049?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9092568?dopt=AbstractPlus>\] and the model peptide used, *i.e*., carnosine \[<http://www.ncbi.nlm.nih.gov/pubmed/16289537?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9092568?dopt=AbstractPlus>\], suggest a similar mode of operation as PEPT1 and PEPT2 proteins.Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4623> \[<http://www.ncbi.nlm.nih.gov/pubmed/11336635?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4623> (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/27845049?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/29305823?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9092568?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4670> \[<http://www.ncbi.nlm.nih.gov/pubmed/16289537?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27543355?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22950754?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27845049?dopt=AbstractPlus>\]CommentsPHT2 interacts with \[^3^H\]carnosine \[<http://www.ncbi.nlm.nih.gov/pubmed/11336635?dopt=AbstractPlus>\].Other PHT1 ligands include \[^3^H\]histidine \[<http://www.ncbi.nlm.nih.gov/pubmed/16289537?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27543355?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22950754?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27845049?dopt=AbstractPlus>\], d3‐L‐histidine \[<http://www.ncbi.nlm.nih.gov/pubmed/29224352?dopt=AbstractPlus>\], \[^3^H\]carnosine \[<http://www.ncbi.nlm.nih.gov/pubmed/16289537?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9092568?dopt=AbstractPlus>\] \[^14^C\]GlySar \[<http://www.ncbi.nlm.nih.gov/pubmed/24548120?dopt=AbstractPlus>\], \[^3^H\]GlySar \[<http://www.ncbi.nlm.nih.gov/pubmed/16289537?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22950754?dopt=AbstractPlus>\] and \[^3^H\]valacyclovir \[<http://www.ncbi.nlm.nih.gov/pubmed/16289537?dopt=AbstractPlus>\].

Comments {#bph14753-sec-0136}
--------

The members of the SLC15 family of peptide transporters are particularly promiscuous in the transport of di/tripeptides, and D‐amino acid containing peptides are also transported. While SLC15A3 and SLC15A4 transport histidine, none of them transport tetrapeptides. In addition, many molecules, among which beta‐lactam antibiotics, angiotensinconverting enzyme inhibitors and sartans, variably interact with the SLC15 family transporters. Known substrates include <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4831>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4824>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4784>, L‐Dopa prodrugs, gemcitabine prodrugs, floxuridine prodrugs, Maillard reaction products, JBP485, zanamivir, oseltamivir prodrugs, doxorubicin prodrugs, polymyxins, and didanosine prodrugs. Frequently used pharmaceutical excipients such as Tween®20, Tween®80, Solutol ®HS 15 and Cremophor EL®strongly inhibit cellular uptake of Gly‐Sar by SLC15A1 and/or SLC15A2 \[<http://www.ncbi.nlm.nih.gov/pubmed/27903454?dopt=AbstractPlus>\]. There is evidence to suggest the existence of a fifth member of this transporter family, [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:33455](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:33455) (<http://www.uniprot.org/uniprot/A6NIM6>; [http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188991;r=12:16188485‐16277685;t=ENST00000344941](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188991;r=12:16188485‐16277685;t=ENST00000344941)), but to date there is no established biological function or reported pharmacology for this protein \[<http://www.ncbi.nlm.nih.gov/pubmed/21044875?dopt=AbstractPlus>\].

Further reading on SLC15 family of peptide transporters {#bph14753-sec-0137}
-------------------------------------------------------

Anderson CM *et al*. (2010) Hijacking solute carriers for proton‐coupled drug transport. *Physiology (Bethesda)* **25**: 364‐77 \[<https://www.ncbi.nlm.nih.gov/pubmed/21186281?dopt=AbstractPlus>\]

Brandsch M. (2013) Drug transport via the intestinal peptide transporter PepT1. *Curr Opin Pharmacol* **13**: 881‐7 \[<https://www.ncbi.nlm.nih.gov/pubmed/24007794?dopt=AbstractPlus>\]

Brandsch M. (2009) Transport of drugs by proton‐coupled peptide transporters: pearls and pitfalls. *Expert Opin Drug Metab Toxicol* **5**: 887‐905 \[<https://www.ncbi.nlm.nih.gov/pubmed/19519280?dopt=AbstractPlus>\]

Fredriksson R *et al*. (2008) The solute carrier (SLC) complement of the human genome: phylogenetic classification reveals four major families. *FEBS Lett*. **582**: 3811‐6 \[<https://www.ncbi.nlm.nih.gov/pubmed/18948099?dopt=AbstractPlus>\]

Newstead S. (2015) Molecular insights into proton coupled peptide transport in the PTR family of oligopeptide transporters. *Biochim. Biophys. Acta* **1850**: 488‐499 \[<https://www.ncbi.nlm.nih.gov/pubmed/24859687?dopt=AbstractPlus>\]

Newstead S. (2017) Recent advances in understanding proton coupled peptide transport via the POT family. *Curr. Opin. Struct. Biol*. **45**: 17‐24 \[<https://www.ncbi.nlm.nih.gov/pubmed/27865112?dopt=AbstractPlus>\]

Newstead S. (2011) Towards a structural understanding of drug and peptide transport within the proton‐dependent oligopeptide transporter (POT) family. *Biochem. Soc. Trans*. **39**: 1353‐8 \[<https://www.ncbi.nlm.nih.gov/pubmed/21936814?dopt=AbstractPlus>\]

Smith DE *et al*. (2013) Proton‐coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. *Mol. Aspects Med*. **34**: 323‐36 \[<https://www.ncbi.nlm.nih.gov/pubmed/23506874?dopt=AbstractPlus>\]

Thwaites DT *et al*. (2007) H+‐coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. *Exp. Physiol*. **92**: 603‐19 \[<https://www.ncbi.nlm.nih.gov/pubmed/17468205?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=188> {#bph14753-sec-0138}
===========================================================================

Overview {#bph14753-sec-0139}
--------

Members of the SLC16 family may be divided into subfamilies on the basis of substrate selectivities, particularly lactate (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809> and ketone bodies, as well as aromatic amino acids. Topology modelling suggests 12 TM domains, with intracellular termini and an extended loop at TM 6/7.

The proton‐coupledmonocarboxylate transporters (monocarboxylate transporters 1, 4, 2 and 3) allowtransport of the products of cellularmetabolism, principally lactate (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932>) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809>.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=988><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=990><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=991><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=989><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=995><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=992><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=993>Systematic nomenclatureSLC16A1SLC16A7SLC16A8SLC16A3SLC16A5SLC16A2SLC16A10Common abbreviationMCT1MCT2MCT3MCT4MCT6MCT8TAT1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10922](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10922), <http://www.uniprot.org/uniprot/P53985>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10928](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10928), <http://www.uniprot.org/uniprot/O60669>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16270](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16270), <http://www.uniprot.org/uniprot/O95907>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10924](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10924), <http://www.uniprot.org/uniprot/O15427>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10926](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10926), <http://www.uniprot.org/uniprot/O15375>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10923](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10923), <http://www.uniprot.org/uniprot/P36021>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17027](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17027), <http://www.uniprot.org/uniprot/Q8TF71>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4711> \[<http://www.ncbi.nlm.nih.gov/pubmed/16707723?dopt=AbstractPlus>\]------------Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1593><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932>--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634> \[<http://www.ncbi.nlm.nih.gov/pubmed/16887882?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635> ~4~ \[<http://www.ncbi.nlm.nih.gov/pubmed/16887882?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791>Stoichiometry1 H^+^ : 1 monocarboxylate^‐^ (out)1 H^+^ : 1 monocarboxylate^‐^ (out)1 H^+^ : 1 monocarboxylate^‐^ (out)1 H^+^ : 1 monocarboxylate^‐^ (out)UnknownUnknownUnknownInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8813>(Compound 30 is a channel blocker.) (pKi 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/16455256?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8818> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/24095010?dopt=AbstractPlus>\]--------Comments--------MCT6 has been reported to transport <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4837>, but not short chain fatty acids \[<http://www.ncbi.nlm.nih.gov/pubmed/16174808?dopt=AbstractPlus>\].----

Comments {#bph14753-sec-0140}
--------

MCT1 and MCT2, but not MCT3 and MCT4, are inhibited by CHC, which also inhibits members of the mitochondrial transporter family, <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=147>.

MCT5‐MCT7, MCT9 and MCT11‐14 are regarded as orphan transporters.

Further reading on SLC16 family of monocarboxylate transporters {#bph14753-sec-0141}
---------------------------------------------------------------

Bernal J *et al*. (2015) Thyroid hormone transporters‐functions and clinical implications. *Nat Rev Endocrinol* **11**: 406‐417 <https://www.ncbi.nlm.nih.gov/pubmed/25942657?dopt=AbstractPlus>

Halestrap AP. (2013) The SLC16 gene family ‐ structure, role and regulation in health and disease. *Mol. Aspects Med*. **34**: 337‐49 <https://www.ncbi.nlm.nih.gov/pubmed/23506875?dopt=AbstractPlus>

Jones RS *et al*. (2016) Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease. *Clin. Pharmacol. Ther*. **100**: 454‐463 <https://www.ncbi.nlm.nih.gov/pubmed/27351344?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=145> {#bph14753-sec-0142}
===========================================================================

Overview {#bph14753-sec-0143}
--------

The SLC17 family are sometimes referred to as Type I sodium‐phosphate co‐transporters, alongside Type II (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=221>) and Type III (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=195>) transporters. Within the SLC17 family, however, further subgroups of organic anion transporters may be defined, allowing the accumulation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4644> in the endoplasmic reticulum and glutamate (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>) or nucleotides in synaptic and secretory vesicles. Topology modelling suggests 12 TM domains.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=189> {#bph14753-sec-0144}
===========================================================================

Overview {#bph14753-sec-0145}
--------

Type I sodium‐phosphate co‐transporters are expressed in the kidney and intestine.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1002><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1003><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1004><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1005>Systematic nomenclatureSLC17A1SLC17A2SLC17A3SLC17A4Common abbreviationNPT1NPT3NPT4--HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10929](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10929), <http://www.uniprot.org/uniprot/Q14916>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10930](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10930), <http://www.uniprot.org/uniprot/O00624>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10931](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10931), <http://www.uniprot.org/uniprot/O00476>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10932](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10932), <http://www.uniprot.org/uniprot/Q9Y2C5>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4357> \[<http://www.ncbi.nlm.nih.gov/pubmed/8643577?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4796> \[<http://www.ncbi.nlm.nih.gov/pubmed/8643577?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2339> \[<http://www.ncbi.nlm.nih.gov/pubmed/20566650?dopt=AbstractPlus>\], organic acids \[306\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4731> \[<http://www.ncbi.nlm.nih.gov/pubmed/20566650?dopt=AbstractPlus>\], phosphate \[<http://www.ncbi.nlm.nih.gov/pubmed/20566650?dopt=AbstractPlus>\]------StoichiometryUnknownUnknownUnknownUnknown

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=190> {#bph14753-sec-0146}
===========================================================================

Overview {#bph14753-sec-0147}
--------

The sialic acid transporter is expressed on both lysosomes and synaptic vesicles, where it appears to allow export of sialic acid and accumulation of acidic amino acids, respectively \[446\], driven by proton gradients. In lysosomes, degradation of glycoproteins generates amino acids and sugar residues, which are metabolized further following export from the lysosome.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1006>Systematic nomenclatureSLC17A5Common abbreviationASTHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10933](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10933), <http://www.uniprot.org/uniprot/Q9NRA2>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4519> (out), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369> (in) \[<http://www.ncbi.nlm.nih.gov/pubmed/21781115?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4723>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309> \[<http://www.ncbi.nlm.nih.gov/pubmed/21781115?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4644>Stoichiometry1 H^+^ : 1 sialic acid (out)

Comments {#bph14753-sec-0148}
--------

Loss‐of‐function mutations in sialin are associated with Salla disease (<http://omim.org/entry/604369>), an autosomal recessive neurodegenerative disorder associated with sialic acid storage disease \[<http://www.ncbi.nlm.nih.gov/pubmed/10581036?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=191> {#bph14753-sec-0149}
===========================================================================

Overview {#bph14753-sec-0150}
--------

Vesicular glutamate transporters (VGLUTs) allow accumulation of glutamate into synaptic vesicles, as well as secretory vesicles in endocrine tissues. The roles of VGLUTs in kidney and liver are unclear. These transporters appear to utilize the proton gradient and also express a chloride conductance \[<http://www.ncbi.nlm.nih.gov/pubmed/10938000?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1007><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1008><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1009>Systematic nomenclatureSLC17A7SLC17A6SLC17A8Common abbreviationVGLUT1VGLUT2VGLUT3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16704](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16704), <http://www.uniprot.org/uniprot/Q9P2U7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16703](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16703), <http://www.uniprot.org/uniprot/Q9P2U8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20151](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20151), <http://www.uniprot.org/uniprot/Q8NDX2>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4708><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4708><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4708>StoichiometryUnknownUnknownUnknown

Comments {#bph14753-sec-0151}
--------

Endogenous ketoacids produced during fasting have been proposed to regulate VGLUT function through blocking chloride ion‐mediated allosteric enhancement of transporter function \[<http://www.ncbi.nlm.nih.gov/pubmed/20920794?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=192> {#bph14753-sec-0152}
===========================================================================

Overview {#bph14753-sec-0153}
--------

The vesicular nucleotide transporter is the most recent member of the SLC17 family to have an assigned function. Uptake of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> was independent of pH, but dependent on chloride ions and membrane potential \[<http://www.ncbi.nlm.nih.gov/pubmed/18375752?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1010>Systematic nomenclatureSLC17A9Common abbreviationVNUTHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16192](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16192), <http://www.uniprot.org/uniprot/Q9BYT1>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2410> \[<http://www.ncbi.nlm.nih.gov/pubmed/18375752?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1742> \[<http://www.ncbi.nlm.nih.gov/pubmed/18375752?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> \[<http://www.ncbi.nlm.nih.gov/pubmed/18375752?dopt=AbstractPlus>\]StoichiometryUnknownSelective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9605> (pIC~50~ 7.8) \[346\]

Comments {#bph14753-sec-0154}
--------

VGLUTs and VNUT can be inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4579>.

Further reading on SLC17 phosphate and organic anion transporter family {#bph14753-sec-0155}
-----------------------------------------------------------------------

Moriyama Y *et al*. (2017) Vesicular nucleotide transporter (VNUT): appearance of an actress on the stage of purinergic signaling. *Purinergic Signal*. **13**: 387‐404 <https://www.ncbi.nlm.nih.gov/pubmed/28616712?dopt=AbstractPlus>

Omote H *et al*. (2016) Structure, Function, and Drug Interactions of Neurotransmitter Transporters in the Postgenomic Era. *Annu. Rev. Pharmacol. Toxicol*. **56**: 385‐402 <https://www.ncbi.nlm.nih.gov/pubmed/26514205?dopt=AbstractPlus>

Reimer RJ. (2013) SLC17: a functionally diverse family of organic anion transporters. *Mol. Aspects Med*. **34**: 350‐9 <https://www.ncbi.nlm.nih.gov/pubmed/23506876?dopt=AbstractPlus>

Takamori S. (2016) Vesicular glutamate transporters as anion channels? *Pflugers Arch*. **468**: 513‐8 <https://www.ncbi.nlm.nih.gov/pubmed/26577586?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=193> {#bph14753-sec-0156}
===========================================================================

Overview {#bph14753-sec-0157}
--------

The vesicular amine transporters (VATs) are putative 12 TM domain proteins that function to transport singly positively charged amine neurotransmitters and hormones from the cytoplasm and concentrate them within secretory vesicles. They function as amine/proton antiporters driven by secondary active transport utilizing the proton gradient established by a multi‐subunit [http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=137\#V‐typeATPase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=137#V‐typeATPase) that acidifies secretory vesicles (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/12827358?dopt=AbstractPlus>\]). The vesicular acetylcholine transporter (VAChT; \[<http://www.ncbi.nlm.nih.gov/pubmed/8071310?dopt=AbstractPlus>\]) localizes to cholinergic neurons, but non‐neuronal expression has also been claimed \[<http://www.ncbi.nlm.nih.gov/pubmed/21482687?dopt=AbstractPlus>\]. Vesicular monoamine transporter 1 (VMAT1, \[<http://www.ncbi.nlm.nih.gov/pubmed/8245983?dopt=AbstractPlus>\]) is mainly expressed in peripheral neuroendocrine cells, but most likely not in the CNS, whereas VMAT2 \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\] distributes between both central and peripheral sympathetic monoaminergic neurones \[<http://www.ncbi.nlm.nih.gov/pubmed/21272013?dopt=AbstractPlus>\]. The vescular polyamine transporter (VPAT) is highly expressed in the lungs and placenta, with moderate expression in brain and testis, and with low expression in heart and skeletal muscle \[<http://www.ncbi.nlm.nih.gov/pubmed/25355561?dopt=AbstractPlus>\]. VPAT mediates vesicular accumulation of polyamines in mast cells \[<http://www.ncbi.nlm.nih.gov/pubmed/28082679?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1011><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1012><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1013>Systematic nomenclatureSLC18A1SLC18A2SLC18A3Common abbreviationVMAT1VMAT2VAChTHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10934](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10934), <http://www.uniprot.org/uniprot/P54219>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10935](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10935), <http://www.uniprot.org/uniprot/Q05940>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10936](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10936), <http://www.uniprot.org/uniprot/Q16572>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2147> (*K* ~i~ 4.7×10^‐5^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2144> (*K* ~i~ 3.4×10^‐5^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4613> (*K* ~i~ 3.1×10^‐6^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4568> (*K* ~i~ 6.9×10^‐5^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4574> (*K* ~i~ 1.9×10^‐5^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2144> (*K* ~i~ 3.7×10^‐6^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2147> (*K* ~i~ 2.1×10^‐6^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4613> (*K* ~i~ 5.1×10^‐6^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4568> (*K* ~i~ 8.9×10^‐6^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], MDMA (*K* ~i~ 6.9×10^‐6^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4558> \[<http://www.ncbi.nlm.nih.gov/pubmed/15979764?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4569> \[<http://www.ncbi.nlm.nih.gov/pubmed/15979764?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4652> \[<http://www.ncbi.nlm.nih.gov/pubmed/15979764?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4773> \[<http://www.ncbi.nlm.nih.gov/pubmed/15979764?dopt=AbstractPlus>\]Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1204> (*K* ~i~ 4.6×10^‐3^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5> (*K* ~i~ 1.4×10^‐6^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940> (*K* ~i~ 3.8×10^‐6^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505> (*K* ~i~ 1.3×10^‐5^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479> (*K* ~i~ 5.5×10^‐6^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1204> (*K* ~i~ 1.4×10^‐4^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940> (*K* ~i~ 1.4×10^‐6^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5> (*K* ~i~ 9×10^‐7^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505> (*K* ~i~ 3.4×10^‐6^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479> (*K* ~i~ 1.9×10^‐6^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294> (*K* ~i~ 7.9×10^‐4^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/15485505?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20225888?dopt=AbstractPlus>\], choline (*K* ~i~ 5×10^‐3^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/15485505?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20225888?dopt=AbstractPlus>\]Stoichiometry1 amine (in): 2H^+^ (out)1 amine (in): 2H^+^ (out)1 amine (in): 2H^+^ (out)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4823> (p*K* ~i~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88> (p*K* ~i~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4834> (p*K* ~i~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4823> (p*K* ~i~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4834> (p*K* ~i~ 7) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88> (p*K* ~i~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4768> (p*K* ~i~ 10.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/7702637?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4759> (p*K* ~i~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/7702637?dopt=AbstractPlus>\]Labelled ligands--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4766> (Inhibitor) (p*K* ~d~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/8910293?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4764> (Inhibitor) (p*K* ~d~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/7855735?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4608> (Inhibitor),<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4763> (Inhibitor) \[<http://www.ncbi.nlm.nih.gov/pubmed/9325342?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4758> (p*K* ~d~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/8910293?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4762>

Comments {#bph14753-sec-0158}
--------

*p*K~i~ values for endogenous and synthetic substrate inhibitors of human VMAT1 and VMAT2 are for inhibition of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3248> uptake in transfected and permeabilised CV‐1 cells as detailed by \[<http://www.ncbi.nlm.nih.gov/pubmed/8643547?dopt=AbstractPlus>\]. In addition to the monoamines listed in the table, the trace amines <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2150> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2144> are probable substrates for VMAT2 \[<http://www.ncbi.nlm.nih.gov/pubmed/21272013?dopt=AbstractPlus>\]. Probes listed in the table are those currently employed; additional agents have been synthesized (*e.g*. \[<http://www.ncbi.nlm.nih.gov/pubmed/19632829?dopt=AbstractPlus>\]).

Further reading on SLC18 family of vesicular amine transporters {#bph14753-sec-0159}
---------------------------------------------------------------

German CL *et al*. (2015) Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease. *Pharmacol. Rev*. **67**: 1005‐24 <https://www.ncbi.nlm.nih.gov/pubmed/26408528?dopt=AbstractPlus>

Lohr KM *et al*. (2017) Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease. *Eur. J. Neurosci*. **45**: 20‐33 <https://www.ncbi.nlm.nih.gov/pubmed/27520881?dopt=AbstractPlus>

Omote H *et al*. (2016) Structure, Function, and Drug Interactions of Neurotransmitter Transporters in the Postgenomic Era. *Annu. Rev. Pharmacol. Toxicol*. **56**: 385‐402 <https://www.ncbi.nlm.nih.gov/pubmed/26514205?dopt=AbstractPlus>

Sitte HH *et al*. (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. *Trends Pharmacol. Sci*. **36**: 41‐50 <https://www.ncbi.nlm.nih.gov/pubmed/25542076?dopt=AbstractPlus>

Wimalasena K. (2011) Vesicular monoamine transporters: structure‐function, pharmacology, and medicinal chemistry. *Med Res Rev* **31**: 483‐519 <https://www.ncbi.nlm.nih.gov/pubmed/20135628?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=194> {#bph14753-sec-0160}
===========================================================================

Overview {#bph14753-sec-0161}
--------

The B vitamins <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4563> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4629> are transported across the cell membrane, particularly in the intestine, kidneys and placenta, using pH differences as driving forces. Topological modelling suggests the transporters have 12 TM domains.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1014><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1015><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1016>Systematic nomenclatureSLC19A1SLC19A2SLC19A3Common abbreviationFOLTThTr1ThTr2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10937](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10937), <http://www.uniprot.org/uniprot/P41440>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10938](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10938), <http://www.uniprot.org/uniprot/O60779>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16266](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16266), <http://www.uniprot.org/uniprot/Q9BZV2>SubstratesN^5^‐formyltetrahydrofolate, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4816>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4815>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4563> \[<http://www.ncbi.nlm.nih.gov/pubmed/7826387?dopt=AbstractPlus>\]----Endogenous substratesOther tetrahydrofolate‐cofactors, Organic phosphates; in particular, adenine nucleotides, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4675> \[<http://www.ncbi.nlm.nih.gov/pubmed/7826387?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4684> \[<http://www.ncbi.nlm.nih.gov/pubmed/7826387?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4580> \[<http://www.ncbi.nlm.nih.gov/pubmed/11997266?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4629><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4629>StoichiometryFolate (in) : organic phosphate (out), precise stoichiometry unknownA facilitative carrier not known to be coupled to an inorganic or organic ion gradientA facilitative carrier not known to be coupled to an inorganic or organic ion gradientInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8890> (p*K* ~i~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/15615544?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4815> (p*K* ~i~ 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/15615544?dopt=AbstractPlus>\]----Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4562> \[<http://www.ncbi.nlm.nih.gov/pubmed/9525913?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4674> \[<http://www.ncbi.nlm.nih.gov/pubmed/9525913?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4628> \[<http://www.ncbi.nlm.nih.gov/pubmed/10542220?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4628> \[<http://www.ncbi.nlm.nih.gov/pubmed/11731220?dopt=AbstractPlus>\]

Comments {#bph14753-sec-0162}
--------

Loss‐of‐function mutations in ThTr1 underlie thiamine‐responsive megaloblastic anemia syndrome \[<http://www.ncbi.nlm.nih.gov/pubmed/10391223?dopt=AbstractPlus>\].

Further reading on SLC19 family of vitamin transporters {#bph14753-sec-0163}
-------------------------------------------------------

Matherly LH *et al*. (2014) The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer. *Drug Metab. Dispos*. **42**: 632‐49 <https://www.ncbi.nlm.nih.gov/pubmed/24396145?dopt=AbstractPlus>

Zhao R *et al*. (2013) Folate and thiamine transporters mediated by facilitative carriers (SLC19A1‐3 and SLC46A1) and folate receptors. *Mol. Aspects Med*. **34**: 373‐85 <https://www.ncbi.nlm.nih.gov/pubmed/23506878?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=195> {#bph14753-sec-0164}
===========================================================================

Overview {#bph14753-sec-0165}
--------

The SLC20 family is looked upon not only as ion transporters, but also as retroviral receptors. As ion transporters, they are sometimes referred to as Type III sodium‐phosphate co‐transporters, alongside Type I (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=145>) and Type II (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=221>). PiTs are cell‐surface transporters, composed of ten TM domains with extracellular C‐ and N‐termini. PiT1 is a focus for dietary phosphate and <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=90> regulation of parathyroid hormone secretion from the parathyroid gland. PiT2 appears to be involved in intestinal absorption of dietary phosphate.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1017><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1018>Systematic nomenclatureSLC20A1SLC20A2Common abbreviationPiT1PiT2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10946](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10946), <http://www.uniprot.org/uniprot/Q8WUM9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10947](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10947), <http://www.uniprot.org/uniprot/Q08357>SubstratesAsO~4~ ^3‐^ \[<http://www.ncbi.nlm.nih.gov/pubmed/17494632?dopt=AbstractPlus>\], phosphate \[<http://www.ncbi.nlm.nih.gov/pubmed/17494632?dopt=AbstractPlus>\]phosphate \[<http://www.ncbi.nlm.nih.gov/pubmed/17494632?dopt=AbstractPlus>\]Stoichiometry\>1 Na^+^ : 1 HPO~4~ ^2‐^ (in)\>1 Na^+^ : 1 HPO~4~ ^2‐^ (in)

Further reading on SLC20 family of sodium‐dependent phosphate transporters {#bph14753-sec-0166}
--------------------------------------------------------------------------

Biber J *et al*. (2013) Phosphate transporters and their function. *Annu. Rev. Physiol*. **75**: 535‐50 <https://www.ncbi.nlm.nih.gov/pubmed/23398154?dopt=AbstractPlus>

Forster IC *et al*. (2013) Phosphate transporters of the SLC20 and SLC34 families. *Mol. Aspects Med*. **34**: 386‐95 <https://www.ncbi.nlm.nih.gov/pubmed/23506879?dopt=AbstractPlus>

Shobeiri N *et al*. (2014) Phosphate: an old bone molecule but new cardiovascular risk factor. *Br J Clin Pharmacol* **77**: 39‐54 <https://www.ncbi.nlm.nih.gov/pubmed/23506202?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=146> {#bph14753-sec-0167}
===========================================================================

Overview {#bph14753-sec-0168}
--------

The SLC22 family of transporters is mostly composed of non‐selective transporters, which are expressed highly in liver, kidney and intestine, playing a major role in drug disposition. The family may be divided into three subfamilies based on the nature of the substrate transported: organic cations (OCTs), organic anions (OATs) and organic zwiterrion/cations (OCTN). Membrane topology is predicted to contain 12 TM domains with intracellular termini, and an extended extracellular loop at TM 1/2.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=196> {#bph14753-sec-0169}
===========================================================================

Overview {#bph14753-sec-0170}
--------

Organic cation transporters (OCT) are electrogenic, Na^+^‐independent and reversible.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1019><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1020><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1021>Systematic nomenclatureSLC22A1SLC22A2SLC22A3Common abbreviationOCT1OCT2OCT3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10963](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10963), <http://www.uniprot.org/uniprot/O15245>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10966](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10966), <http://www.uniprot.org/uniprot/O15244>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10967](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10967), <http://www.uniprot.org/uniprot/O75751>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4568>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2399>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4779> \[<http://www.ncbi.nlm.nih.gov/pubmed/17476361?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4829><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4568> \[<http://www.ncbi.nlm.nih.gov/pubmed/9260930?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4001> \[<http://www.ncbi.nlm.nih.gov/pubmed/9260930?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> \[<http://www.ncbi.nlm.nih.gov/pubmed/9260930?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> \[<http://www.ncbi.nlm.nih.gov/pubmed/9260930?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5343> \[<http://www.ncbi.nlm.nih.gov/pubmed/23506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4779> \[<http://www.ncbi.nlm.nih.gov/pubmed/23506881?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4568>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4779> \[<http://www.ncbi.nlm.nih.gov/pubmed/23506881?dopt=AbstractPlus>\]Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883> \[<http://www.ncbi.nlm.nih.gov/pubmed/11907186?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940> \[<http://www.ncbi.nlm.nih.gov/pubmed/10385678?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1204> \[<http://www.ncbi.nlm.nih.gov/pubmed/10385678?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505> \[<http://www.ncbi.nlm.nih.gov/pubmed/20402963?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5> \[<http://www.ncbi.nlm.nih.gov/pubmed/20402963?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940> \[<http://www.ncbi.nlm.nih.gov/pubmed/20402963?dopt=AbstractPlus>\]StoichiometryUnknownUnknownUnknownInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=516> (p*K* ~i~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/9655880?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8482> (p*K* ~i~ 7) \[<http://www.ncbi.nlm.nih.gov/pubmed/9260930?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8826> (p*K* ~i~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/10196521?dopt=AbstractPlus>\]

Comments {#bph14753-sec-0171}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2510> are able to inhibit all three organic cation transporters.

Further reading on Organic cation transporters (OCT) {#bph14753-sec-0172}
----------------------------------------------------

Koepsell H. (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. *Mol. Aspects Med*. **34**: 413‐35 <https://www.ncbi.nlm.nih.gov/pubmed/23506881?dopt=AbstractPlus>

Lozano E *et al*. (2013) Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. *Biomed Res Int* **2013**: 692071 <https://www.ncbi.nlm.nih.gov/pubmed/23984399?dopt=AbstractPlus>

Pelis RM *et al*. (2014) SLC22, SLC44, and SLC47 transporters--organic anion and cation transporters: molecular and cellular properties. *Curr Top Membr* **73**: 233‐61 <https://www.ncbi.nlm.nih.gov/pubmed/24745985?dopt=AbstractPlus>

Yin J *et al*. (2016) Renal drug transporters and their significance in drug‐drug interactions. *Acta Pharm Sin B* **6**: 363‐373 <https://www.ncbi.nlm.nih.gov/pubmed/27709005?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=197> {#bph14753-sec-0173}
===========================================================================

Overview {#bph14753-sec-0174}
--------

Organic zwitterions/cation transporters (OCTN) function as organic cation uniporters, organic cation/proton exchangers or sodium/<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4780> co‐transporters.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1022><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1023><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1024>Systematic nomenclatureSLC22A4SLC22A5SLC22A16Common abbreviationOCTN1OCTN2CT2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10968](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10968), <http://www.uniprot.org/uniprot/Q9H015>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10969](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10969), <http://www.uniprot.org/uniprot/O76082>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20302](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20302), <http://www.uniprot.org/uniprot/Q86VW1>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1227>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4568><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4568>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1227>--Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4780><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4780>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4520><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4780>StoichiometryUnknownUnknownUnknown

Comments {#bph14753-sec-0175}
--------

Mutations in the SLC22A5 gene lead to primary carnitine deficiency \[<http://www.ncbi.nlm.nih.gov/pubmed/26828774?dopt=AbstractPlus>\].

Further reading on Organic zwitterions/cation transporters (OCTN) {#bph14753-sec-0176}
-----------------------------------------------------------------

Pochini L *et al*. (2013) OCTN cation transporters in health and disease: role as drug targets and assay development. *J Biomol Screen* **18**: 851‐67 <https://www.ncbi.nlm.nih.gov/pubmed/23771822?dopt=AbstractPlus>

Tamai I. (2013) Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). *Biopharm Drug Dispos* **34**: 29‐44 <https://www.ncbi.nlm.nih.gov/pubmed/22952014?dopt=AbstractPlus>

Yin J *et al*. (2016) Renal drug transporters and their significance in drug‐drug interactions. *Acta Pharm Sin B* **6**: 363‐373 <https://www.ncbi.nlm.nih.gov/pubmed/27709005?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=198> {#bph14753-sec-0177}
===========================================================================

Overview {#bph14753-sec-0178}
--------

Organic anion transporters (OATs) are non‐selective transporters prominent in the kidney, placenta and blood‐brain barrier.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1025><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1026><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1027><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1030><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1029><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1028>Systematic nomenclatureSLC22A6SLC22A7SLC22A8SLC22A11SLC22A10SLC22A9Common abbreviationOAT1OAT2OAT3--OAT5OAT4HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10970](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10970), <http://www.uniprot.org/uniprot/Q4U2R8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10971](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10971), <http://www.uniprot.org/uniprot/Q9Y694>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10972](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10972), <http://www.uniprot.org/uniprot/Q8TCC7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18120](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18120), <http://www.uniprot.org/uniprot/Q9NSA0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18057](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18057), <http://www.uniprot.org/uniprot/Q63ZE4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16261](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16261), <http://www.uniprot.org/uniprot/Q8IVM8>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4810>, non‐steroidal anti‐inflammatory drugs<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4810>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883>, non‐steroidal anti‐inflammatory drugs<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4731> \[<http://www.ncbi.nlm.nih.gov/pubmed/29847376?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4749> \[<http://www.ncbi.nlm.nih.gov/pubmed/10224140?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4810> \[<http://www.ncbi.nlm.nih.gov/pubmed/10224140?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1231> \[<http://www.ncbi.nlm.nih.gov/pubmed/10224140?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4672> \[<http://www.ncbi.nlm.nih.gov/pubmed/10224140?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4731> \[<http://www.ncbi.nlm.nih.gov/pubmed/29847376?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4528> \[<http://www.ncbi.nlm.nih.gov/pubmed/10660625?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4749> \[<http://www.ncbi.nlm.nih.gov/pubmed/10660625?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4672> \[<http://www.ncbi.nlm.nih.gov/pubmed/10660625?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4672> \[<http://www.ncbi.nlm.nih.gov/pubmed/15068970?dopt=AbstractPlus>\]--StoichiometryUnknownUnknownUnknownUnknownUnknownUnknownInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4357> (Inhibition of urate transport by human SCL22A6.) (pIC~50~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/12472777?dopt=AbstractPlus>\]----------

Further reading on Organic anion transporters (OATs) {#bph14753-sec-0179}
----------------------------------------------------

Burckhardt G *et al*. (2011) In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. *Handb Exp Pharmacol* 29‐104 <https://www.ncbi.nlm.nih.gov/pubmed/21103968?dopt=AbstractPlus>

Koepsell H. (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. *Mol. Aspects Med*. **34**: 413‐35 <https://www.ncbi.nlm.nih.gov/pubmed/23506881?dopt=AbstractPlus>

Shen H *et al*. (2017) Organic Anion Transporter 2: An Enigmatic Human Solute Carrier. *Drug Metab. Dispos*. **45**: 228‐236 <https://www.ncbi.nlm.nih.gov/pubmed/27872146?dopt=AbstractPlus>

Yin J *et al*. (2016) Renal drug transporters and their significance in drug‐drug interactions. *Acta Pharm Sin B* **6**: 363‐373 <https://www.ncbi.nlm.nih.gov/pubmed/27709005?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=199> {#bph14753-sec-0180}
===========================================================================

Overview {#bph14753-sec-0181}
--------

URAT1, a member of the OAT (organic anion transporter) family, is an anion‐exchanging uptake transporter localized to the apical (brush border) membrane of renal proximal tubular cells. It is an anion exchanger that specifically reabsorbs uric acid from the proximal tubule in exchange for monovalent anions such as lactate, nicotinoate, acetoacetate, and hydroxybutyrate \[<http://www.ncbi.nlm.nih.gov/pubmed/12024214?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1031>Systematic nomenclatureSLC22A12Common abbreviationURAT1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17989](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17989), <http://www.uniprot.org/uniprot/Q96S37>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4731> \[<http://www.ncbi.nlm.nih.gov/pubmed/12024214?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4690> \[<http://www.ncbi.nlm.nih.gov/pubmed/12024214?dopt=AbstractPlus>\]StoichiometryUnknownSelective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5826> (pIC~50~ 4) \[<http://www.ncbi.nlm.nih.gov/pubmed/17325024?dopt=AbstractPlus>\]CommentsURAT1 is expressed in the proximal tubule of the kidney and regulates uric acid excretion from the body. Inhibitors of this transporter, such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=590>, find clinical utility in managing hyperuricemia in patients with gout \[<http://www.ncbi.nlm.nih.gov/pubmed/20719377?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18670416?dopt=AbstractPlus>\].

Further reading on Urate transporter {#bph14753-sec-0182}
------------------------------------

Nigam SK *et al*. (2018) The systems biology of uric acid transporters: the role of remote sensing and signaling. *Curr. Opin. Nephrol. Hypertens*. **27**: 305‐313 <https://www.ncbi.nlm.nih.gov/pubmed/29847376?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=859> {#bph14753-sec-0183}
===========================================================================

Overview {#bph14753-sec-0184}
--------

This family of transporters has previously been classified as part of the atypical major facilitator superfamily (MSF) protein superfamily \[<http://www.ncbi.nlm.nih.gov/pubmed/9529885?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/28878041?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27939446?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22458847?dopt=AbstractPlus>\]. The atypical SLCs share sequence similarities and phylogenetic ancestry with other SLCs, and they have historically been classified in to subfamilies (also referred to as atypical MFS transporter families (AMTF1‐15)) based on phylogenetic, sequence and structural analyses \[<http://www.ncbi.nlm.nih.gov/pubmed/28878041?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2634>Systematic nomenclatureSLC22B1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20566](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20566), <http://www.uniprot.org/uniprot/Q7L0J3>SubstratesGalactose \[<http://www.ncbi.nlm.nih.gov/pubmed/25326386?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9041> (pIC~50~ 7) \[<http://www.ncbi.nlm.nih.gov/pubmed/14736235?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6826> (p*K* ~i~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/8605950?dopt=AbstractPlus>\] -- Rat

Comments {#bph14753-sec-0185}
--------

There are three human synaptic vesicle glycoprotein 2 family members, SV2A, SV2B and SV2C. They have transmembrane transporter activity and can be classified in to the SLC superfamily of solute carriers in subfamily SLC22, as SCL22B1, B2 and B3 respectively. SV2A (SCL22B1) has been identified as the brain binding‐site for the antiepileptic drugs levetiracetam \[<http://www.ncbi.nlm.nih.gov/pubmed/23484603?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27752944?dopt=AbstractPlus>\] and brivaracetam \[<http://www.ncbi.nlm.nih.gov/pubmed/26663401?dopt=AbstractPlus>\].

Further reading on Atypical SLC22B subfamily {#bph14753-sec-0186}
--------------------------------------------

Löscher W *et al*. (2016) Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond. *CNS Drugs* **30**: 1055‐1077 <https://www.ncbi.nlm.nih.gov/pubmed/27752944?dopt=AbstractPlus>

Mendoza‐Torreblanca JG *et al*. (2013) Synaptic vesicle protein 2A: basic facts and role in synaptic function. *Eur. J. Neurosci*. **38**: 3529‐39 <https://www.ncbi.nlm.nih.gov/pubmed/24102679?dopt=AbstractPlus>

Further reading on SLC22 family of organic cation and anion transporters {#bph14753-sec-0187}
------------------------------------------------------------------------

Burckhardt G. (2012) Drug transport by Organic Anion Transporters (OATs). *Pharmacol. Ther*. **136**: 106‐30 <https://www.ncbi.nlm.nih.gov/pubmed/22841915?dopt=AbstractPlus>

Hillgren KM *et al*. (2013) Emerging transporters of clinical importance: an update from the International Transporter Consortium. *Clin. Pharmacol. Ther*. **94**: 52‐63 <https://www.ncbi.nlm.nih.gov/pubmed/23588305?dopt=AbstractPlus>

International Transporter Consortium *et al*. (2010) Membrane transporters in drug development. *Nat Rev Drug Discov* **9**: 215‐36 <https://www.ncbi.nlm.nih.gov/pubmed/20190787?dopt=AbstractPlus>

Koepsell H. (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. *Mol. Aspects Med*. **34**: 413‐35 <https://www.ncbi.nlm.nih.gov/pubmed/23506881?dopt=AbstractPlus>

Lozano E *et al*. (2018) Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition. *J Pers Med* **8**: <https://www.ncbi.nlm.nih.gov/pubmed/29659532?dopt=AbstractPlus>

Nigam SK. (2018) The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease. *Annu. Rev. Pharmacol. Toxicol*. **58**: 663‐687 <https://www.ncbi.nlm.nih.gov/pubmed/29309257?dopt=AbstractPlus>

Zamek‐Gliszczynski MJ *et al*. (2018) Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. *Clin. Pharmacol. Ther*. **104**: 890‐899 <https://www.ncbi.nlm.nih.gov/pubmed/30091177?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=201> {#bph14753-sec-0188}
===========================================================================

Overview {#bph14753-sec-0189}
--------

Predicted to be 12 TM segment proteins, members of this family transport the reduced form of ascorbic acid (while the oxidized form may be handled by members of the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=140> (GLUT1/SLC2A1, GLUT3/SLC2A3 and GLUT4/SLC2A4). <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4285> is considered a non‐selective inhibitor of these transporters, with an affinity in the micromolar range.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1041><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1042><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1043>Systematic nomenclatureSLC23A1SLC23A2SLC23A3Common abbreviationSVCT1SVCT2SVCT3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10974](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10974), <http://www.uniprot.org/uniprot/Q9UHI7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10973](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10973), <http://www.uniprot.org/uniprot/Q9UGH3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20601](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20601), <http://www.uniprot.org/uniprot/Q6PIS1>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4781> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4651> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4733> \[<http://www.ncbi.nlm.nih.gov/pubmed/10331392?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4781> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4651> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4733> \[<http://www.ncbi.nlm.nih.gov/pubmed/10331392?dopt=AbstractPlus>\]--Stoichiometry2 Na^+^: 1 ascorbic acid (in) \[<http://www.ncbi.nlm.nih.gov/pubmed/10331392?dopt=AbstractPlus>\]2 Na^+^: 1 ascorbic acid (in) \[<http://www.ncbi.nlm.nih.gov/pubmed/10331392?dopt=AbstractPlus>\]--Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4285> (p*K* ~i~ 4.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/10331392?dopt=AbstractPlus>\]----Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4532> (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/11895172?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4532>--Comments----SLC23A3 does not transport ascorbic acid and remains an orphan transporter.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1044>Systematic nomenclatureSLC23A4Common abbreviationSNBT1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20602](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20602), --Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4789> \[<http://www.ncbi.nlm.nih.gov/pubmed/20042597?dopt=AbstractPlus>\]Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4560> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4581> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4556>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4555> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4557>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4566> \[<http://www.ncbi.nlm.nih.gov/pubmed/20042597?dopt=AbstractPlus>\]Stoichiometry1 Na^+^ : 1 uracil (in) \[<http://www.ncbi.nlm.nih.gov/pubmed/20042597?dopt=AbstractPlus>\]CommentsSLC23A4/SNBT1 is found in rodents and non‐human primates, but the sequence is truncated in the human genome and named as a pseudogene, SLC23A4P

Further reading on SLC23 family of ascorbic acid transporters {#bph14753-sec-0190}
-------------------------------------------------------------

Bürzle M *et al*. (2013) The sodium‐dependent ascorbic acid transporter family SLC23. *Mol. Aspects Med*. **34**: 436‐54 <https://www.ncbi.nlm.nih.gov/pubmed/23506882?dopt=AbstractPlus>

May JM. (2011) The SLC23 family of ascorbate transporters: ensuring that you get and keep your daily dose of vitamin *C. Br. J. Pharmacol*. **164**: 1793‐801 <https://www.ncbi.nlm.nih.gov/pubmed/21418192?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=202> {#bph14753-sec-0191}
===========================================================================

Overview {#bph14753-sec-0192}
--------

The sodium/potassium/calcium exchange family of transporters utilize the extracellular sodium gradient to drive calcium and potassium co‐transport out of the cell. As is the case for NCX transporters (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=180>), NKCX transporters are thought to be bidirectional, with the possibility of calcium influx following depolarization of the plasma membrane. Topological modeling suggests the presence of 10 TM domains, with a large intracellular loop between the fifth and sixth TM regions.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1045><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1050>Systematic nomenclatureSLC24A1SLC24A6Common abbreviationNKCX1NKCX6HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10975](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10975), <http://www.uniprot.org/uniprot/O60721>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:26175](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26175), <http://www.uniprot.org/uniprot/Q6J4K2>Stoichiometry4Na^+^:(1Ca^2+^ + 1K^+^)--

Comments {#bph14753-sec-0193}
--------

NKCX6 has been proposed to be the sole member of a CAX Na^+^/Ca^2+^ exchanger family, which may be the mitochondrial transporter responsible for calcium accumulation from the cytosol \[<http://www.ncbi.nlm.nih.gov/pubmed/25998733?dopt=AbstractPlus>\].

Further reading on SLC24 family of sodium/potassium/calcium exchangers {#bph14753-sec-0194}
----------------------------------------------------------------------

Schnetkamp PP. (2013) The SLC24 gene family of Na^+^/Ca^2+^‐K^+^ exchangers: from sight and smell to memory consolidation and skin pigmentation. *Mol. Aspects Med*. **34**: 455‐64 <https://www.ncbi.nlm.nih.gov/pubmed/23506883?dopt=AbstractPlus>

Schnetkamp PP *et al*. (2014) The SLC24 family of K^+^‐dependent Na^+^‐Ca^2+^ exchangers: structure‐function relationships. *Curr Top Membr* **73**: 263‐87 <https://www.ncbi.nlm.nih.gov/pubmed/24745986?dopt=AbstractPlus>

Sekler I. (2015) Standing of giants shoulders the story of the mitochondrial Na(+)Ca(2+) exchanger. *Biochem. Biophys. Res. Commun*. **460**: 50‐2 <https://www.ncbi.nlm.nih.gov/pubmed/25998733?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=147> {#bph14753-sec-0195}
===========================================================================

Overview {#bph14753-sec-0196}
--------

Mitochondrial transporters are nuclear‐encoded proteins, which convey solutes across the inner mitochondrial membrane. Topological modelling suggests homodimeric transporters, each with six TM segments and termini in the cytosol.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=203> {#bph14753-sec-0197}
===========================================================================

Overview {#bph14753-sec-0198}
--------

Mitochondrial di‐ and tri‐carboxylic acid transporters are grouped on the basis of commonality of substrates and include the citrate transporter which facilitates <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2478> export from the mitochondria to allow the generation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5236> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038> through the action of ATP:citrate lyase.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1051><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1052><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1053><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1057>Systematic nomenclatureSLC25A1SLC25A10SLC25A11SLC25A21Common abbreviationCICDICOGCODCHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10979](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10979), <http://www.uniprot.org/uniprot/P53007>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10980](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10980), <http://www.uniprot.org/uniprot/Q9UBX3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10981](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10981), <http://www.uniprot.org/uniprot/Q02978>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14411](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14411), <http://www.uniprot.org/uniprot/Q9BQT8>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4692>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2480>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2478>SO~4~ ^2‐^, phosphate, S~2~O~3~ ^2‐^, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3637>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2480><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2480><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4657>StoichiometryMalate^2‐^ (in) : H‐citrate^2‐^ (out)PO~3~ ^4‐^ (in) : malate^2‐^ (out)Malate^2‐^ (in) : oxoglutarate^2‐^ (out)Oxoadipate (in) : oxoglutarate (out)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4701>------

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=204> {#bph14753-sec-0199}
===========================================================================

Overview {#bph14753-sec-0200}
--------

Mitochondrial amino acid transporters can be subdivided on the basis of their substrates. Mitochondrial ornithine transporters play a role in the <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4539> cycle by exchanging cytosolic ornithine (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4682>) for mitochondrial citrulline (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4683>) in equimolar amounts. Further members of the family include transporters of S‐adenosylmethionine and carnitine.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1054><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1055><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1056><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1058><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1059><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1060><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1076>Systematic nomenclatureSLC25A12SLC25A13SLC25A18SLC25A22SLC25A2SLC25A15SLC25A20Common abbreviation----GC2GC1ORC2ORC1CACHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10982](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10982), <http://www.uniprot.org/uniprot/O75746>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10983](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10983), <http://www.uniprot.org/uniprot/Q9UJS0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10988](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10988), <http://www.uniprot.org/uniprot/Q9H1K4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19954](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19954), <http://www.uniprot.org/uniprot/Q9H936>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:22921](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:22921), <http://www.uniprot.org/uniprot/Q9BXI2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10985](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10985), <http://www.uniprot.org/uniprot/Q9Y619>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1421](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1421), <http://www.uniprot.org/uniprot/O43772>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4695>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4695>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=724> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4681> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4680> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4683> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4682> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4679> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=724> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721> \[<http://www.ncbi.nlm.nih.gov/pubmed/12807890?dopt=AbstractPlus>\]--StoichiometryAspartate : glutamate H^+^ (bidirectional)Aspartate : glutamate H^+^ (bidirectional)Glutamate : H^+^ (bidirectional)Glutamate : H^+^ (bidirectional)1 Ornithine (in) :1 citrulline : 1 H^+^ (out)1 Ornithine (in) :1 citrulline : 1 H^+^ (out)--Comments------------Exchanges cytosolic acylcarnitine for mitochondrial carnitine

Comments {#bph14753-sec-0201}
--------

Both ornithine transporters are inhibited by the polyamine <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710> \[<http://www.ncbi.nlm.nih.gov/pubmed/19429682?dopt=AbstractPlus>\]. Loss‐of‐function mutations in these genes are associated with hyperornithinemia‐hyperammonemia‐homocitrullinuria.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=205> {#bph14753-sec-0202}
===========================================================================

Overview {#bph14753-sec-0203}
--------

Mitochondrial phosphate transporters allow the import of inorganic phosphate for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> production.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1061>Systematic nomenclatureSLC25A3Common abbreviationPHCHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10989](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10989), <http://www.uniprot.org/uniprot/Q00325>StoichiometryPO~3~ ^4‐^ (in) : OH^‐^ (out) or PO~3~ ^4‐^ : H^+^ (in)

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=206> {#bph14753-sec-0204}
===========================================================================

Overview {#bph14753-sec-0205}
--------

Mitochondrial nucleotide transporters, defined by structural similarlities, include the adenine nucleotide translocator family (SLC25A4, SLC25A5, SLC25A6 and SLC25A31), which under conditions of aerobic metabolism, allow coupling between mitochondrial oxidative phosphorylation and cytosolic energy consumption by exchanging cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712> for mitochondrial <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713>. Further members of the mitochondrial nucleotide transporter subfamily convey diverse substrates including CoA, although not all members have had substrates identified.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1062><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1063><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1064><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1065><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1071><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1072>Systematic nomenclatureSLC25A4SLC25A5SLC25A6SLC25A31SLC25A16SLC25A17Common abbreviationANT1ANT2ANT3ANT4GDCPMP34HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10990](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10990), <http://www.uniprot.org/uniprot/P12235>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10991](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10991), <http://www.uniprot.org/uniprot/P05141>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10992](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10992), <http://www.uniprot.org/uniprot/P12236>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:25319](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:25319), <http://www.uniprot.org/uniprot/Q9H0C2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10986](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10986), <http://www.uniprot.org/uniprot/P16260>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10987](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10987), <http://www.uniprot.org/uniprot/O43808>Substrates--------CoA and congeners<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2455>StoichiometryADP^3‐^ (in) : ATP^4‐^ (out)ADP^3‐^ (in) : ATP^4‐^ (out)ADP^3‐^ (in) : ATP^4‐^ (out)ADP^3‐^ (in) : ATP^4‐^ (out)CoA (in)ATP (in)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4689>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4572>----------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1073><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1074><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1077><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1078><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1079>Systematic nomenclatureSLC25A19SLC25A26SLC25A24SLC25A23SLC25A25Common abbreviationDNCSAMC1APC1APC2APC3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14409](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14409), <http://www.uniprot.org/uniprot/Q9HC21>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20661](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20661), <http://www.uniprot.org/uniprot/Q70HW3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20662](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20662), <http://www.uniprot.org/uniprot/Q6NUK1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19375](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19375), <http://www.uniprot.org/uniprot/Q9BV35>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20663](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20663), <http://www.uniprot.org/uniprot/Q6KCM7>SubstratesNucleotide Diphosphates (NDPs), Deoxynucleotide Diphosphates (dNDPs), Dideoxynucleotide Triphosphates (ddNTPs), Deoxynucleotide Triphosphates (dNTPs)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786>------StoichiometrydNDP (in) : ATP (out)--------

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=207> {#bph14753-sec-0206}
===========================================================================

Overview {#bph14753-sec-0207}
--------

Mitochondrial uncoupling proteins allow dissipation of the mitochondrial proton gradient associated with thermogenesis and regulation of radical formation.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1066><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1067><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1068><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1069><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1070><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1082>Systematic nomenclatureSLC25A7SLC25A8SLC25A9SLC25A27SLC25A14SLC25A30Common abbreviationUCP1UCP2UCP3UCP4UCP5--HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12517](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12517), <http://www.uniprot.org/uniprot/P25874>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12518](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12518), <http://www.uniprot.org/uniprot/P55851>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12519](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12519), <http://www.uniprot.org/uniprot/P55916>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21065](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21065), <http://www.uniprot.org/uniprot/O95847>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10984](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10984), <http://www.uniprot.org/uniprot/O95258>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:27371](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:27371), <http://www.uniprot.org/uniprot/Q5SVS4>StoichiometryH^+^ (in)H^+^ (in)H^+^ (in)H^+^ (in)H^+^ (in)--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=209> {#bph14753-sec-0208}
===========================================================================

Overview {#bph14753-sec-0209}
--------

Many of the transporters identified below have yet to be assigned functions and are currently regarded as orphans.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=209>.

Further reading on SLC25 family of mitochondrial transporters {#bph14753-sec-0210}
-------------------------------------------------------------

Baffy G. (2017) Mitochondrial uncoupling in cancer cells: Liabilities and opportunities. *Biochim. Biophys. Acta* **1858**: 655‐664 <https://www.ncbi.nlm.nih.gov/pubmed/28088333?dopt=AbstractPlus>

Bertholet AM *et al*. (2017) UCP1: A transporter for H^+^ and fatty acid anions. *Biochimie* **134**: 28‐34 <https://www.ncbi.nlm.nih.gov/pubmed/27984203?dopt=AbstractPlus>

Clémençon B *et al*. (2013) The mitochondrial ADP/ATP carrier (SLC25 family): pathological implications of its dysfunction. *Mol. Aspects Med*. **34**: 485‐93 <https://www.ncbi.nlm.nih.gov/pubmed/23506884?dopt=AbstractPlus>

Palmieri F. (2013) The mitochondrial transporter family SLC25: identification, properties and physiopathology. *Mol. Aspects Med*. **34**: 465‐84 <https://www.ncbi.nlm.nih.gov/pubmed/23266187?dopt=AbstractPlus>

Seifert EL *et al*. (2015) The mitochondrial phosphate carrier: Role in oxidative metabolism, calcium handling and mitochondrial disease. *Biochem. Biophys. Res. Commun*. **464**: 369‐75 <https://www.ncbi.nlm.nih.gov/pubmed/26091567?dopt=AbstractPlus>

Taylor EB. (2017) Functional Properties of the Mitochondrial Carrier System. *Trends Cell Biol*. **27**: 633‐644 <https://www.ncbi.nlm.nih.gov/pubmed/28522206?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=148> {#bph14753-sec-0211}
===========================================================================

Overview {#bph14753-sec-0212}
--------

Along with the SLC4 family, the SLC26 family acts to allow movement of monovalent and divalent anions across cell membranes. The predicted topology is of 10‐14 TM domains with intracellular C‐ and N‐termini, probably existing as dimers. Within the family, subgroups may be identified on the basis of functional differences, which appear to function as anion exchangers and anion channels (SLC26A7 and SLC26A9).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=210> {#bph14753-sec-0213}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1097><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1098>Systematic nomenclatureSLC26A1SLC26A2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10993](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10993), <http://www.uniprot.org/uniprot/Q9H2B4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10994](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10994), <http://www.uniprot.org/uniprot/P50443>SubstratesSO~4~ ^2‐^, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4538>SO~4~ ^2‐^StoichiometrySO~4~ ^2‐^ (in) : anion (out)1 SO~4~ ^2‐^ (in) : 2 Cl^‐^ (out)

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=211> {#bph14753-sec-0214}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1099><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1100><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1101>Systematic nomenclatureSLC26A3SLC26A4SLC26A6HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3018](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3018), <http://www.uniprot.org/uniprot/P40879>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8818](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8818), <http://www.uniprot.org/uniprot/O43511>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14472](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14472), <http://www.uniprot.org/uniprot/Q9BXS9>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2339><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4540>, HCO~3~ ^‐^, OH^‐^ , I^‐^ , <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2339><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4540>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4538>, SO~4~ ^2‐^, OH^‐^ , <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2339>, HCO~3~ ^‐^, I^‐^IStoichiometry2 Cl^‐^ (in) : 1 HCO~3~ ^‐^ (out) or 2 Cl^‐^ (in) : 1 OH^‐^ (out)Unknown1 SO~4~ ^2‐^ (in) : 2 HCO~3~ ^‐^ (out) or 1 Cl^‐^ (in) : 2 HCO~3~ ^‐^ (out)

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=212> {#bph14753-sec-0215}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1102><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1103>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14467](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14467), <http://www.uniprot.org/uniprot/Q8TE54>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14469](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14469), <http://www.uniprot.org/uniprot/Q7LBE3>SubstratesNO~3~ ^‐^ ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2339> = Br^‐^ = I^‐^ \> SO~4~ ^2‐^ = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>I^‐^ \> Br^‐^ \> NO~3~ ^‐^ \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2339> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>Functional CharacteristicsVoltage‐ and time‐independent current, linear I‐V relationship \[<http://www.ncbi.nlm.nih.gov/pubmed/15591059?dopt=AbstractPlus>\]Voltage‐ and time‐independent current, linear I‐V relationship \[<http://www.ncbi.nlm.nih.gov/pubmed/17673510?dopt=AbstractPlus>\]Comments--SLC26A9 has been suggested to operate in two additional modes as a Cl^‐^‐HCO~3~ ^‐^exchanger and as a Na^+^‐anion cotransporter \[<http://www.ncbi.nlm.nih.gov/pubmed/19365592?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=213> {#bph14753-sec-0216}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1104>Systematic nomenclatureSLC26A5HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9359](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9359), <http://www.uniprot.org/uniprot/P58743>SubstratesHCO~3~ ^‐^ \[<http://www.ncbi.nlm.nih.gov/pubmed/22890707?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2339> \[<http://www.ncbi.nlm.nih.gov/pubmed/22890707?dopt=AbstractPlus>\]StoichiometryUnknownCommentsPrestin has been suggested to function as a molecular motor, rather than a transporter

Further reading on SLC26 family of anion exchangers {#bph14753-sec-0217}
---------------------------------------------------

Alper SL *et al*. (2013) The SLC26 gene family of anion transporters and channels. *Mol. Aspects Med*. **34**: 494‐515 <https://www.ncbi.nlm.nih.gov/pubmed/23506885?dopt=AbstractPlus>

Kato A *et al*. (2011) Regulation of electroneutral NaCl absorption by the small intestine. *Annu. Rev. Physiol*. **73**: 261‐81 <https://www.ncbi.nlm.nih.gov/pubmed/21054167?dopt=AbstractPlus>

Nofziger C *et al*. (2011) Pendrin function in airway epithelia. *Cell. Physiol. Biochem*. **28**: 571‐8 <https://www.ncbi.nlm.nih.gov/pubmed/22116372?dopt=AbstractPlus>

Soleimani M. (2013) SLC26 Cl‐/HCO3‐ exchangers in the kidney: roles in health and disease. *Kidney Int*. **84**: 657‐66 <https://www.ncbi.nlm.nih.gov/pubmed/23636174?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=214> {#bph14753-sec-0218}
===========================================================================

Overview {#bph14753-sec-0219}
--------

Fatty acid transporter proteins (FATPs) are a family (SLC27) of six transporters (FATP1‐6). They have at least one, and possibly six \[<http://www.ncbi.nlm.nih.gov/pubmed/11470793?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7954810?dopt=AbstractPlus>\], transmembrane segments, and are predicted on the basis of structural similarities to form dimers. SLC27 members have several structural domains: integral membrane associated domain, peripheral membrane associated domain, FATP signature, intracellular AMP binding motif, dimerization domain, lipocalin motif, and an ER localization domain (identified in FATP4 only) \[<http://www.ncbi.nlm.nih.gov/pubmed/9079682?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17062637?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17065791?dopt=AbstractPlus>\]. These transporters are unusual in that they appear to express intrinsic very longchain acyl‐CoA synthetase ([http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=6.2.1.‐](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=6.2.1.‐) , [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=6.2.1.7](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=6.2.1.7)) enzyme activity. Within the cell, these transporters may associate with plasma and peroxisomal membranes. FATP1‐4 and ‐6 transport long‐ and very long‐chain fatty acids, while FATP5 transports long‐chain fatty acids as well as bile acids \[<http://www.ncbi.nlm.nih.gov/pubmed/11980911?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7954810?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1108><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1109><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1110><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1111><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1112><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1113>Systematic nomenclatureSLC27A1SLC27A2SLC27A3SLC27A4SLC27A5SLC27A6Common abbreviationFATP1FATP2FATP3FATP4FATP5FATP6HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10995](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10995), <http://www.uniprot.org/uniprot/Q6PCB7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10996](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10996), <http://www.uniprot.org/uniprot/O14975>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10997](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10997), <http://www.uniprot.org/uniprot/Q5K4L6>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10998](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10998), <http://www.uniprot.org/uniprot/Q6P1M0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10999](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10999), <http://www.uniprot.org/uniprot/Q9Y2P5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11000](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11000), <http://www.uniprot.org/uniprot/Q9Y2P4>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4710> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4585> \[<http://www.ncbi.nlm.nih.gov/pubmed/12556534?dopt=AbstractPlus>\] <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059> \[<http://www.ncbi.nlm.nih.gov/pubmed/7954810?dopt=AbstractPlus>\]----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4710> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4585> \[<http://www.ncbi.nlm.nih.gov/pubmed/12556534?dopt=AbstractPlus>\] <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4710> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> \[<http://www.ncbi.nlm.nih.gov/pubmed/10518211?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4710> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4585> \[<http://www.ncbi.nlm.nih.gov/pubmed/12556534?dopt=AbstractPlus>\]Inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8810> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/16644217?dopt=AbstractPlus>\]----Comments------FATP4 is genetically linked to <http://www.omim.org/entry/275210?search=275210&highlight=275210>.----

Comments {#bph14753-sec-0220}
--------

Although the stoichiometry of fatty acid transport is unclear, it has been proposed to be facilitated by the coupling of fatty acid transport to conjugation with <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044> to form fatty acyl CoA esters. Small molecule inhibitors of FATP2 \[<http://www.ncbi.nlm.nih.gov/pubmed/17928635?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19913517?dopt=AbstractPlus>\] and FATP4 \[<http://www.ncbi.nlm.nih.gov/pubmed/16644217?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20448275?dopt=AbstractPlus>\], as well as bile acid inhibitors of FATP5 \[<http://www.ncbi.nlm.nih.gov/pubmed/20448275?dopt=AbstractPlus>\], have been described; analysis of the mechanism of action of some of these inhibitors suggests that transport may be selectively inhibited without altering enzymatic activity of the FATP.

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5496> accumulation has been used as a non‐selective index of fatty acid transporter activity.

FATP2 has two variants: Variant 1 encodes the full‐length protein, while Variant 2 encodes a shorter isoform missing an internal protein segment. FATP6 also has two variants: Variant 2 encodes the same protein as Variant 1 but has an additional segment in the 5′ UTR.

Further reading on SLC27 family of fatty acid transporters {#bph14753-sec-0221}
----------------------------------------------------------

Anderson CM *et al*. (2013) SLC27 fatty acid transport proteins. *Mol. Aspects Med*. **34**: 516--28 <https://www.ncbi.nlm.nih.gov/pubmed/23506886?dopt=AbstractPlus>

Dourlen P *et al*. (2015) Fatty acid transport proteins in disease: New insights from invertebrate models. *Prog. Lipid Res*. **60**: 30--40 <https://www.ncbi.nlm.nih.gov/pubmed/26416577?dopt=AbstractPlus>

Schwenk RW *et al*. (2010) Fatty acid transport across the cell membrane: regulation by fatty acid transporters. *Prostaglandins Leukot. Essent. Fatty Acids* **82**: 149--54 <https://www.ncbi.nlm.nih.gov/pubmed/20206486?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=149> {#bph14753-sec-0222}
===========================================================================

Overview {#bph14753-sec-0223}
--------

Nucleoside transporters are divided into two families, the sodium‐dependent, concentrative solute carrier family 28 (SLC28) and the equilibrative, solute carrier family 29 (SLC29). The endogenous substrates are typically nucleosides, although some family members can also transport nucleobases and organic cations.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=215> {#bph14753-sec-0224}
===========================================================================

Overview {#bph14753-sec-0225}
--------

SLC28 family membersappear to have 13 TM segments with cytoplasmic N‐termini and extracellular C‐termini, and function as concentrative nucleoside transporters.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1114><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1115><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1116>Systematic nomenclatureSLC28A1SLC28A2SLC28A3Common abbreviationCNT1CNT2CNT3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11001](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11001), <http://www.uniprot.org/uniprot/O00337>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11002](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11002), <http://www.uniprot.org/uniprot/O43868>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16484](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16484), <http://www.uniprot.org/uniprot/Q9HAS3>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842> \[<http://www.ncbi.nlm.nih.gov/pubmed/25011570?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4793> \[<http://www.ncbi.nlm.nih.gov/pubmed/22644860?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4828>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4825><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4799> \[<http://www.ncbi.nlm.nih.gov/pubmed/16840788?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4833>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4806>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4802> \[<http://www.ncbi.nlm.nih.gov/pubmed/16837649?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4737> \[<http://www.ncbi.nlm.nih.gov/pubmed/16837649?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4828>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4737>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4799>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4614>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4801>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4833>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4825>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4729>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4793>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4566>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4728>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4718><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4567>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4718><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4566>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4567>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4718>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4728>Stoichiometry1 Na^+^ : 1 nucleoside (in)1 Na^+^ : 1 nucleoside (in)2 Na^+^/H^+^Inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8837> (p*K* ~i~ 5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/19097778?dopt=AbstractPlus>\]Comments----CNT3 forms cyclic homotrimers \[<http://www.ncbi.nlm.nih.gov/pubmed/28661652?dopt=AbstractPlus>\]. Genetic variants of *SLC28A3* are associated with increased risk of anthracycline‐induced cardiomyopathy \[<http://www.ncbi.nlm.nih.gov/pubmed/30351207?dopt=AbstractPlus>\].

Further reading on SLC28 family {#bph14753-sec-0226}
-------------------------------

Johnson ZL *et al*. (2014) Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters. *Elife* **3**: e03604 <https://www.ncbi.nlm.nih.gov/pubmed/25082345?dopt=AbstractPlus>

Pastor‐Anglada M *et al*. (2008) SLC28 genes and concentrative nucleoside transporter (CNT) proteins. *Xenobiotica* **38**: 972--94 <https://www.ncbi.nlm.nih.gov/pubmed/18668436?dopt=AbstractPlus>

Pastor‐Anglada M *et al*. (2015) Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. *Front Pharmacol* **6**: 13 <https://www.ncbi.nlm.nih.gov/pubmed/25713533?dopt=AbstractPlus>

Pastor‐Anglada M *et al*. (2018) Who Is Who in Adenosine Transport. *Front Pharmacol* **9**: 627 <https://www.ncbi.nlm.nih.gov/pubmed/29962948?dopt=AbstractPlus>

Young JD *et al*. (2013) The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. *Mol. Aspects Med*. **34**: 529--47 <https://www.ncbi.nlm.nih.gov/pubmed/23506887?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=216> {#bph14753-sec-0227}
===========================================================================

Overview {#bph14753-sec-0228}
--------

SLC29 family members appear to be composed of 11 TM segments with cytoplasmic N‐termini and extracellular C‐termini. ENT1, ENT2 and ENT4 are cell‐surface transporters, while ENT3 is intracellular, possibly lysosomal \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\]. ENT1‐3 are described as broad‐spectrum equilibrative nucleoside transporters, while ENT4 is primarily a polyspecific organic cation transporter at neutral pH \[<http://www.ncbi.nlm.nih.gov/pubmed/21816955?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1117><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1118>Systematic nomenclatureSLC29A1SLC29A2Common abbreviationENT1ENT2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11003](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11003), <http://www.uniprot.org/uniprot/Q99808>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11004](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11004), <http://www.uniprot.org/uniprot/Q14542>Endogenous substrates in order of increasing Km:<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844> \< <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554> \< <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4566> \< <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4567> \< <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4728> \< <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4555> \< <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4788> \< <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4581>--Substratesabacavir \[<http://www.ncbi.nlm.nih.gov/pubmed/30097436?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=548> \[<http://www.ncbi.nlm.nih.gov/pubmed/28089688?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4805>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4806>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4793>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=372>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4827>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4828>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4833>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4755>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4737>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4799>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842> \[<http://www.ncbi.nlm.nih.gov/pubmed/25011570?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4801><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4737>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=372>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4827>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4755>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4799>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4793>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4806>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4825>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4581> \[<http://www.ncbi.nlm.nih.gov/pubmed/21795683?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4567> \[<http://www.ncbi.nlm.nih.gov/pubmed/21795683?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4555> \[<http://www.ncbi.nlm.nih.gov/pubmed/21795683?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4566> \[<http://www.ncbi.nlm.nih.gov/pubmed/21795683?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554> \[<http://www.ncbi.nlm.nih.gov/pubmed/21795683?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4788> \[<http://www.ncbi.nlm.nih.gov/pubmed/21795683?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4728> \[<http://www.ncbi.nlm.nih.gov/pubmed/21795683?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4718> \[<http://www.ncbi.nlm.nih.gov/pubmed/21795683?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844> \[<http://www.ncbi.nlm.nih.gov/pubmed/21795683?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4556>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4581>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4566>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4567>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4555>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4718>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8490>StoichiometryEquilibrativeEquilibrativeInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4512> (p*K* ~i~ 9.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4590> (p*K* ~i~ 9.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/10763851?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4734> (p*K* ~i~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/14634039?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4513> (p*K* ~i~ 9.3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4717> (p*K* ~i~ 9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807> (p*K* ~i~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/14634039?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1765> (p*K* ~i~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/24414167?dopt=AbstractPlus>\]--Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4511> ^3^H\]nitrobenzylmercaptopurine ribonucleoside (p*K* ~d~ 9.3)--CommentsENT1 has 100‐1000‐fold lower affinity for nucleobases as compared with nucleosides \[<http://www.ncbi.nlm.nih.gov/pubmed/21795683?dopt=AbstractPlus>\]. The affinities of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4590>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4717>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4734> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807> at ENT1 transporters are species dependent, exhibiting lower affinity at rat transporters than at human transporters \[<http://www.ncbi.nlm.nih.gov/pubmed/14634039?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9705281?dopt=AbstractPlus>\]. The loss of ENT1 activity in ENT1‐null mice has been associated with a hypermineralization disorder similar to human diffuse idiopathic skeletal hyperostosis \[<http://www.ncbi.nlm.nih.gov/pubmed/23184610?dopt=AbstractPlus>\]. Lack of ENT1 also results in the Augustine‐null blood type \[<http://www.ncbi.nlm.nih.gov/pubmed/25896650?dopt=AbstractPlus>\].--

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1119><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1120>Systematic nomenclatureSLC29A3SLC29A4Common abbreviationENT3PMATHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23096](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23096), <http://www.uniprot.org/uniprot/Q9BZD2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23097](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23097), <http://www.uniprot.org/uniprot/Q7RTT9>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4825> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4828> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4833> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4802> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4630> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4801> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4799> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4755> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4729> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4568> \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4779> \[<http://www.ncbi.nlm.nih.gov/pubmed/17600084?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=548> \[<http://www.ncbi.nlm.nih.gov/pubmed/28089688?dopt=AbstractPlus>\]Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4566> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4718> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4567> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4788> \[<http://www.ncbi.nlm.nih.gov/pubmed/15701636?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1204> \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2150> \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844> \[<http://www.ncbi.nlm.nih.gov/pubmed/20592246?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5> \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940> \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\]StoichiometryEquilibrativeEquilibrativeInhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8482> (p*K* ~i~ 7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4607> (p*K* ~i~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807> (p*K* ~i~ 5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/24021350?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406> (p*K* ~i~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=203> (p*K* ~i~ 4.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342> (p*K* ~i~ 4.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2510> (p*K* ~i~ 4.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2399> (p*K* ~i~ 4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1231> (p*K* ~i~ \<3.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/16099839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>\]CommentsDefects in *SLC29A3* have been implicated in histiocytosis‐lymphadenopathy plus syndrome (<http://omim.org/entry/602782>) and lysosomal storage diseases \[<http://www.ncbi.nlm.nih.gov/pubmed/22174130?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20595384?dopt=AbstractPlus>\].Uptake of substrates by PMAT is pH dependent, with greater uptake observed at acidic extracellular pH \[<http://www.ncbi.nlm.nih.gov/pubmed/16873718?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17600084?dopt=AbstractPlus>\].

Further reading on SLC29 family {#bph14753-sec-0229}
-------------------------------

Boswell‐Casteel RC *et al*. (2017) Equilibrative nucleoside transporters‐A review. *Nucleosides Nucleotides Nucleic Acids* **36**: 7--30 <https://www.ncbi.nlm.nih.gov/pubmed/27759477?dopt=AbstractPlus>

Pastor‐Anglada M *et al*. (2018) Who Is Who in Adenosine Transport. *Front Pharmacol* **9**: 627 <https://www.ncbi.nlm.nih.gov/pubmed/29962948?dopt=AbstractPlus>

Wang J. (2016) The plasma membranemonoamine transporter (PMAT): Structure, function, and role in organic cation disposition. *Clin. Pharmacol. Ther*. **100**: 489--499 <https://www.ncbi.nlm.nih.gov/pubmed/27506881?dopt=AbstractPlus>

Further reading on SLC28 and SLC29 families of nucleoside transporters {#bph14753-sec-0230}
----------------------------------------------------------------------

Boswell‐Casteel RC *et al*. (2017) Equilibrative nucleoside transporters‐A review. *Nucleosides Nucleotides Nucleic Acids* **36**: 7--30 <https://www.ncbi.nlm.nih.gov/pubmed/27759477?dopt=AbstractPlus>

Pastor‐Anglada M *et al*. (2015) Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. *Front Pharmacol* **6**: 13 <https://www.ncbi.nlm.nih.gov/pubmed/25713533?dopt=AbstractPlus>

Young JD. (2016) The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30‐year collaborative odyssey. *Biochem. Soc. Trans*. **44**: 869--76 <https://www.ncbi.nlm.nih.gov/pubmed/27284054?dopt=AbstractPlus>

Young JD *et al*. (2013) The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. *Mol. Aspects Med*. **34**: 529--47 <https://www.ncbi.nlm.nih.gov/pubmed/23506887?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=217> {#bph14753-sec-0231}
===========================================================================

Overview {#bph14753-sec-0232}
--------

Along with the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=228>, SLC30 transporters regulate the movement of zinc ions around the cell. In particular, these transporters remove zinc ions from the cytosol, allowing accumulation into intracellular compartments or efflux through the plasma membrane. ZnT1 is thought to be placed on the plasma membrane extruding zinc, while ZnT3 is associated with synaptic vesicles and ZnT4 and ZnT5 are linked with secretory granules. Membrane topology predictions suggest a multimeric assembly, potentially heteromultimeric \[<http://www.ncbi.nlm.nih.gov/pubmed/15994300?dopt=AbstractPlus>\], with subunits having six TM domains, and both termini being cytoplasmic. Dityrosine covalent linking has been suggested as a mechanism for dimerisation, particularly for ZnT3 \[<http://www.ncbi.nlm.nih.gov/pubmed/19521526?dopt=AbstractPlus>\]. The mechanism for zinc transport is unknown.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=217>.

Comments {#bph14753-sec-0233}
--------

ZnT8/SLC30A8 is described as a type 1 diabetes susceptibility gene.

Zinc fluxes may be monitored through the use of radioisotopic Zn‐65 or the fluorescent dye FluoZin 3.

Further reading on SLC30 zinc transporter family {#bph14753-sec-0234}
------------------------------------------------

Bouron A *et al*. (2014) Contribution of calcium‐conducting channels to the transport of zinc ions. *Pflugers Arch*. **466**: 381--7 <https://www.ncbi.nlm.nih.gov/pubmed/23719866?dopt=AbstractPlus>

Hojyo S *et al*. (2016) Zinc transporters and signaling in physiology and pathogenesis. *Arch. Biochem. Biophys*. **611**: 43--50 <https://www.ncbi.nlm.nih.gov/pubmed/27394923?dopt=AbstractPlus>

Huang L *et al*. (2013) The SLC30 family of zinc transporters ‐ a review of current understanding of their biological and pathophysiological roles. *Mol. Aspects Med*. **34**: 548‐60 <https://www.ncbi.nlm.nih.gov/pubmed/23506888?dopt=AbstractPlus>

Kambe T *et al*. (2014) Current understanding of ZIP and ZnT zinc transporters in human health and diseases. *Cell. Mol. Life Sci*. **71**: 3281--95 <https://www.ncbi.nlm.nih.gov/pubmed/24710731?dopt=AbstractPlus>

Kambe T *et al*. (2015) The Physiological, Biochemical, and Molecular Roles of Zinc Transporters in Zinc Homeostasis and Metabolism. *Physiol. Rev*. **95**: 749--784 <https://www.ncbi.nlm.nih.gov/pubmed/26084690?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=218> {#bph14753-sec-0235}
===========================================================================

Overview {#bph14753-sec-0236}
--------

SLC31 family members, alongside the [http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=138\#Cu2+‐ATPase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=138#Cu2+‐ATPase) are involved in the regulation of cellular copper levels. The CTR1 transporter is a cell‐surface transporter to allow monovalent copper accumulation into cells, while CTR2 appears to be a vacuolar/vesicular transporter \[<http://www.ncbi.nlm.nih.gov/pubmed/15494390?dopt=AbstractPlus>\]. Functional copper transporters appear to be trimeric with each subunit having three TM regions and an extracellular N‐terminus. CTR1 is considered to be a higher affinity copper transporter compared to CTR2. The stoichiometry of copper accumulation is unclear, but appears to be energy‐independent \[<http://www.ncbi.nlm.nih.gov/pubmed/11734551?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1131><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1132>Systematic nomenclatureSLC31A1SLC31A2Common abbreviationCTR1CTR2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11016](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11016), <http://www.uniprot.org/uniprot/O15431>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11017](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11017), <http://www.uniprot.org/uniprot/O15432>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5343> \[<http://www.ncbi.nlm.nih.gov/pubmed/12370430?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5343> \[<http://www.ncbi.nlm.nih.gov/pubmed/19509135?dopt=AbstractPlus>\]Endogenous substratescopper \[<http://www.ncbi.nlm.nih.gov/pubmed/11734551?dopt=AbstractPlus>\]copperStoichiometryUnknownUnknown

Comments {#bph14753-sec-0237}
--------

Copper accumulation through CTR1 is sensitive to silver ions, but not divalent cations \[<http://www.ncbi.nlm.nih.gov/pubmed/11734551?dopt=AbstractPlus>\].

Further reading on SLC31 family of copper transporters {#bph14753-sec-0238}
------------------------------------------------------

Howell SB *et al*. (2010) Copper transporters and the cellular pharmacology of the platinumcontaining cancer drugs. *Mol. Pharmacol*. **77**: 887--94 <https://www.ncbi.nlm.nih.gov/pubmed/20159940?dopt=AbstractPlus>

Kaplan JH *et al*. (2016) How Mammalian Cells Acquire Copper: An Essential but Potentially Toxic Metal. *Biophys. J*. **110**: 7--13 <https://www.ncbi.nlm.nih.gov/pubmed/26745404?dopt=AbstractPlus>

Kim H *et al*. (2013) SLC31 (CTR) family of copper transporters in health and disease. *Mol. Aspects Med*. **34**: 561--70 <https://www.ncbi.nlm.nih.gov/pubmed/23506889?dopt=AbstractPlus>

Monne M *et al*. (2014) Antiporters of the mitochondrial carrier family. *Curr Top Membr* **73**: 289--320 <https://www.ncbi.nlm.nih.gov/pubmed/24745987?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=219> {#bph14753-sec-0239}
===========================================================================

Overview {#bph14753-sec-0240}
--------

The vesicular inhibitory amino acid transporter, VIAAT (also termed the vesicular GABA transporter VGAT), which is the sole representative of the SLC32 family, transports <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067>, or <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727>, into synaptic vesicles \[<http://www.ncbi.nlm.nih.gov/pubmed/12750892?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10865121?dopt=AbstractPlus>\], and is a member of the structurally‐defined amino acid‐polyamineorganocation/ APC clan composed of SLC32, SLC36 and SLC38 transporter families (see \[<http://www.ncbi.nlm.nih.gov/pubmed/23506890?dopt=AbstractPlus>\]). VIAAT was originally suggested to be composed of 10 TM segments with cytoplasmic N‐ and C‐termini \[<http://www.ncbi.nlm.nih.gov/pubmed/9349821?dopt=AbstractPlus>\]. However, an alternative 9TM structure with the N terminus facing the cytoplasm and the C terminus residing in the synaptic vesicle lumen has subsequently been reported \[<http://www.ncbi.nlm.nih.gov/pubmed/19052203?dopt=AbstractPlus>\]. VI‐AAT acts as an antiporter for inhibitory amino acids and protons. The accumulation ofGABA and glycine within vesicles is driven by both the chemical (ΔpH) and electrical (Δψ) components of the proton electrochemical gradient (Δμ~H~ ^+^) established by a vacuolar H^+^‐ATPase \[<http://www.ncbi.nlm.nih.gov/pubmed/9349821?dopt=AbstractPlus>\]. However, one study, \[<http://www.ncbi.nlm.nih.gov/pubmed/19843525?dopt=AbstractPlus>\], presented evidence that VIAAT is instead a Cl^‐^/GABA co‐transporter. VIAAT co‐exists with <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=145#show_object_1007> (SLC17A7), or <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=145#show_object_1008> (SLC17A6), in the synaptic vesicles of selected nerve terminals \[<http://www.ncbi.nlm.nih.gov/pubmed/19627441?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20519538?dopt=AbstractPlus>\]. VIAAT knock out mice die between embryonic day 18.5 and birth \[<http://www.ncbi.nlm.nih.gov/pubmed/16701208?dopt=AbstractPlus>\]. In cultures of spinal cord neurones established from earlier embryos, the corelease of of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> from synaptic vesicles is drastically reduced, providing direct evidence for the role of VIAAT in the sequestration of both transmitters \[<http://www.ncbi.nlm.nih.gov/pubmed/21190592?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16701208?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1133>Systematic nomenclatureSLC32A1Common abbreviationVIAATHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11018](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11018), <http://www.uniprot.org/uniprot/Q9H598>Endogenous substratesβ‐alanine, γ‐hydroxybutyric acid, GABA (*K* ~m~ 5×10^‐3^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/9349821?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727>Stoichiometry1 amino acid (in): 1 H^+^ (out) \[<http://www.ncbi.nlm.nih.gov/pubmed/12750892?dopt=AbstractPlus>\] or 1 amino acid: 2Cl^‐^ (in) \[<http://www.ncbi.nlm.nih.gov/pubmed/19843525?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4821> (pIC~50~ 2.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9349821?dopt=AbstractPlus>\]

Further reading on SLC32 vesicular inhibitory amino acid transporter {#bph14753-sec-0241}
--------------------------------------------------------------------

Anne C *et al*. (2014) Vesicular neurotransmitter transporters: mechanistic aspects. *Curr Top Membr* **73**: 149‐74 <https://www.ncbi.nlm.nih.gov/pubmed/24745982?dopt=AbstractPlus>

Schiöth HB *et al*. (2013) Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects. *Mol. Aspects Med*. **34**: 571‐85 <https://www.ncbi.nlm.nih.gov/pubmed/23506890?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=220> {#bph14753-sec-0242}
===========================================================================

Overview {#bph14753-sec-0243}
--------

Acetylation of proteins is a post‐translational modification mediated by specific acetyltransferases, using the donor <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038>. SLC33A1/AT1 is a putative 11 TM transporter present on the endoplasmic reticulum, expressed in all tissues, but particularly abundant in the pancreas \[<http://www.ncbi.nlm.nih.gov/pubmed/9096318?dopt=AbstractPlus>\], which imports cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038> into these intracellular organelles.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1134>Systematic nomenclatureSLC33A1Common abbreviationACATN1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:95](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:95), <http://www.uniprot.org/uniprot/O00400>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038>StoichiometryUnknownLabelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4541> (Binding)

Comments {#bph14753-sec-0244}
--------

In heterologous expression studies, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038> transport through AT1 was inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044>, but not <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> or <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1782>\[<http://www.ncbi.nlm.nih.gov/pubmed/20826464?dopt=AbstractPlus>\]. A loss‐of‐function mutation in ACATN1/SLC33A1 has been associated with spastic paraplegia (SPG42, \[<http://www.ncbi.nlm.nih.gov/pubmed/19061983?dopt=AbstractPlus>\]), although this observation could not be replicated in a subsequent study \[<http://www.ncbi.nlm.nih.gov/pubmed/20461110?dopt=AbstractPlus>\].

Further reading on SLC33 acetylCoA transporter {#bph14753-sec-0245}
----------------------------------------------

Hirabayashi Y *et al*. (2004) The acetyl‐CoA transporter family SLC33. *Pflugers Arch*. **447**: 760‐2 <https://www.ncbi.nlm.nih.gov/pubmed/12739170?dopt=AbstractPlus>

Hirabayashi Y *et al*. (2013) The acetyl‐CoA transporter family SLC33. *Mol. Aspects Med*. **34**: 586‐9 <https://www.ncbi.nlm.nih.gov/pubmed/23506891?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=221> {#bph14753-sec-0246}
===========================================================================

Overview {#bph14753-sec-0247}
--------

The SLC34 family are sometimes referred to as Type II sodium‐phosphate co‐transporters, alongside Type I (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=145>) and Type III (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=195>) transporters. Topological modelling suggests eight TM domains with C‐ and N‐ termini in the cytoplasm, and a re‐entrant loop at TM7/8. SLC34 family members are expressed on the apical surfaces of epithelia in the intestine and kidneys to regulate body phosphate levels, principally NaPi‐IIa and NaPi‐IIb, respectively. NaPi‐IIa and NaPi‐IIb are electrogenic, while NaPiIIc is electroneutral \[<http://www.ncbi.nlm.nih.gov/pubmed/18989094?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1135><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1136><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1137>Systematic nomenclatureSLC34A1SLC34A2SLC34A3Common abbreviationNaPi‐IIaNaPi‐IIbNaPi‐IIcHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11019](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11019), <http://www.uniprot.org/uniprot/Q06495>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11020](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11020), <http://www.uniprot.org/uniprot/O95436>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20305](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20305), <http://www.uniprot.org/uniprot/Q8N130>Stoichiometry3 Na^+^ : 1 HPO~4~ ^2‐^ (in) \[<http://www.ncbi.nlm.nih.gov/pubmed/10198426?dopt=AbstractPlus>\]3 Na^+^ : 1 HPO~4~ ^2‐^ (in) \[<http://www.ncbi.nlm.nih.gov/pubmed/18989094?dopt=AbstractPlus>\]2 Na^+^ : 1 HPO~4~ ^2‐^ (in) \[<http://www.ncbi.nlm.nih.gov/pubmed/18989094?dopt=AbstractPlus>\]Antibodies--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8405> (Binding) \[[146](#bph14753-bib-0146){ref-type="ref"}\]--

Comments {#bph14753-sec-0248}
--------

These transporters can be inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5497>, in contrast to type III sodium‐phosphate cotransporters, the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=195>.

Further reading on SLC34 family of sodium phosphate co‐transporters {#bph14753-sec-0249}
-------------------------------------------------------------------

Biber J *et al*. (2013) Phosphate transporters and their function. *Annu. Rev. Physiol*. **75**: 535‐50 <https://www.ncbi.nlm.nih.gov/pubmed/23398154?dopt=AbstractPlus>

Forster IC *et al*. (2013) Phosphate transporters of the SLC20 and SLC34 families. *Mol. Aspects Med*. **34**: 386‐95 <https://www.ncbi.nlm.nih.gov/pubmed/23506879?dopt=AbstractPlus>

Shobeiri N *et al*. (2014) Phosphate: an old bone molecule but new cardiovascular risk factor. *Br J Clin Pharmacol* **77**: 39‐54 <https://www.ncbi.nlm.nih.gov/pubmed/23506202?dopt=AbstractPlus>

Wagner CA *et al*. (2014) The SLC34 family of sodium‐dependent phosphate transporters. *Pflugers Arch*. **466**: 139‐53 <https://www.ncbi.nlm.nih.gov/pubmed/24352629?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=222> {#bph14753-sec-0250}
===========================================================================

Overview {#bph14753-sec-0251}
--------

Glycoprotein formation in the Golgi and endoplasmic reticulum relies on the accumulation of nucleotide‐conjugated sugars via the SLC35 family of transporters. These transporters have a predicted topology of 10 TM domains, with cytoplasmic termini, and function as exchangers, swopping nucleoside monophosphates for the corresponding nucleoside diphosphate conjugated sugar. Five subfamilies of transporters have been identified on the basis of sequence similarity, namely SLC35A1, SLC35A2, SLC35A3, SLC35A4 and SLC35A5; SLC35B1, SLC35B2, SLC35B3 and SLC35B4; SLC35C1 and SLC35C2; SLC35D1, SL35D1, SLC35D2 and SLC35D3, and the subfamily of orphan SLC35 transporters, SLC35E1‐4 and SLC35F1‐5.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1138><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1139><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1140><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1144><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1145>Systematic nomenclatureSLC35A1SLC35A2SLC35A3SLC35B2SLC35B3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11021](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11021), <http://www.uniprot.org/uniprot/P78382>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11022](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11022), <http://www.uniprot.org/uniprot/P78381>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11023](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11023), <http://www.uniprot.org/uniprot/Q9Y2D2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16872](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16872), <http://www.uniprot.org/uniprot/Q8TB61>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21601](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21601), <http://www.uniprot.org/uniprot/Q9H1N7>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4663> \[<http://www.ncbi.nlm.nih.gov/pubmed/9644260?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1782> \[<http://www.ncbi.nlm.nih.gov/pubmed/9010752?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8889805?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1779> \[<http://www.ncbi.nlm.nih.gov/pubmed/9010752?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8889805?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1779> \[<http://www.ncbi.nlm.nih.gov/pubmed/10393322?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1719> \[<http://www.ncbi.nlm.nih.gov/pubmed/12716889?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1719> \[<http://www.ncbi.nlm.nih.gov/pubmed/16492677?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1146><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1147><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1149><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1150>Systematic nomenclatureSLC35B4SLC35C1SLC35D1SLC35D2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20584](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20584), <http://www.uniprot.org/uniprot/Q969S0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20197](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20197), <http://www.uniprot.org/uniprot/Q96A29>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20800](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20800), <http://www.uniprot.org/uniprot/Q9NTN3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20799](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20799), <http://www.uniprot.org/uniprot/Q76EJ3>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4730> \[<http://www.ncbi.nlm.nih.gov/pubmed/15911612?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1779> \[<http://www.ncbi.nlm.nih.gov/pubmed/15911612?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4578> \[<http://www.ncbi.nlm.nih.gov/pubmed/11326279?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4741> \[<http://www.ncbi.nlm.nih.gov/pubmed/11322953?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1784> \[<http://www.ncbi.nlm.nih.gov/pubmed/11322953?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4741> \[<http://www.ncbi.nlm.nih.gov/pubmed/15607426?dopt=AbstractPlus>\]

Further reading on SLC35 family of nucleotide sugar transporters {#bph14753-sec-0252}
----------------------------------------------------------------

Ishida N *et al*. (2004) Molecular physiology and pathology of the nucleotide sugar transporter family (SLC35). *Pflugers Arch*. **447**: 768‐75 <https://www.ncbi.nlm.nih.gov/pubmed/12759756?dopt=AbstractPlus>

Orellana A *et al*. (2016) Overview of Nucleotide Sugar Transporter Gene Family Functions Across Multiple Species. *J. Mol. Biol*. **428**: 3150‐3165 <https://www.ncbi.nlm.nih.gov/pubmed/27261257?dopt=AbstractPlus>

Song Z. (2013) Roles of the nucleotide sugar transporters (SLC35 family) in health and disease. *Mol. Aspects Med*. **34**: 590‐600 <https://www.ncbi.nlm.nih.gov/pubmed/23506892?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=223> {#bph14753-sec-0253}
===========================================================================

Overview {#bph14753-sec-0254}
--------

Members of the SLC36 family of proton‐coupled amino acid transporters are involved in membrane transport of amino acids and derivatives. The four transporters show variable tissue expression patterns and are expressed in various cell types at the plasma‐membrane and in intracellular organelles. PAT1 is expressed at the luminal surface of the small intestine and absorbs amino acids and derivatives \[3\]. In lysosomes, PAT1 functions as an effluxmechanism for amino acids produced during intralysosomal proteolysis \[<http://www.ncbi.nlm.nih.gov/pubmed/12761825?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11390972?dopt=AbstractPlus>\]. PAT2 is expressed at the apical membrane of the renal proximal tubule \[<http://www.ncbi.nlm.nih.gov/pubmed/19033659?dopt=AbstractPlus>\] and at the plasma‐membrane in brown/beige adipocytes \[<http://www.ncbi.nlm.nih.gov/pubmed/25080478?dopt=AbstractPlus>\]. PAT1 and PAT4 are involved in regulation of the mTORC1 pathway \[<http://www.ncbi.nlm.nih.gov/pubmed/29971004?dopt=AbstractPlus>\]. More comprehensive lists of substrates can be found within the reviews under Further Reading and in the references.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1161><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1162>Systematic nomenclatureSLC36A1SLC36A2Common abbreviationPAT1PAT2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18761](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18761), <http://www.uniprot.org/uniprot/Q7Z2H8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18762](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18762), <http://www.uniprot.org/uniprot/Q495M3>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9487> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4550> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9488> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4784> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322> \[<http://www.ncbi.nlm.nih.gov/pubmed/19594759?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4707> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9489> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4697> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4821> \[<http://www.ncbi.nlm.nih.gov/pubmed/16331283?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4686> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4727> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4697> \[<http://www.ncbi.nlm.nih.gov/pubmed/12727219?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9489>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9488>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4686> \[<http://www.ncbi.nlm.nih.gov/pubmed/15644866?dopt=AbstractPlus>\]Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2365> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2379> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4171> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4676> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4704> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4713> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4537> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4678> \[<http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4713>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4704>Stoichiometry1 H^+^ : 1 amino acid (symport)1 H^+^ : 1 amino acid (symport)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671> (p*K* ~i~ 3) \[<http://www.ncbi.nlm.nih.gov/pubmed/16126914?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717> (p*K* ~i~ 2.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/16126914?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4709> (p*K* ~i~ 2.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/16126914?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5> (p*K* ~i~ 2.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/16126914?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671> (pIC~50~ 2.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20691150?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4693> (pIC~50~ 2.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/20691150?dopt=AbstractPlus>\]Comments\[^3^H\] or \[^14^C\] labelled substrates as listed above are used as probes. PAT1 can also function as an electroneutral transport system for protons and fatty acids including acetic acid, propanoic acid and butyric acid \[<http://www.ncbi.nlm.nih.gov/pubmed/15345686?dopt=AbstractPlus>\]. In addition, forskolin, phosphodiesterase inhibitors, amiloride analogues and SLC9A3 (NHE3) selective inhibitors all reduce PAT1 activity indirectly (in intact mammalian intestinal epithelia such as human intestinal Caco‐2 cells) by inhibiting the Na^+^/H^+^ exchanger NHE3 which is required to maintain the H^+^‐electrochemical gradient driving force for H^+^/amino acid cotransport \[<http://www.ncbi.nlm.nih.gov/pubmed/15521011?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15754324?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>\].\[^3^H\] or \[^14^C\] labelled substrates as listed above are used as probes. Loss‐of‐function mutations in PAT2 lead to iminoglycinuria and hyperglycinuria in man \[<http://www.ncbi.nlm.nih.gov/pubmed/19033659?dopt=AbstractPlus>\]. PAT2 can also function as an electroneutral transport system for protons and fatty acids including acetic acid, propanoic acid and butyric acid \[<http://www.ncbi.nlm.nih.gov/pubmed/15345686?dopt=AbstractPlus>\]. Replacement of a Phe residue in transmembrane domain 3 with Cys (that has a smaller side‐chain) broadens substrate specificity to include larger substrates (*e.g*. methionine, leucine) \[<http://www.ncbi.nlm.nih.gov/pubmed/29058016?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1163><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1164>Systematic nomenclatureSLC36A3SLC36A4Common abbreviationPAT3PAT4HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19659](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19659), <http://www.uniprot.org/uniprot/Q495N2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19660](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19660), <http://www.uniprot.org/uniprot/Q6YBV0>Endogenous substrates--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717> \[<http://www.ncbi.nlm.nih.gov/pubmed/21097500?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314> \[<http://www.ncbi.nlm.nih.gov/pubmed/21097500?dopt=AbstractPlus>\]StoichiometryUnknownUnknownCommentsThe function of the testes‐specific PAT3 remains unknown.PAT4 is not proton‐coupled and functions by facilitated diffusion in an electroneutral, Na^+^‐independent, manner \[<http://www.ncbi.nlm.nih.gov/pubmed/21097500?dopt=AbstractPlus>\]. PAT4 is expressed ubiquitously and is predominantly associated with the Golgi \[<http://www.ncbi.nlm.nih.gov/pubmed/26434594?dopt=AbstractPlus>\].. High PAT4 expression is associated with reduced relapse‐free survival after colorectal cancer surgery \[<http://www.ncbi.nlm.nih.gov/pubmed/26434594?dopt=AbstractPlus>\].

Further reading on SLC36 family of proton‐coupled amino acid transporters {#bph14753-sec-0255}
-------------------------------------------------------------------------

Schiöth HB *et al*. (2013) Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects. *Mol. Aspects Med*. **34**: 571‐85 <https://www.ncbi.nlm.nih.gov/pubmed/23506890?dopt=AbstractPlus>

Thwaites DT *et al*. (2011) The SLC36 family of proton‐coupled amino acid transporters and their potential role in drug transport. *Br. J. Pharmacol*. **164**: 1802‐16 <https://www.ncbi.nlm.nih.gov/pubmed/21501141?dopt=AbstractPlus>

Thwaites DT *et al*. (2007) Deciphering the mechanisms of intestinal imino (and amino) acid transport: the redemption of SLC36A1. *Biochim. Biophys. Acta* **1768**: 179‐97 <https://www.ncbi.nlm.nih.gov/pubmed/17123464?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=224> {#bph14753-sec-0256}
===========================================================================

Overview {#bph14753-sec-0257}
--------

The family of sugar‐phosphate exchangers pass particular phosphorylated sugars across intracellular membranes, exchanging for inorganic phosphate. Of the family of sugar phosphate transporters, most information is available on SPX4, the glucose‐6‐phosphate transporter. This is a 10 TM domain protein with cytoplasmic termini and is associated with the endoplasmic reticulum, with tissue‐specific splice variation.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1165><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1166><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1168>Systematic nomenclatureSLC37A1SLC37A2SLC37A4Common abbreviationSPX1SPX2SPX4HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11024](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11024), <http://www.uniprot.org/uniprot/P57057>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20644](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20644), <http://www.uniprot.org/uniprot/Q8TED4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4061](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4061), <http://www.uniprot.org/uniprot/O43826>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4740>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4647><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4647><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4647>StoichiometryGlucose 6‐phosphate (in): phosphate (out) \[<http://www.ncbi.nlm.nih.gov/pubmed/21949678?dopt=AbstractPlus>\].Glucose 6‐phosphate (in): phosphate (out) \[<http://www.ncbi.nlm.nih.gov/pubmed/21949678?dopt=AbstractPlus>\].Glucose 6‐phosphate (in): phosphate (out) \[<http://www.ncbi.nlm.nih.gov/pubmed/18337460?dopt=AbstractPlus>\].Inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8845> (pIC~50~ 8.7) \[[101](#bph14753-bib-0101){ref-type="ref"}\] -- RatComments----Multiple polymorphisms have been described for the SLC37A4 gene, some of which associate with a glycogen storage disease \[<http://www.ncbi.nlm.nih.gov/pubmed/15260472?dopt=AbstractPlus>\].

Further reading on SLC37 family of phosphosugar/phosphate exchangers {#bph14753-sec-0258}
--------------------------------------------------------------------

Chou JY *et al*. (2014) The SLC37 family of sugar‐phosphate/phosphate exchangers. *Curr Top Membr* **73**: 357--82 <https://www.ncbi.nlm.nih.gov/pubmed/24745989?dopt=AbstractPlus>

Chou JY *et al*. (2013) The SLC37 family of phosphate‐linked sugar phosphate antiporters. *Mol. Aspects Med*. **34**: 601--11 <https://www.ncbi.nlm.nih.gov/pubmed/23506893?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=150> {#bph14753-sec-0259}
===========================================================================

Overview {#bph14753-sec-0260}
--------

The SLC38 family of transporters appears to be responsible for the functionally‐defined system A and system N mechanisms of amino acid transport and are mostly expressed in the CNS. Two distinct subfamilies are identifiable within the SLC38 transporters. SNAT1, SNAT2 and SNAT4 appear to resemble system A transporters in accumulating neutral amino acids under the influence of the sodium gradient. SNAT3 and SNAT5 appear to resemble system N transporters in utilizing proton co‐transport to accumulate amino acids. The predicted membrane topology is of 11 TM domains with an extracellular C‐terminus and intracellular N‐terminus \[<http://www.ncbi.nlm.nih.gov/pubmed/23506890?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=225> {#bph14753-sec-0261}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1169><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1170><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1171>Systematic nomenclatureSLC38A1SLC38A2SLC38A4Common abbreviationSNAT1SNAT2SNAT4HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13447](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13447), <http://www.uniprot.org/uniprot/Q9H2H9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13448](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13448), <http://www.uniprot.org/uniprot/Q96QD8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14679](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14679), <http://www.uniprot.org/uniprot/Q969I6>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4697> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4533>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4814> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4785>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4794> \[<http://www.ncbi.nlm.nih.gov/pubmed/11692272?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4697> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4814> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4533>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4785>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3312>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313> \[<http://www.ncbi.nlm.nih.gov/pubmed/10930503?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4697> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4533>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=724> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3312>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313> \[<http://www.ncbi.nlm.nih.gov/pubmed/11342143?dopt=AbstractPlus>\]Stoichiometry1 Na^+^ : 1 amino acid (in) \[<http://www.ncbi.nlm.nih.gov/pubmed/11692272?dopt=AbstractPlus>\]1 Na^+^ : 1 amino acid (in) \[<http://www.ncbi.nlm.nih.gov/pubmed/10930503?dopt=AbstractPlus>\]1 Na^+^ : 1 neutral amino acid (in) \[<http://www.ncbi.nlm.nih.gov/pubmed/11342143?dopt=AbstractPlus>\]Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4542>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4543><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4542>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4543><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4542>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4635>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4543>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4084>Comments----Transport of cationic amino acids by SNAT4 was sodium‐independent \[<http://www.ncbi.nlm.nih.gov/pubmed/11342143?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=226> {#bph14753-sec-0262}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1172><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1173>Systematic nomenclatureSLC38A3SLC38A5Common abbreviationSNAT3SNAT5HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18044](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18044), <http://www.uniprot.org/uniprot/Q99624>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18070](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18070), <http://www.uniprot.org/uniprot/Q8WUX1>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4697> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310> , <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4533>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369> \[<http://www.ncbi.nlm.nih.gov/pubmed/10823827?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4697> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4533>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720> \[<http://www.ncbi.nlm.nih.gov/pubmed/11243884?dopt=AbstractPlus>\]Stoichiometry1 Na^+^ : 1 amino acid (in) : 1 H^+^ (out) \[<http://www.ncbi.nlm.nih.gov/pubmed/11850497?dopt=AbstractPlus>\]1 Na^+^ : 1 amino acid (in) : 1 H^+^ (out) \[<http://www.ncbi.nlm.nih.gov/pubmed/11243884?dopt=AbstractPlus>\]Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4633>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4634><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4623>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4670>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=227> {#bph14753-sec-0263}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1175>Systematic nomenclatureSLC38A7Common abbreviationSNAT7HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:25582](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:25582), <http://www.uniprot.org/uniprot/Q9NVC3>CommentsSNAT7/SLC38A7 has been described to be a system N‐like transporter allowing preferential accumulation of glutamine (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723>), histidine (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310>) and asparagine (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4533>) \[<http://www.ncbi.nlm.nih.gov/pubmed/21511949?dopt=AbstractPlus>\].

Further reading on SLC38 family of sodium‐dependent neutral amino acid transporters {#bph14753-sec-0264}
-----------------------------------------------------------------------------------

Bhutia YD *et al*. (2016) Glutamine transporters inmammalian cells and their functions in physiology and cancer. *Biochim. Biophys. Acta* **1863**: 2531--9 <https://www.ncbi.nlm.nih.gov/pubmed/26724577?dopt=AbstractPlus>

Bröer S. (2014) The SLC38 family of sodium‐amino acid co‐transporters. *Pflugers Arch*. **466**: 155--72 <https://www.ncbi.nlm.nih.gov/pubmed/24193407?dopt=AbstractPlus>

Bröer S *et al.* (2011) The role of amino acid transporters in inherited and acquired diseases. *Biochem. J*. **436**: 193--211 <https://www.ncbi.nlm.nih.gov/pubmed/21568940?dopt=AbstractPlus>

Hägglund MG *et al*. (2011) Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. *J. Biol. Chem*. **286**: 20500--11 <https://www.ncbi.nlm.nih.gov/pubmed/21511949?dopt=AbstractPlus>

Schiöth HB *et al*. (2013) Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects. *Mol. Aspects Med*. **34**: 571--85 <https://www.ncbi.nlm.nih.gov/pubmed/23506890?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=228> {#bph14753-sec-0265}
===========================================================================

Overview {#bph14753-sec-0266}
--------

Along with the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=217>, SLC39 family members regulate zinc movement in cells. SLC39 metal ion transporters accumulate zinc into the cytosol. Membrane topology modelling suggests the presence of eight TM regions with both termini extracellular or in the lumen of intracellular organelles. The mechanism for zinc transport for many members is unknown but appears to involve co‐transport of bicarbonate ions \[<http://www.ncbi.nlm.nih.gov/pubmed/18270315?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18037372?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1187><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1193>Systematic nomenclatureSLC39A8SLC39A14Common abbreviationZIP8ZIP14HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20862](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20862), <http://www.uniprot.org/uniprot/Q9C0K1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20858](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20858), <http://www.uniprot.org/uniprot/Q15043>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440> \[<http://www.ncbi.nlm.nih.gov/pubmed/15722412?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18037372?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440> \[<http://www.ncbi.nlm.nih.gov/pubmed/18270315?dopt=AbstractPlus>\], Mn^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/18270315?dopt=AbstractPlus>\], Fe^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/16950869?dopt=AbstractPlus>\]Stoichiometry1 Zn^2+^ (in) : 2 HCO~3~ ^‐^(in) \[<http://www.ncbi.nlm.nih.gov/pubmed/18037372?dopt=AbstractPlus>\]--

Comments {#bph14753-sec-0267}
--------

Zinc fluxes may be monitored through the use of radioisotopic Zn‐65 or the fluorescent dye FluoZin 3. The bicarbonate transport inhibitor <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177> has been reported to inhibit cation accumulation through ZIP14 \[<http://www.ncbi.nlm.nih.gov/pubmed/18270315?dopt=AbstractPlus>\].

Further reading on SLC39 family of metal ion transporters {#bph14753-sec-0268}
---------------------------------------------------------

Hojyo S *et al*. (2016) Zinc transporters and signaling in physiology and pathogenesis. *Arch. Biochem. Biophys*. **611**: 43--50 <https://www.ncbi.nlm.nih.gov/pubmed/27394923?dopt=AbstractPlus>

Jeong J *et al*. (2013) The SLC39 family of zinc transporters. *Mol. Aspects Med*. **34**: 612--9 <https://www.ncbi.nlm.nih.gov/pubmed/23506894?dopt=AbstractPlus>

Kambe T *et al*. (2014) Current understanding of ZIP and ZnT zinc transporters in human health and diseases. Cell. *Mol. Life Sci*. **71**: 3281--95 <https://www.ncbi.nlm.nih.gov/pubmed/24710731?dopt=AbstractPlus>

Kambe T *et al*. (2015) The Physiological, Biochemical, and Molecular Roles of Zinc Transporters in Zinc Homeostasis and Metabolism. *Physiol. Rev*. **95**: 749--784 <https://www.ncbi.nlm.nih.gov/pubmed/26084690?dopt=AbstractPlus>

Marger L *et al*. (2014) Zinc: an underappreciated modulatory factor of brain function. *Biochem. Pharmacol*. **91**: 426--35 <https://www.ncbi.nlm.nih.gov/pubmed/25130547?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=229> {#bph14753-sec-0269}
===========================================================================

Overview {#bph14753-sec-0270}
--------

Alongside the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=183> of proton‐coupled metal transporters, ferroportin allows the accumulation of iron from the diet. Whilst SLC11A2 functions on the apical membrane, ferroportin acts on the basolateral side of the enterocyte, as well as regulating macrophage and placental iron levels. The predicted topology is of 12 TM domains, with intracellular termini \[<http://www.ncbi.nlm.nih.gov/pubmed/19150361?dopt=AbstractPlus>\], with the functional transporter potentially a dimeric arrangement \[<http://www.ncbi.nlm.nih.gov/pubmed/15667655?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17077321?dopt=AbstractPlus>\]. Ferroportin is essential for iron homeostasis \[<http://www.ncbi.nlm.nih.gov/pubmed/16054062?dopt=AbstractPlus>\]. Ferroportin is expressed on the surface of cells that store and transport iron, such as duodenal enterocytes, hepatocytes, adipocytes and reticuloendothelial macrophages. Levels of ferroportin are regulated by its association with (binding to) hepcidin, a 25 amino acid hormone responsive to circulating iron levels (amongst other signals). Hepcidin binding targets ferroportin for internalisation and degradation, lowering the levels of iron export to the blood. Novel therapeutic agents which stabilise ferroportin or protect it from hepcidin‐induced degradation are being developed as antianemia agents. Anti‐ferroportin monoclonal antibodies are such an agent.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1194>Systematic nomenclatureSLC40A1Common abbreviationIREG1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10909](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10909), <http://www.uniprot.org/uniprot/Q9NP59>Endogenous substratesFe^2+^StoichiometryUnknownAntibodies<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8416> (Binding) \[[395](#bph14753-bib-0395){ref-type="ref"}\]

Comments {#bph14753-sec-0271}
--------

Hepcidin ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15598](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15598), <http://www.uniprot.org/uniprot/P81172>), cleaved into <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5378> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15598](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15598), <http://www.uniprot.org/uniprot/P81172>) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5379> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15598](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15598), <http://www.uniprot.org/uniprot/P81172>), is a small protein that increases upon inflammation, binds to ferroportin to regulate its cellular distribution and degradation. Gene disruption in mice results in embryonic lethality \[<http://www.ncbi.nlm.nih.gov/pubmed/16054062?dopt=AbstractPlus>\], while loss‐of‐function mutations in man are associated with haemochromatosis \[<http://www.ncbi.nlm.nih.gov/pubmed/15956209?dopt=AbstractPlus>\].

Further reading on SLC40 iron transporter {#bph14753-sec-0272}
-----------------------------------------

McKie AT *et al*. (2004) The SLC40 basolateral iron transporter family (IREG1/ferroportin/MTP1). *Pflugers Arch*. **447**: 801--6 <https://www.ncbi.nlm.nih.gov/pubmed/12836025?dopt=AbstractPlus>

Montalbetti N *et al*. (2013) Mammalian iron transporters: families SLC11 and SLC40. *Mol. Aspects Med*. **34**: 270--87 <https://www.ncbi.nlm.nih.gov/pubmed/23506870?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=230> {#bph14753-sec-0273}
===========================================================================

Overview {#bph14753-sec-0274}
--------

By analogy with bacterial orthologues, this family is probably magnesium transporters. The prokaryote orthologue, MgtE, is responsible for uptake of divalent cations, while the heterologous expression studies of mammalian proteins suggest Mg^2+^ efflux \[<http://www.ncbi.nlm.nih.gov/pubmed/22031603?dopt=AbstractPlus>\], possibly as a result of co‐expression of particular protein partners (see \[<http://www.ncbi.nlm.nih.gov/pubmed/23506895?dopt=AbstractPlus>\]). Topological modelling suggests 10 TM domains with cytoplasmic C‐ and N‐ termini.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1195><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1196>Systematic nomenclatureSLC41A1SLC41A2Common abbreviationMgtE--HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19429](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19429), <http://www.uniprot.org/uniprot/Q8IVJ1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:31045](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:31045), <http://www.uniprot.org/uniprot/Q96JW4>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4160> \[<http://www.ncbi.nlm.nih.gov/pubmed/15713785?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4164> \[<http://www.ncbi.nlm.nih.gov/pubmed/15713785?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> \[<http://www.ncbi.nlm.nih.gov/pubmed/15713785?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440> \[<http://www.ncbi.nlm.nih.gov/pubmed/15713785?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> \[<http://www.ncbi.nlm.nih.gov/pubmed/15713785?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> \[<http://www.ncbi.nlm.nih.gov/pubmed/15713785?dopt=AbstractPlus>\], Sr^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/15713785?dopt=AbstractPlus>\], Fe^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/15713785?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> \[<http://www.ncbi.nlm.nih.gov/pubmed/15809054?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> \[<http://www.ncbi.nlm.nih.gov/pubmed/15809054?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4160> \[<http://www.ncbi.nlm.nih.gov/pubmed/15809054?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2476> \[<http://www.ncbi.nlm.nih.gov/pubmed/15809054?dopt=AbstractPlus>\], Mn^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/15809054?dopt=AbstractPlus>\], Fe^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/15809054?dopt=AbstractPlus>\]StoichiometryUnknownUnknown

Further reading on SLC41 family of divalent cation transporters {#bph14753-sec-0275}
---------------------------------------------------------------

Payandeh J *et al*. (2013) The structure and regulation of magnesium selective ion channels. *Biochim. Biophys. Acta* **1828**: 2778‐92 <https://www.ncbi.nlm.nih.gov/pubmed/23954807?dopt=AbstractPlus>

Sahni J *et al*. (2013) The SLC41 family of MgtE‐like magnesium transporters. *Mol. Aspects Med*. **34**: 620‐8 <https://www.ncbi.nlm.nih.gov/pubmed/23506895?dopt=AbstractPlus>

Schweigel‐Röntgen M *et al*. (2014) SLC41 transporters--molecular identification and functional role. *Curr Top Membr* **73**: 383‐410 <https://www.ncbi.nlm.nih.gov/pubmed/24745990?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=231> {#bph14753-sec-0276}
===========================================================================

Overview {#bph14753-sec-0277}
--------

Rhesus is commonly defined as a 'factor' that determines, in part, blood type, and whether neonates suffer from haemolytic disease of the newborn. These glycoprotein antigens derive from two genes, [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10008](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10008) (<http://www.uniprot.org/uniprot/P18577>) and [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10009](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10009) (<http://www.uniprot.org/uniprot/Q02161>), expressed on the surface of erythrocytes. On erythrocytes, RhAG associates with these antigens and functions as an ammonium transporter. RhBG and RhBG are non‐erythroid related sequences associated with epithelia. Topological modelling suggests the presence of 12TM with cytoplasmic N‐ and C‐ termini. The majority of information on these transporters derives from orthologues in yeast, plants and bacteria. More recent evidence points to family members being permeable to carbon dioxide, leading to the term gas channels.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1198><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1199><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1200>Systematic nomenclatureSLC42A1SLC42A2SLC42A3Common abbreviationRhAGRhBGRhCGHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10006](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10006), <http://www.uniprot.org/uniprot/Q02094>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14572](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14572), <http://www.uniprot.org/uniprot/Q9H310>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18140](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18140), <http://www.uniprot.org/uniprot/Q9UBD6>SubstratesNH~4~ ^+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/11861637?dopt=AbstractPlus>\], NH~3~ \[<http://www.ncbi.nlm.nih.gov/pubmed/15572441?dopt=AbstractPlus>\], CO~2~ \[<http://www.ncbi.nlm.nih.gov/pubmed/17712059?dopt=AbstractPlus>\]--NH~3~ \[<http://www.ncbi.nlm.nih.gov/pubmed/19553567?dopt=AbstractPlus>\]StoichiometryUnknownUnknownUnknownLabelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4624> (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/12846905?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4624> (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/16131648?dopt=AbstractPlus>\] -- Mouse

Further reading on SLC42 family of Rhesus glycoprotein ammonium transporters {#bph14753-sec-0278}
----------------------------------------------------------------------------

Nakhoul NL *et al*. (2013) Characteristics of mammalian Rh glycoproteins (SLC42 transporters) and their role in acid‐base transport. *Mol. Aspects Med*. **34**: 629‐37 <https://www.ncbi.nlm.nih.gov/pubmed/23506896?dopt=AbstractPlus>

Weiner ID *et al*. (2011) Role of NH~3~ and NH~4~ ^+^ transporters in renal acid‐base transport. *Am. J. Physiol. Renal Physiol*. **300**: F11‐23 <https://www.ncbi.nlm.nih.gov/pubmed/21048022?dopt=AbstractPlus>

Weiner ID *et al*. (2014) Ammonia transport in the kidney by Rhesus glycoproteins. *Am. J. Physiol. Renal Physiol*. **306**: F1107‐20 <https://www.ncbi.nlm.nih.gov/pubmed/24647713?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=232> {#bph14753-sec-0279}
===========================================================================

Overview {#bph14753-sec-0280}
--------

LAT3 (SLC43A1) and LAT4 (SLC43A2) are transporters with system L amino acid transporter activity, along with the structurally and functionally distinct transporters LAT1 and LAT2 that are members of the [http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=141\#SLC7 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=141#SLC7family). LAT3 and LAT4 contain 12 put.ative TM domains with both N and C termini located intracellularly. They transport neutral amino acids in a manner independent of Na^+^ and Cl^‐^ and with two kinetic components \[<http://www.ncbi.nlm.nih.gov/pubmed/12930836?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15659399?dopt=AbstractPlus>\]. LAT3/SLC43A1 is expressed in human tissues at high levels in the pancreas, liver, skeletal muscle and fetal liver \[<http://www.ncbi.nlm.nih.gov/pubmed/12930836?dopt=AbstractPlus>\] whereas LAT4/SLC43A2 is primarily expressed in the placenta, kidney and peripheral blood leukocytes \[<http://www.ncbi.nlm.nih.gov/pubmed/15659399?dopt=AbstractPlus>\]. SLC43A3 is expressed in vascular endothelial cells \[<http://www.ncbi.nlm.nih.gov/pubmed/18483404?dopt=AbstractPlus>\] but remains to be characterised.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1201><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1202>Systematic nomenclatureSLC43A1SLC43A2Common abbreviationLAT3LAT4HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9225](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9225), <http://www.uniprot.org/uniprot/O75387>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23087](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23087), <http://www.uniprot.org/uniprot/Q8N370>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3311> \[<http://www.ncbi.nlm.nih.gov/pubmed/12930836?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4750> \[<http://www.ncbi.nlm.nih.gov/pubmed/12930836?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4751> \[<http://www.ncbi.nlm.nih.gov/pubmed/12930836?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4752> \[<http://www.ncbi.nlm.nih.gov/pubmed/12930836?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3312> \[<http://www.ncbi.nlm.nih.gov/pubmed/12930836?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313> \[<http://www.ncbi.nlm.nih.gov/pubmed/12930836?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4794> \[<http://www.ncbi.nlm.nih.gov/pubmed/12930836?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4814> \[<http://www.ncbi.nlm.nih.gov/pubmed/12930836?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3311>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4750>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4751>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3312>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4794>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4814>StoichiometryOperates by facilitative diffusionOperates by facilitative diffusion

Comments {#bph14753-sec-0281}
--------

Covalent modification of LAT3 by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5335> inhibits its function \[<http://www.ncbi.nlm.nih.gov/pubmed/12930836?dopt=AbstractPlus>\] and at LAT4 inhibits the low‐, but not high‐affinity component of transport \[<http://www.ncbi.nlm.nih.gov/pubmed/15659399?dopt=AbstractPlus>\].

Further reading on SLC43 family of large neutral amino acid transporters {#bph14753-sec-0282}
------------------------------------------------------------------------

Bodoy S *et al*. (2013) The small SLC43 family: facilitator system l amino acid transporters and the orphan EEG1. *Mol. Aspects Med*. **34**: 638‐45 <https://www.ncbi.nlm.nih.gov/pubmed/23268354?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=233> {#bph14753-sec-0283}
===========================================================================

Overview {#bph14753-sec-0284}
--------

Members of the choline transporter‐like family are encoded by five genes (CTL1‐CTL5) with further diversity occurring through alternative splicing of CTL1, 4 and 5 \[<http://www.ncbi.nlm.nih.gov/pubmed/15715662?dopt=AbstractPlus>\]. CTL family members are putative 10TM domain proteins with extracellular termini that mediate Na^+^‐independent transport of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551> with an affinity that is intermediate to that of the high affinity choline transporter CHT1 (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=143#show_object_914>) and the low affinity organiccation transporters \[OCT1 (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=146#show_object_1019>) andOCT2 (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=146#show_object_1020>)\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16636297?dopt=AbstractPlus>\]. CLT1 is expressed almost ubiquitously in human tissues \[<http://www.ncbi.nlm.nih.gov/pubmed/11698453?dopt=AbstractPlus>\] and mediates <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551> transport across the plasma and mitochondrial membranes \[<http://www.ncbi.nlm.nih.gov/pubmed/19357133?dopt=AbstractPlus>\]. Transport of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551> by CTL2, which in rodents is expressed as two isoforms (CTL2P1 and CLTP2; \[<http://www.ncbi.nlm.nih.gov/pubmed/20665236?dopt=AbstractPlus>\]) in lung, colon, inner ear and spleen and to a lesser extent in brain, tongue, liver, and kidney, has only recently been demonstrated \[<http://www.ncbi.nlm.nih.gov/pubmed/20665236?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20410607?dopt=AbstractPlus>\]. CTL3‐5 remain to be characterized functionally.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1204>Systematic nomenclatureSLC44A1Common abbreviationCTL1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18798](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18798), <http://www.uniprot.org/uniprot/Q8WWI5>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551>StoichiometryUnknown: uptake enhanced in the absence of extracellular Na^+^, reduced by membrane depolarization, extracellular acidification and collapse of plasma membrane H^+^ electrochemical gradientInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4494> (p*K* ~i~ 3.5--4.5)

Comments {#bph14753-sec-0285}
--------

Data tabulated are features observed for CLT1 endogenous to: rat astrocytes \[<http://www.ncbi.nlm.nih.gov/pubmed/16000150?dopt=AbstractPlus>\]; rat renal tubule epithelial cells \[<http://www.ncbi.nlm.nih.gov/pubmed/19236841?dopt=AbstractPlus>\]; human colon carcinoma cells \[<http://www.ncbi.nlm.nih.gov/pubmed/19135976?dopt=AbstractPlus>\]; human keratinocytes \[<http://www.ncbi.nlm.nih.gov/pubmed/19122366?dopt=AbstractPlus>\] and human neuroblastoma cells \[<http://www.ncbi.nlm.nih.gov/pubmed/21185344?dopt=AbstractPlus>\]. Choline uptake by CLT1 is inhibited by numerous organic cations (*e.g*. \[<http://www.ncbi.nlm.nih.gov/pubmed/16000150?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19236841?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21185344?dopt=AbstractPlus>\]). In the guinea‐pig, CTL2 is a target for antibody‐induced hearing loss \[<http://www.ncbi.nlm.nih.gov/pubmed/14973250?dopt=AbstractPlus>\] and in man, a polymorphism in CTL2 constitutes the human neutrophil alloantigen‐3a (HNA‐3a; \[<http://www.ncbi.nlm.nih.gov/pubmed/20037594?dopt=AbstractPlus>\]).

Further reading on SLC44 choline transporter‐like family {#bph14753-sec-0286}
--------------------------------------------------------

Inazu M. (2014) Choline transporter‐like proteins CTLs/SLC44 family as a novel molecular target for cancer therapy. *Biopharm Drug Dispos* **35**: 431‐49 <https://www.ncbi.nlm.nih.gov/pubmed/24532461?dopt=AbstractPlus>

Traiffort E *et al*. (2013) The choline transporter‐like family SLC44: properties and roles in human diseases. *Mol. Aspects Med*. **34**: 646‐54 <https://www.ncbi.nlm.nih.gov/pubmed/23506897?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=234> {#bph14753-sec-0287}
===========================================================================

Overview {#bph14753-sec-0288}
--------

Members of the SLC45 family remain to be fully characterised. SLC45A1 was initially identified in the rat brain, particularly predominant in the hindbrain, as a proton‐associated sugar transport, induced by hypercapnia \[<http://www.ncbi.nlm.nih.gov/pubmed/12417639?dopt=AbstractPlus>\]. The protein is predicted to have 12TM domains, with intracellular termini. The *SLC45A2* gene is thought to encode a transporter protein that mediates <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5415> synthesis. Mutations in SLC45A2 are a cause of oculocutaneous albinism type 4 (*e.g*. \[<http://www.ncbi.nlm.nih.gov/pubmed/11574907?dopt=AbstractPlus>\]), and polymorphisms in this gene are associated with variations in skin and hair color (*e.g*. \[<http://www.ncbi.nlm.nih.gov/pubmed/15714523?dopt=AbstractPlus>\]).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1209>Systematic nomenclatureSLC45A1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17939](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17939), <http://www.uniprot.org/uniprot/Q9Y2W3>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4719> \[<http://www.ncbi.nlm.nih.gov/pubmed/12417639?dopt=AbstractPlus>\], Galactose \[<http://www.ncbi.nlm.nih.gov/pubmed/12417639?dopt=AbstractPlus>\]StoichiometryUnknown; increased at acid pH \[<http://www.ncbi.nlm.nih.gov/pubmed/12417639?dopt=AbstractPlus>\].

Further reading on SLC45 family of putative sugar transporters {#bph14753-sec-0289}
--------------------------------------------------------------

Bartölke R *et al*. (2014) Proton‐associated sucrose transport of mammalian solute carrier family 45: an analysis in Saccharomyces cerevisiae. *Biochem. J*. **464**: 193‐201 <https://www.ncbi.nlm.nih.gov/pubmed/25164149?dopt=AbstractPlus>

Vitavska O *et al*. (2013) The SLC45 gene family of putative sugar transporters. *Mol. Aspects Med*. **34**: 655‐60 <https://www.ncbi.nlm.nih.gov/pubmed/23506898?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=235> {#bph14753-sec-0290}
===========================================================================

Overview {#bph14753-sec-0291}
--------

Based on the proptypicalmember of this family, PCFT, this family includes proton‐driven transporters with 11 TMsegments. SLC46A1 has been described to act as an intestinal proton‐coupled high‐affinity <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4563> transporter \[<http://www.ncbi.nlm.nih.gov/pubmed/17129779?dopt=AbstractPlus>\], with lower affinity for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349>. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4563> accumulation is independent of Na^+^ or K^+^ ion concentrations, but driven by extracellular protons with an as yet undefined stoichiometry.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213>Systematic nomenclatureSLC46A1Common abbreviationPCFTHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30521](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30521), <http://www.uniprot.org/uniprot/Q96NT5>Substratespemetrexed, N‐formyltetrahydrofolate, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4815> \[<http://www.ncbi.nlm.nih.gov/pubmed/17129779?dopt=AbstractPlus>\] <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4563> (1.3μM) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349> (\>100 μM) \[<http://www.ncbi.nlm.nih.gov/pubmed/17475902?dopt=AbstractPlus>\]Endogenous substratesN^5^‐methyltetrafolate \[<http://www.ncbi.nlm.nih.gov/pubmed/17129779?dopt=AbstractPlus>\]Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6689> (Binding), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4562>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6690> (Binding), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4674>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6688> (Binding)CommentsLoss‐of‐function mutations in PCFT (SLC46A1) are the molecular basis for hereditary folate maladsorption \[<http://www.ncbi.nlm.nih.gov/pubmed/21346251?dopt=AbstractPlus>\].

Further reading on SLC46 family of folate transporters {#bph14753-sec-0292}
------------------------------------------------------

Hou Z *et al*. (2014) Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. *Curr Top Membr* **73**: 175‐204 <https://www.ncbi.nlm.nih.gov/pubmed/24745983?dopt=AbstractPlus>

Matherly LH *et al*. (2014) The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer. *Drug Metab. Dispos*. **42**: 632‐49 <https://www.ncbi.nlm.nih.gov/pubmed/24396145?dopt=AbstractPlus>

Wilson MR *et al*. (2015) Structural determinants of human proton‐coupled folate transporter oligomerization: role of GXXXG motifs and identification of oligomeric interfaces at transmembrane domains 3 and 6. *Biochem. J*. **469**: 33‐44 <https://www.ncbi.nlm.nih.gov/pubmed/25877470?dopt=AbstractPlus>

Zhao R *et al*. (2011) Mechanisms of membrane transport of folates into cells and across epithelia. *Annu. Rev. Nutr*. **31**: 177‐201 <https://www.ncbi.nlm.nih.gov/pubmed/21568705?dopt=AbstractPlus>

Zhao R *et al*. (2013) Folate and thiamine transporters mediated by facilitative carriers (SLC19A1‐3 and SLC46A1) and folate receptors. *Mol. Aspects Med*. **34**: 373‐85 <https://www.ncbi.nlm.nih.gov/pubmed/23506878?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=236> {#bph14753-sec-0293}
===========================================================================

Overview {#bph14753-sec-0294}
--------

These proton:organic cation exchangers are predicted to have 13 TM segments \[<http://www.ncbi.nlm.nih.gov/pubmed/19515813?dopt=AbstractPlus>\] and are suggested to be responsible for excretion of many drugs in the liver and kidneys.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1216><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1217>Systematic nomenclatureSLC47A1SLC47A2Common abbreviationMATE1MATE2‐KHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:25588](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:25588), <http://www.uniprot.org/uniprot/Q96FL8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:26439](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26439), <http://www.uniprot.org/uniprot/Q86VL8>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342> \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4830> \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4779> (*K* ~m~ 7.8×10^‐4^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4832> \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1231> (*K* ~m~ 1.7×10^‐4^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/16928787?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4552> \[<http://www.ncbi.nlm.nih.gov/pubmed/17495125?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4783> \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4811> \[<http://www.ncbi.nlm.nih.gov/pubmed/16807400?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4779> (*K* ~m~ 1.9×10^‐3^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/16807400?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4829> \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4568> \[<http://www.ncbi.nlm.nih.gov/pubmed/16807400?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1231> (*K* ~m~ 1.2×10^‐4^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/16807400?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4658> \[<http://www.ncbi.nlm.nih.gov/pubmed/16807400?dopt=AbstractPlus>\]Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4629> \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4496> \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4496> \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4629> \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\]Sub/family‐selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4800> (p*K* ~i~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/20065018?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1231> (p*K* ~i~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/19164462?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4800> (p*K* ~i~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/20065018?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1231> (p*K* ~i~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/19164462?dopt=AbstractPlus>\]Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4575> \[<http://www.ncbi.nlm.nih.gov/pubmed/16330770?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16850272?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4503> \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16850272?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4575> \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4503> \[<http://www.ncbi.nlm.nih.gov/pubmed/17509534?dopt=AbstractPlus>\]

Comments {#bph14753-sec-0295}
--------

DAPI has been used to allow quantification of MATE1 and MATE2‐mediated transport activity \[<http://www.ncbi.nlm.nih.gov/pubmed/20047987?dopt=AbstractPlus>\]. MATE2 and MATE2‐B are inactive splice variants of MATE2‐K \[<http://www.ncbi.nlm.nih.gov/pubmed/16807400?dopt=AbstractPlus>\].

Further reading on SLC47 family of multidrug and toxin extrusion transporters {#bph14753-sec-0296}
-----------------------------------------------------------------------------

Damme K *et al*. (2011) Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics. *Drug Metab. Rev*. **43**: 499‐523 <https://www.ncbi.nlm.nih.gov/pubmed/21923552?dopt=AbstractPlus>

Motohashi H *et al*. (2013) Multidrug and toxin extrusion family SLC47: physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2‐K. *Mol. Aspects Med*. **34**: 661‐8 <https://www.ncbi.nlm.nih.gov/pubmed/23506899?dopt=AbstractPlus>

Nies AT *et al*. (2016) Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine. *Arch. Toxicol*. **90**: 1555‐84 <https://www.ncbi.nlm.nih.gov/pubmed/27165417?dopt=AbstractPlus>

Wagner DJ *et al*. (2016) Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. *Pharmacol. Res*. **111**: 237‐246 <https://www.ncbi.nlm.nih.gov/pubmed/27317943?dopt=AbstractPlus>

Yonezawa A *et al*. (2011) Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. *Br. J. Pharmacol*. **164**: 1817‐25 <https://www.ncbi.nlm.nih.gov/pubmed/21457222?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=237> {#bph14753-sec-0297}
===========================================================================

Overview {#bph14753-sec-0298}
--------

HRG1 has been identified as a cell surface and lysosomal heme transporter \[<http://www.ncbi.nlm.nih.gov/pubmed/18418376?dopt=AbstractPlus>\]. In addition, evidence suggests this 4TM‐containing protein associates with the [http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=137\#V‐type ATPase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=137#V‐typeATPase) in lysosomes \[<http://www.ncbi.nlm.nih.gov/pubmed/19875448?dopt=AbstractPlus>\]. Recent studies confirm its lysosomal location and demonstrate that it has an important physiological function in macrophages ingesting senescent red blood cells (erythrophagocytosis), recycling heme (released from the red cell hemoglobin) from the phagolysosome into the cytosol, where the heme is subsequently catabolized to recycle the iron \[<http://www.ncbi.nlm.nih.gov/pubmed/23395172?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1218>Systematic nomenclatureSLC48A1Common abbreviationHRG1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:26035](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26035), <http://www.uniprot.org/uniprot/Q6P1K1>

Further reading on SLC48 heme transporter {#bph14753-sec-0299}
-----------------------------------------

Khan AA *et al*. (2013) Heme and FLVCR‐related transporter families SLC48 and SLC49. *Mol. Aspects Med*. **34**: 669‐82 <https://www.ncbi.nlm.nih.gov/pubmed/23506900?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=335> {#bph14753-sec-0300}
===========================================================================

Overview {#bph14753-sec-0301}
--------

FLVCR1 was initially identified as a cell‐surface attachment site for feline leukemia virus subgroup C \[<http://www.ncbi.nlm.nih.gov/pubmed/10400745?dopt=AbstractPlus>\], and later identified as a cell surface accumulation which exports heme from the cytosol \[<http://www.ncbi.nlm.nih.gov/pubmed/15369674?dopt=AbstractPlus>\]. A recent study indicates that an isoform of FLVCR1 is located in the mitochondria, the site of the final steps of heme synthesis, and appears to transport heme into the cytosol \[<http://www.ncbi.nlm.nih.gov/pubmed/23187127?dopt=AbstractPlus>\]. FLVCR‐mediated heme transport is essential for erythropoiesis. Flvcr1 gene mutations have been identified as the cause of PCARP (<http://www.omim.org/entry/609033?search=609033&highlight=609033> (PCARP) \[<http://www.ncbi.nlm.nih.gov/pubmed/21070897?dopt=AbstractPlus>\].There are three paralogs of FLVCR1 in the human genome.

FLVCR2, most similar to FLVCR1 \[<http://www.ncbi.nlm.nih.gov/pubmed/11943475?dopt=AbstractPlus>\], has been reported to function as a heme importer \[<http://www.ncbi.nlm.nih.gov/pubmed/20823265?dopt=AbstractPlus>\]. In addition, a congenital syndrome of proliferative vasculopathy and hydranencephaly, also known as Fowler&apos;s syndrome, is associated with a loss‐of‐function mutation in FLVCR2 \[<http://www.ncbi.nlm.nih.gov/pubmed/20206334?dopt=AbstractPlus>\].

The functions of the other two members of the SLC49 family, MFSD7 and DIRC2, are unknown, although DIRC2 has been implicated in hereditary renal carcinomas \[<http://www.ncbi.nlm.nih.gov/pubmed/11912179?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1910><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1911>Systematic nomenclatureSLC49A1SLC49A2Common abbreviationFLVCR1FLVCR2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24682](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24682), <http://www.uniprot.org/uniprot/Q9Y5Y0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20105](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20105), <http://www.uniprot.org/uniprot/Q9UPI3>Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349> \[<http://www.ncbi.nlm.nih.gov/pubmed/15369674?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349> \[<http://www.ncbi.nlm.nih.gov/pubmed/20823265?dopt=AbstractPlus>\]StoichiometryUnknownUnknown

Comments {#bph14753-sec-0302}
--------

Non‐functional splice alternatives of FLVCR1 have been implicated as a cause of a congenital red cell aplasia, <http://omim.org/entry/105650> \[<http://www.ncbi.nlm.nih.gov/pubmed/18815190?dopt=AbstractPlus>\].

Further reading on SLC49 family of FLVCR‐related heme transporters {#bph14753-sec-0303}
------------------------------------------------------------------

Khan AA *et al*. (2013) Heme and FLVCR‐related transporter families SLC48 and SLC49. *Mol. Aspects Med*. **34**: 669‐82 <https://www.ncbi.nlm.nih.gov/pubmed/23506900?dopt=AbstractPlus>

Khan AA *et al*. (2011) Control of intracellular heme levels: heme transporters and heme oxygenases. *Biochim. Biophys. Acta* **1813**: 668‐82 <https://www.ncbi.nlm.nih.gov/pubmed/21238504?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=336> {#bph14753-sec-0304}
===========================================================================

Overview {#bph14753-sec-0305}
--------

A mouse stromal cell cDNA library was used to clone C2.3 \[<http://www.ncbi.nlm.nih.gov/pubmed/8630032?dopt=AbstractPlus>\], later termed Rag1‐activating protein 1, with a sequence homology predictive of a 4TM topology. The plant orthologues, termed SWEETs, appear to be 7 TM proteins, with extracellular N‐termini, and the capacity for bidirectional flux of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4536> \[<http://www.ncbi.nlm.nih.gov/pubmed/21107422?dopt=AbstractPlus>\]. Expression of mouse SWEET in the mammary gland was suggestive of a role in Golgi lactose synthesis \[<http://www.ncbi.nlm.nih.gov/pubmed/21107422?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1914>Systematic nomenclatureSLC50A1Common abbreviationRAG1AP1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30657](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30657), <http://www.uniprot.org/uniprot/Q9BRV3>

Further reading on SLC50 sugar transporter {#bph14753-sec-0306}
------------------------------------------

Wright EM. (2013) Glucose transport families SLC5 and SLC50. *Mol. Aspects Med*. **34**: 183‐96 <https://www.ncbi.nlm.nih.gov/pubmed/23506865?dopt=AbstractPlus>

Wright EM *et al*. (2011) Biology of human sodium glucose transporters. *Physiol. Rev*. **91**: 733‐94 <https://www.ncbi.nlm.nih.gov/pubmed/21527736?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=337> {#bph14753-sec-0307}
===========================================================================

Overview {#bph14753-sec-0308}
--------

The SLC51 organic solute transporter family of transporters is a pair of heterodimeric proteins which regulate bile salt movements in the small intestine, bile duct, and liver, as part of the enterohepatic circulation \[<http://www.ncbi.nlm.nih.gov/pubmed/16317684?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15563450?dopt=AbstractPlus>\]. OSTα/OSTβ is also expressed in steroidogenic cells of the brain and adrenal gland, where it may contribute to steroid movement \[<http://www.ncbi.nlm.nih.gov/pubmed/20649839?dopt=AbstractPlus>\]. Bile acid transport is suggested to be facilitative and independent of sodium, potassium, chloride ions or protons \[<http://www.ncbi.nlm.nih.gov/pubmed/16317684?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15563450?dopt=AbstractPlus>\]. OSTα/OSTβ heterodimers have been shown to transport <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4546>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5577>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4748>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6504> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5577> \[<http://www.ncbi.nlm.nih.gov/pubmed/16317684?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15563450?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20649839?dopt=AbstractPlus>\]. OSTα/OSTβ‐mediated transport of bile salts is inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9184> \[<http://www.ncbi.nlm.nih.gov/pubmed/29675448?dopt=AbstractPlus>\]. OSTα is suggested to be a seven TM protein, while OSTβ is a single TM 'ancillary' protein, both of which are thought to have intracellular C‐termini \[<http://www.ncbi.nlm.nih.gov/pubmed/17650074?dopt=AbstractPlus>\]. Both proteins function in solute transport and bimolecular fluorescence complementation studies suggest the possibility of OSTα homooligomers, as well as OSTα/OSTβ hetero‐oligomers \[<http://www.ncbi.nlm.nih.gov/pubmed/22535958?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17650074?dopt=AbstractPlus>\]. An inherited mutation in OSTβ is associated with congenital diarrhea in children \[<http://www.ncbi.nlm.nih.gov/pubmed/28898457?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1915><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1916>Systematic nomenclatureSLC51A1SLC51BCommon abbreviationOSTαOSTβHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29955](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29955), <http://www.uniprot.org/uniprot/Q86UW1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29956](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29956), <http://www.uniprot.org/uniprot/Q86UW2>

Further reading on SLC51 family of steroid‐derived molecule transporters {#bph14753-sec-0309}
------------------------------------------------------------------------

Ballatori N. (2011) Pleiotropic functions of the organic solute transporter Ostα‐Ostβ. *Dig Dis* **29**: 13‐7 <https://www.ncbi.nlm.nih.gov/pubmed/21691099?dopt=AbstractPlus>

Ballatori N *et al*. (2013) The heteromeric organic solute transporter, OSTα‐OSTβ/SLC51: a transporter for steroid‐derived molecules. *Mol. Aspects Med*. **34**: 683‐92 <https://www.ncbi.nlm.nih.gov/pubmed/23506901?dopt=AbstractPlus>

Dawson PA. (2011) Role of the intestinal bile acid transporters in bile acid and drug disposition. *Handb Exp Pharmacol* 169‐203 <https://www.ncbi.nlm.nih.gov/pubmed/21103970?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=786> {#bph14753-sec-0310}
===========================================================================

Overview {#bph14753-sec-0311}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6578>, also known as vitamin B2, is a precursor of the enzyme cofactors <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5185> (FMN) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184> (FAD). Riboflavin transporters are predicted to possess 10 or 11 TM segments.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2571><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2572><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2573>Systematic nomenclatureSLC52A1SLC52A2SLC52A3Common abbreviationRFVT1RFVT2RFVT3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30225](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30225), <http://www.uniprot.org/uniprot/Q9NWF4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30224](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30224), <http://www.uniprot.org/uniprot/Q9HAB3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16187](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16187), <http://www.uniprot.org/uniprot/Q9NQ40>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6578> (*K* ~m~ 1.3×10^‐3^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/20463145?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6578> (*K* ~m~ 9.8×10^‐4^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/20463145?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6578> (*K* ~m~ 3.3×10^‐4^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/20463145?dopt=AbstractPlus>\]StoichiometryUnknownUnknownH^+^‐dependent

Comments {#bph14753-sec-0312}
--------

Although expressed elsewhere, RFVT3 is found on the luminal surface of intestinal epithelium and is thought to mediate uptake of dietary riboflavin, while RFVT1 and RFVT2 are thought to allow movement from the epithelium into the blood.

Further reading on SLC52 family of riboflavin transporters {#bph14753-sec-0313}
----------------------------------------------------------

Yonezawa A *et al*. (2013) Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52. *Mol. Aspects Med*. **34**: 693‐701 \[<https://www.ncbi.nlm.nih.gov/pubmed/23506902?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1005> {#bph14753-sec-0314}
============================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3021>Systematic nomenclatureSLC53A1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12827](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12827), <http://www.uniprot.org/uniprot/Q9UBH6>SubstratesPhosphate \[<http://www.ncbi.nlm.nih.gov/pubmed/23791524?dopt=AbstractPlus>\]CommentsXPR1/SLC53A1 is a phosphate carrier which appears to play a role in bone and tooth mineralization. It is ubiquitously expressed \[<http://www.ncbi.nlm.nih.gov/pubmed/9990033?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9927670?dopt=AbstractPlus>\]. The pathological consequences of defective SLC53A1 expression in the brain \[<http://www.ncbi.nlm.nih.gov/pubmed/25938945?dopt=AbstractPlus>\] and kidney \[<http://www.ncbi.nlm.nih.gov/pubmed/27799484?dopt=AbstractPlus>\] have been reported.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1006> {#bph14753-sec-0315}
============================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3022><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3023><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3024>Systematic nomenclatureSLC54A1SLC54A2SLC54A3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21606](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21606), <http://www.uniprot.org/uniprot/Q9Y5U8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24515](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24515), <http://www.uniprot.org/uniprot/O95563>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:44205](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:44205), <http://www.uniprot.org/uniprot/P0DKB6>SubstratesPyruvate \[<http://www.ncbi.nlm.nih.gov/pubmed/22628558?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22628554?dopt=AbstractPlus>\]Pyruvate \[<http://www.ncbi.nlm.nih.gov/pubmed/22628558?dopt=AbstractPlus>\]Pyruvate \[<http://www.ncbi.nlm.nih.gov/pubmed/27317664?dopt=AbstractPlus>\]CommentsSLC54A1 is ubiquitously expressed \[<http://www.ncbi.nlm.nih.gov/pubmed/27317664?dopt=AbstractPlus>\].SLC54A2 is ubiquitously expressed \[<http://www.ncbi.nlm.nih.gov/pubmed/27317664?dopt=AbstractPlus>\].SLC54A3 is expressed in testis, postmeiotic spermatids and sperm cells \[<http://www.ncbi.nlm.nih.gov/pubmed/27317664?dopt=AbstractPlus>\].

Comments {#bph14753-sec-0316}
--------

SLC54 family transporters appear to function as mechanisms for accumulating pyruvate into mitochondria to link glycolysis with oxidative phosphorylation.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1007> {#bph14753-sec-0317}
============================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3025><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3026><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3027>Systematic nomenclatureSLC55A1SLC55A2SLC55A3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6556](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6556), <http://www.uniprot.org/uniprot/O95202>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14648](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14648), <http://www.uniprot.org/uniprot/Q2VYF4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24241](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24241), <http://www.uniprot.org/uniprot/Q6P1Q0>Transport typeExchanger / Ca^2+^:H^+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/19797662?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27669901?dopt=AbstractPlus>\] Exchanger / K^+^:H^+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/17925330?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15138253?dopt=AbstractPlus>\]----SubstratesCa^2+^, K^+^, H^+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/17925330?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15138253?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17541427?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20197279?dopt=AbstractPlus>\]----CommentsSLC55A1 is ubiquitously expressed \[<http://www.ncbi.nlm.nih.gov/pubmed/10486213?dopt=AbstractPlus>\]. Arguments against SLC55A1&apos;s role as a Ca^2+^ transporter are outlined by Zotova *et al*. (2010) \[<http://www.ncbi.nlm.nih.gov/pubmed/20197279?dopt=AbstractPlus>\].----

Comments {#bph14753-sec-0318}
--------

The family of SLC55 mitochondrial transporters appear to regulate ion fluxes and to maintain tubular networks.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1008> {#bph14753-sec-0319}
============================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3028><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3029><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3030><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3031><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3032>Systematic nomenclatureSLC56A1SLC56A2SLC56A3SLC56A4SLC56A5HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16085](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16085), <http://www.uniprot.org/uniprot/Q9H9B4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16086](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16086), <http://www.uniprot.org/uniprot/Q96NB2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16087](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16087), <http://www.uniprot.org/uniprot/Q9BWM7>--[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16073](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16073), <http://www.uniprot.org/uniprot/Q8TD22>CommentsSideroflexin 1 (SFXN1/SLC56A1) was probably falsely identified as a tricarboxylate carrier in the 1993 article by Azzi *et al*. \[<http://www.ncbi.nlm.nih.gov/pubmed/8132491?dopt=AbstractPlus>\], as discussed several years later in \[<http://www.ncbi.nlm.nih.gov/pubmed/11274051?dopt=AbstractPlus>\]. SFXN1 likely transports pyridoxin or another heme precursor or the 5′‐aminolevulinate synthase 2 ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:397](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:397); <https://www.uniprot.org/uniprot/P22557>) cofactor \[<http://www.ncbi.nlm.nih.gov/pubmed/11274051?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12670026?dopt=AbstractPlus>\]. SFXN1 has recently been suggested to be a mitochondrial serine transporter \[<http://www.ncbi.nlm.nih.gov/pubmed/30442778?dopt=AbstractPlus>\]. It is mainly expressed in adult kidney and liver (mouse) \[<http://www.ncbi.nlm.nih.gov/pubmed/11274051?dopt=AbstractPlus>\].In mice sideroflexin 2 expression is mainly detected in adult kidney and liver \[<http://www.ncbi.nlm.nih.gov/pubmed/11274051?dopt=AbstractPlus>\]. In human tissues it is detected at highest levels in kidney, liver and pancreas \[<http://www.ncbi.nlm.nih.gov/pubmed/12670026?dopt=AbstractPlus>\].Sideroflexin 3 is ubiquitously expressed in mouse tissues \[<http://www.ncbi.nlm.nih.gov/pubmed/11274051?dopt=AbstractPlus>\].Sideroflexin 4 is expressed in mouse kidney, brain and heart \[<http://www.ncbi.nlm.nih.gov/pubmed/11274051?dopt=AbstractPlus>\]. The SFXN4a isoform is most highly expressed in human kidney and pancreas, and the SFXN4b isoform is barely detectable in brain \[<http://www.ncbi.nlm.nih.gov/pubmed/14756423?dopt=AbstractPlus>\].Sideroflexin 5 is expressed in mouse brain and liver \[<http://www.ncbi.nlm.nih.gov/pubmed/11274051?dopt=AbstractPlus>\].

Comments {#bph14753-sec-0320}
--------

These are a family of incompletely‐characterised mitochondrial transporters.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1009> {#bph14753-sec-0321}
============================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3033><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3034><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3035><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3037>Systematic nomenclatureSLC57A1SLC57A2SLC57A3SLC57A5HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17043](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17043), <http://www.uniprot.org/uniprot/Q7RTP0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17044](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17044), <http://www.uniprot.org/uniprot/Q8N8Q9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:27194](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:27194), <http://www.uniprot.org/uniprot/Q6NVV3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:25233](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:25233), <http://www.uniprot.org/uniprot/Q6P499>SubstratesSr^2+^, Fe^2+^ and Co^2+^ to a lesser extent \[<http://www.ncbi.nlm.nih.gov/pubmed/18667602?dopt=AbstractPlus>\], Mg^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/17166836?dopt=AbstractPlus>\]Mg^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/18667602?dopt=AbstractPlus>\]Mg^2+^, Sr^2+^, Ba^2+^, Fe^2+^, Cu^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/18667602?dopt=AbstractPlus>\]--CommentsHuman tissue expression: Constitutively expressed at low levels, with significant enrichment in the brain \[<http://www.ncbi.nlm.nih.gov/pubmed/14508710?dopt=AbstractPlus>\]. Mouse tissue expression: Widely expressed, including in the heart, kidney, liver, colon, less in the brain, and not in the small intestine \[<http://www.ncbi.nlm.nih.gov/pubmed/17166836?dopt=AbstractPlus>\].------

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1010> {#bph14753-sec-0322}
============================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3039><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3040>Systematic nomenclatureSLC58A1SLC58A2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:28880](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28880), <http://www.uniprot.org/uniprot/Q9H0U3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30242](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30242), <http://www.uniprot.org/uniprot/Q13454>Transport typeChannel‐like \[<http://www.ncbi.nlm.nih.gov/pubmed/19940067?dopt=AbstractPlus>\]--SubstratesMg^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/15804357?dopt=AbstractPlus>\]Mg^2+^, Fe^2+^, Cu^2+^, Mn^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/18667602?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19940067?dopt=AbstractPlus>\]CommentsExpressed in kidney, colon, heart and liver (the latter only at the mRNA level) \[<http://www.ncbi.nlm.nih.gov/pubmed/15804357?dopt=AbstractPlus>\]; universally expressed \[<http://www.ncbi.nlm.nih.gov/pubmed/19717468?dopt=AbstractPlus>\].Expressed in placenta, pancreas, testis, ovary, heart, and prostate \[<http://www.ncbi.nlm.nih.gov/pubmed/8661104?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1011> {#bph14753-sec-0323}
============================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3041><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3042>Systematic nomenclatureSLC59A1SLC59A2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:25897](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:25897), <http://www.uniprot.org/uniprot/Q8NA29>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:37207](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:37207), <http://www.uniprot.org/uniprot/A6NFX1>Transport typeCo‐transporter: LPC:Na^+^, uptake--SubstratesLPC (lysophosphatidylcholine) form of DHA (docosahexaenoic acid) \[<http://www.ncbi.nlm.nih.gov/pubmed/24828044?dopt=AbstractPlus>\]--CommentsMFSD2B/SLC59A has been suggested to be a sphingosine 1‐phosphate transporter in erythropoietic cells \[<http://www.ncbi.nlm.nih.gov/pubmed/29563527?dopt=AbstractPlus>\]. It is expressed in brain, intestine, kidney, liver, lung, mammary gland, and prostate \[<http://www.ncbi.nlm.nih.gov/pubmed/18694395?dopt=AbstractPlus>\]; relatively low expression in BAT (brown adipose tissue), but upregulated during cold‐induced thermogenesis \[<http://www.ncbi.nlm.nih.gov/pubmed/18694395?dopt=AbstractPlus>\]. Subcellular locations: plasma membrane \[<http://www.ncbi.nlm.nih.gov/pubmed/26747400?dopt=AbstractPlus>\] and ER \[<http://www.ncbi.nlm.nih.gov/pubmed/18694395?dopt=AbstractPlus>\].Expressed in the spleen, lung, testis and subcellularly in the ER \[<http://www.ncbi.nlm.nih.gov/pubmed/18694395?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1012> {#bph14753-sec-0324}
============================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3043><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3044>Systematic nomenclatureSLC60A1SLC60A2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:25433](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:25433), <http://www.uniprot.org/uniprot/Q8N468>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21053](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21053), <http://www.uniprot.org/uniprot/Q5TF39>Transport type--Co‐transporter / Na^+^ (1:1) uptake (Rat) \[<http://www.ncbi.nlm.nih.gov/pubmed/12590146?dopt=AbstractPlus>\]Substrates‐α‐Me‐glucose, D‐glucose \[<http://www.ncbi.nlm.nih.gov/pubmed/12590146?dopt=AbstractPlus>\]Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4285> \[<http://www.ncbi.nlm.nih.gov/pubmed/12590146?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4757> \[<http://www.ncbi.nlm.nih.gov/pubmed/12590146?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4539> \[<http://www.ncbi.nlm.nih.gov/pubmed/26423860?dopt=AbstractPlus>\] -- RatComments--Expressed in rat kidney (cortex and medulla), brain, liver and lung \[<http://www.ncbi.nlm.nih.gov/pubmed/12590146?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1013> {#bph14753-sec-0325}
============================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3045>Systematic nomenclatureSLC61A1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:28156](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28156), <http://www.uniprot.org/uniprot/Q6N075>Substratesmolybdate \[<http://www.ncbi.nlm.nih.gov/pubmed/21464289?dopt=AbstractPlus>\]CommentsMFSD5/SLC61 is a putative 12TM cell‐surface protein which appears to allow the accumulation of molybdate, and where the neural expression appears to respond to changes in the diet. It is expressed in cervix, stomach, nerve and skin \[<http://www.ncbi.nlm.nih.gov/pubmed/21464289?dopt=AbstractPlus>\]; ubiquitous but higher in skeletal muscle, olfactory bulb \[<http://www.ncbi.nlm.nih.gov/pubmed/18948099?dopt=AbstractPlus>\]; blood, cortex, hypothalamus, cerebellum and spinal cord (mouse) \[<http://www.ncbi.nlm.nih.gov/pubmed/27272503?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1014> {#bph14753-sec-0326}
============================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3046>Systematic nomenclatureSLC62A1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15492](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15492), Q<http://www.uniprot.org/uniprot/Q9HCJ1>SubstratesPyrophosphate \[<http://www.ncbi.nlm.nih.gov/pubmed/10894769?dopt=AbstractPlus>\]CommentsANKH/SLC62 is a putative 8TM membrane protein, also known as progressive ankylosis protein homolog. Mutations in this protein are associated with bone and joint abnormalities. It is expressed in kidney and bone \[<http://www.ncbi.nlm.nih.gov/pubmed/19910700?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1015> {#bph14753-sec-0327}
============================================================================

Overview {#bph14753-sec-0328}
--------

The SLC63 family of transporters has roles inside the cell (SLC63A1/SPNS1) or on the cell surface (SLC63A2/SPNS2) in sphingolipid transport.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3047>Systematic nomenclatureSLC63A1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30621](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30621), <http://www.uniprot.org/uniprot/Q9H2V7>CommentsExpressed in mitochondria \[<http://www.ncbi.nlm.nih.gov/pubmed/12815463?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1016> {#bph14753-sec-0329}
============================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3050>Systematic nomenclatureSLC64A1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30760](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30760), <http://www.uniprot.org/uniprot/Q9HC07>Transport typeExchanger/ Ca^2+^:H^+^SubstratesMn^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/28270545?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27008884?dopt=AbstractPlus>\], Ca^2+^, H^+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/23569283?dopt=AbstractPlus>\]CommentsTMEM165/SLC64 is a putative 6TM intracellular membrane protein. Mutations in the protein are associated with congenital disorder of glycosylation. It has been suggested to be essential for milk production in the mammary gland \[<http://www.ncbi.nlm.nih.gov/pubmed/30622138?dopt=AbstractPlus>\]. TMEM165 deficiency (*via* siRNA knockdown) causes Golgi glycosylation defects in transfected HEK cells \[<http://www.ncbi.nlm.nih.gov/pubmed/22683087?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1017> {#bph14753-sec-0330}
============================================================================

Overview {#bph14753-sec-0331}
--------

The SLC65 family of intracellular cholesterol transporters are 13TM membrane proteins. NPC1/SLC65A1 is an intracellular cholesterol transporter, which together with NPC2 (Uniprot ID <https://www.uniprot.org/uniprot/P61916>), allows the accumulation into the cytosol of cholesterol acquired from low density lipoproteins.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3051><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2629>Systematic nomenclatureSLC65A1SLC65A2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7897](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7897), <http://www.uniprot.org/uniprot/O15118>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7898](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7898), <http://www.uniprot.org/uniprot/Q9UHC9>SubstratesCholesterol \[<http://www.ncbi.nlm.nih.gov/pubmed/17989073?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17989072?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27410046?dopt=AbstractPlus>\]Cholesterol \[<http://www.ncbi.nlm.nih.gov/pubmed/14976318?dopt=AbstractPlus>\]Selective antagonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6816> (Inhibition) (p*K* ~d~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/15928087?dopt=AbstractPlus>\]CommentsExpression is ubiquitous \[<http://www.ncbi.nlm.nih.gov/pubmed/14976318?dopt=AbstractPlus>\], with highest levels detected in liver, lung, and pancreas \[<http://www.ncbi.nlm.nih.gov/pubmed/10783261?dopt=AbstractPlus>\]. NPC1 plays a critical role in the regulation of intracellular cholesterol trafficking \[<http://www.ncbi.nlm.nih.gov/pubmed/9211849?dopt=AbstractPlus>\]. Mutations in the NPC1 gene have been identified in patients with the lipid storage disorder Niemann‐Pick disease type C1 \[<http://www.ncbi.nlm.nih.gov/pubmed/12554680?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9211849?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10521290?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10480349?dopt=AbstractPlus>\].Expressed in small intestine, gallbladder, liver, testis and stomach \[<http://www.ncbi.nlm.nih.gov/pubmed/14976318?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=238> {#bph14753-sec-0332}
===========================================================================

Overview {#bph14753-sec-0333}
--------

The SLCO superfamily is comprised of the organic anion transporting polypeptides (OATPs). The 11 human OATPs are divided into 6 families and ten subfamilies based on amino acid identity. These proteins are located on the plasma membrane of cells throughout the body. They have 12 TM domains and intracellular termini, with multiple putative glycosylation sites. OATPs mediate the sodium‐independent uptake of a wide range of amphiphilic substrates, including many drugs and toxins. Due to the multispecificity of these proteins, this guide lists classes of substrates and inhibitors for each family member. More comprehensive lists of substrates, inhibitors, and their relative affinities may be found in the review articles listed below.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1219><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1220><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1221><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1222>Systematic nomenclatureSLCO1A2SLCO1B1SLCO1B3SLCO1C1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10956](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10956), <http://www.uniprot.org/uniprot/P46721>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10959](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10959), <http://www.uniprot.org/uniprot/Q9Y6L6>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10961](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10961), <http://www.uniprot.org/uniprot/Q9NPD5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13819](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13819), <http://www.uniprot.org/uniprot/Q9NYB5>Substratesfluoroquinolones, beta blockers, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1615>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2954>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4819>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4506>, anticancer drugs, antibiotics, HIV protease inhibitors, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4664>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4826>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4735> \[<http://www.ncbi.nlm.nih.gov/pubmed/15737679?dopt=AbstractPlus>\]statins, opioids, β‐lactam antibiotics, bile acid derivatives and conjugates, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4506>, anticancer drugs, HIV protease inhibitors, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4819>, antifungals, ACE inhibitors, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765>, endothelin receptor antagonists, sartans<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765>, opioids, sartans, statins, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4726>, anticancer drugs, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4506>, bile acid derivatives and conjugates, β‐lactam antibiotics, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4826>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4632>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4813>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4819>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1456>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4736>statins, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4506>Endogenous substratesbile acids, thyroid hormones, steroid conjugates, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4577>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883>leukotrienes, steroid conjugates, thyroid hormones, bile acids, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4577>steroid conjugates, thyroid hormones, bile acids, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=864> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1569](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569), <http://www.uniprot.org/uniprot/P06307>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4577>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354>thyroid hormones, steroid conjugatesLigands--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2953> (Binding)----Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4570> (p*K* ~i~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/12085361?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765> (p*K* ~i~ 4.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/12085361?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4738> \[<http://www.ncbi.nlm.nih.gov/pubmed/17301733?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1024> (p*K* ~i~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/14530907?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22541068?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4749> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/20448812?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765> (p*K* ~i~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/22541068?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4570> (p*K* ~i~ 5.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/12085361?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3439> \[<http://www.ncbi.nlm.nih.gov/pubmed/17470528?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4688>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4844><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1024> (pIC~50~ 6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22541068?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17496208?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743> (pIC~50~ 6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/17496208?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765> (pIC~50~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/22541068?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17496208?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3439>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4688>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4570><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1608>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4357>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4547>Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4505>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3819>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4748><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4687>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4748><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4505>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4765>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4687><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4627>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4505>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4748>CommentsAlthough rat and mouse OATP1A4 are considered the orthologs of human OATP1A2 we do not cross‐link to gene or protein databases for these since in reality there are five genes in rodents that arose through gene duplication in this family and it is not clear which one of these is the \"true\" ortholog.Other inhibitors include, fibrates, flavonoids, glitazones and macrolide antibiotics. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4749> or the drug substrates <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2949>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2953> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2954> are used as a probe.Other inhibitors include, HIV protease inhibitors, glitazones and macrolide antibiotics. CCK‐8 is used as an OATP1B3‐selective probe.--

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1223><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1224><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1225><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1226><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1227>Systematic nomenclatureSLCO2A1SLCO2B1SLCO3A1SLCO4A1SLCO4C1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10955](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10955), <http://www.uniprot.org/uniprot/Q92959>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10962](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10962), <http://www.uniprot.org/uniprot/O94956>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10952](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10952), <http://www.uniprot.org/uniprot/Q9UIG8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10953](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10953), <http://www.uniprot.org/uniprot/Q96BD0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23612](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23612), <http://www.uniprot.org/uniprot/Q6ZQN7>Substratessynthetic prostaglandin derivatives<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2566>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4506>, statins, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2414>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4812>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4819>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4664>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3494>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=592>--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4796>dipeptidyl peptidase‐4 inhibitors, anticancer drugs, cardiac glycosidesEndogenous substratesprostaglandins, eicosanoids<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4749>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4528>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=997>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:894](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:894), <http://www.uniprot.org/uniprot/P01185>), thyroid hormones, prostaglandinsthyroid hormones, prostaglandins, bile acids, steroid conjugatesthyroid hormones, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352>, steroid conjugatesInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4530> (Inhibition of PGF~2α~ uptake in PGT‐expressing HeLa cells) (p*K* ~i~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/7754369?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4506> (Inhibition of PGF~2α~ uptake in PGT‐expressing HeLa cells) (p*K* ~i~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/7754369?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4920> (p*K* ~i~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/22541068?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6193> (p*K* ~i~ 5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/22541068?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3439>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2414>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4570>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743> \[<http://www.ncbi.nlm.nih.gov/pubmed/17496208?dopt=AbstractPlus>\]------Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1916> (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/9506966?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4505>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4748><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1916>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4748><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4748><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4725>CommentsOther inhibitors include NSAIDsOther inhibitors include glitazones and citrus juices------
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